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ABSTRACT 
 
Epithelial ovarian cancer (EOC) is a leading cause of morbidity and mortality among 
women in the United States, and the etiology is incompletely understood.  Common, low 
penetrant genetic variants such as single nucleotide polymorphisms (SNPs) likely contribute to a 
significant proportion of EOC. We examined whether SNPs in two understudied yet biologically 
important types of genes, mitochondrial-related and miRNA-related genes, may contribute to 
EOC susceptibility using data from a large, homogeneous study population of 1,815 EOC cases 
and 1,900 controls (frequency-matched on age-group and race/ethnicity) genotyped through stage 
1 of an ongoing genome-wide association study. Inter-individual variation in genes involved in 
mitochondrial biogenesis was strongly associated with EOC risk (empirical P=0.050), especially 
for genes NRF1, PPARGC1A, MTERF, ESRRA, and CAMK2D. SNPs in several genes involved in 
the biogenesis of miRNAs (LIN28, LIN28B, AGO2, DICER, and DROSHA) also demonstrated 
associations with EOC risk; a joint meta-analysis and in vitro investigations reinforced evidence 
for a protective role of LIN28B rs12194974 (combined OR= 0.90, 95% CI: 0.82-0.98), a G>A 
SNP predicted to reside in a transcription factor binding site in the highly conserved LIN28B 
promoter. Our findings provide valuable insight into the pathogenesis of EOC, and support the 
consideration of variants in these genes as candidates when building risk prediction models.  
Most importantly, this work has provided a strong foundation for further lines of research that 
may aid in reducing the burden of this disease.  
  
 
 
CHAPTER 1: 
 
INTRODUCTION AND THEORETICAL FRAMEWORK 
 
Epithelial ovarian cancer (EOC), the predominant and most lethal subtype of ovarian 
cancer, is a leading cause of morbidity and mortality in the United States, causing more deaths 
per year than any other gynecologic malignancy. 1 Annually, approximately 22,000 new cases of 
ovarian cancer are diagnosed and 15,000 ovarian cancer-related deaths are expected.1  Mortality 
is high because women typically present with advanced disease when the overall 5-year survival 
rate is 30%. 2 Despite the high incidence and mortality rates, the etiology of this heterogeneous 
disease is only partially understood.  
Aside from age, reproductive and hormonal factors are the main risk factors for the 
disease. While factors such as age at menarche, age at menopause, and age at first birth are only 
slightly positively associated with EOC risk 3,4, increasing parity is a well established protective 
factor. Parous women are estimated to have a 30-60% lower risk cancer compared to nulliparous 
women, 5-10 with each additional full-term pregnancy estimated to lower risk by approximately 
15% 4,8,11 . Breastfeeding may confer a slight decrease in EOC risk, with odds ratios 
approximating 0.6-0.7 4,7,10,12-17.  The most consistent protective factor against EOC is oral 
contraceptive (OC) use; the overall estimated risk reduction is approximately 30-40% amongst 
ever users, with greater protection observed with longer duration of use 4,17-21. Prolonged use of 
post-menopausal HRT, especially unopposed estrogen therapy, may increase the risk for certain 
subtypes of EOC. 22-24 Obesity, a condition that influences circulating levels of hormones, has 
also been found to impact EOC risk. 25-30  It is hypothesized that pregnancy, breastfeeding, and 
OC use may be protective by reducing the number of lifetime ovulatory cycles (LOC), which may 
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in turn reduce levels of gonadotropins, oxidative stress, DNA replication errors, and formation of 
inclusion cysts in the ovarian surface epithelium, thereby decreasing EOC risk. 5,31,32 
Additionally, pregnancy and OC use are characterized by surges of progesterone which may 
subsequently exert protective effects by inducing apoptosis of genetically damaged ovarian 
epithelial cells. 33 Thus, it is most probable that a combination of mechanisms underlie ovarian 
carcinogenesis. 
Risk factors that do not affect hormonal or ovulatory events have also been identified. A 
reduced risk of EOC has also been associated with either a hysterectomy or tubal ligation, with 
the protective effect for each of these procedures ranging from 30-40% 6,17,34-38, possibly by 
preventing potential carcinogens such as talc from ascending the genital tract 39.  EOC risk may 
also be increased by lifestyle factors such as cigarette smoking 40-43, alcohol consumption, 44-46 
and certain aspects of diet 47.  
A family history of EOC also represents a significant risk factor for the disease. First-
degree relatives of EOC probands have an approximately 2-3 fold increased risk, with higher 
risks associated with multiple affected relatives and earlier ages at onset 48-52.  Although familial 
aggregation may be due to a combination of genetic and shared environmental factors, twin 
studies suggest that the majority of familial ovarian cancer risk is attributed to genetic factors.53  
It is clear that a subset of EOC occur as part of a hereditary cancer syndrome that is inherited in 
an autosomal dominant pattern. The majority of hereditary ovarian cancers can be attributed to 
highly penetrant mutations in the BRCA1 and BRCA2 genes 54,55, with risks for ovarian cancer by 
age 70 years approaching up to 44% in BRCA1 families 56 and up to 27% in BRCA2 families  57.  
Ovarian cancer also occurs in families with Hereditary Non-Polyposis Colorectal Cancer 
Syndrome (HNPCC), also known as Lynch Syndrome II 58. The genetic defects underlying 
HNPCC (the mismatch repair genes hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6), 58,59 may 
account for roughly 2% of EOC, 60 and confer up to a 12% lifetime risk of ovarian cancer 61-63.  
Overall, mutations in highly penetrant genes are believed to account for 10-15% of epithelial 
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ovarian cancers 64,65. Studies to identify other major ovarian cancer susceptibility genes provide 
little evidence for their existence 66,67. Thus, it is generally held that most of the inherited 
component of ovarian cancer may be attributed to low penetrant variants that have yet to be 
identified. 68 The most common type of variant, a single nucleotide polymorphism (SNP), 
involves a single base pair substitution at a particular site in the DNA sequence.  Our global 
hypothesis is that inter-individual variation in two understudied yet biologically important types 
of genes, mitochondrial-related genes and miRNA-related genes, may contribute to EOC 
susceptibility.  In the remainder of this section, we summarize our rationale for evaluating the 
association between individual SNPs in these genes and EOC risk. 
Emerging evidence suggests that the development and progression of various cancer types, 
including EOC, may be caused by oxidative stress 69-73, a process arising due to an imbalance 
between the production of reactive oxygen species (ROS) and antioxidant defenses.  This 
imbalance favors overproduction of ROS, which can lead to increased DNA damage and altered 
regulation of genes involved in apoptosis and proliferation, ultimately leading to cancer.73 ROS is 
generated by mitochondria, cellular organelles that contain their own genome (mtDNA) and serve 
as the energy powerhouse of the cell. 74 Because mitochondria have been implicated in 
carcinogenesis due to their key role in apoptosis, free radical production, and cellular energy 
metabolism 74, it seems plausible that inherited variation in mtDNA may impair mitochondrial 
function and promote EOC development. Furthermore, since the majority of mitochondrial 
proteins are encoded by the nuclear genome (nDNA)75, it is possible that mtDNA and nDNA may 
interact with each other or with other non-genetic factors (i.e. hormones, ovulation, cigarette 
smoke) to influence oxidative stress and EOC risk. 76-78 Due to the heterogeneous nature of EOC 
and the reported etiologic differences according to histology, 40,41,79-84 it is also possible that the 
most promising associations may vary by histological subtype.  
Thus, for our first manuscript, we evaluate the hypothesis that SNPs or haplotypes (block 
of SNPs in physical close proximity that are often inherited together) in mitochondrial-related 
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genes (i.e. mitochondrial genes encoded by mtDNA or nDNA) may play an important role in the 
etiology of EOC. We further hypothesize that the germline mitochondrial variation-EOC link 
may be influenced by hormones, ovulation, and smoking, and that observed associations may 
differ by histologic subtype.  
Specific Aim 1: To comprehensively examine associations between SNPs and haplotypes 
in mitochondrial DNA (mtDNA) and/or nuclear-encoded mitochondrial DNA (nDNA) and EOC 
risk.  
Sub-aim a.  To evaluate whether lifetime ovulation, hormone replacement therapy use, 
and/or cigarette smoking confound or modify the most promising 
observed associations. 
Sub-aim b.  To determine whether the most promising associations differ by histologic 
subtype.  
Since gene deregulation is one of the main mechanisms by which carcinogenesis can 
occur 85, the evaluation of genetic variants in regulators of gene expression represents another 
research area of high importance. MicroRNAs (miRNAs), a class of short, non-coding RNAs 
involved in the post-transcriptional regulation of up to one-third of human protein-coding 
genes, have been implicated in cancer development and progression. 86   By binding to the 3’ 
untranslated region (UTR) of the target mRNA, miRNAs cause translational inhibition and/or 
mRNA degradation. 87 Ovarian tumors exhibit differential miRNA expression profiles compared 
to normal tissues. 88  Defects in miRNA biogenesis, the synthesis and maturation of miRNAs, 
have been shown to dramatically affect miRNA expression and clinical outcomes in EOC. 89,90 
Since SNPs in miRNA biogenesis genes may alter miRNA expression 91, and a few published 
studies of diverse tumor types have found an association between such SNPs and cancer risk, 92-95 
for our second manuscript we evaluate the hypothesis that SNPs or haplotypes in miRNA 
biogenesis genes may influence EOC risk. 
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Specific Aim 2: To comprehensively evaluate associations between SNPs and haplotypes 
in miRNA biogenesis genes and a) EOC risk and b) serous carcinomas.  
To evaluate our hypotheses and corresponding aims, we utilized genotype and 
epidemiologic data obtained through stage 1 of an ongoing, multi-center, case-control study that 
uses a genome-wide association (GWA) study approach to investigate the influence of >550,000 
SNPs in the human genome and EOC risk. Stage 1 of the parent study and the investigations 
reported herein include data from 4 participating study sites, for a combined study population of 
3,715 subjects (1,815 primary invasive EOC cases and 1,900 controls frequency-matched to cases 
on age-group, race, and geographic region).  The literature review, a description of the parent 
study and component case-control studies, study eligibility criteria, the genotyping platform, 
quality assurance and quality control procedures, integration of covariate data used, definitions of 
outcome and independent variables, and sample size calculations appear in Appendices A-H, 
respectively.    
This research is significant because it is the first to comprehensively investigate 
associations between SNPs in mitochondrial-related and miRNA-related genes and EOC risk. 
This research is innovative because it evaluates underexplored yet biologically relevant 
paradigms for EOC susceptibility. The knowledge gained in this endeavor will not only allow for 
identification of women at high-risk for EOC, but will advance our understanding of the 
pathogenesis and progression of this incompletely understood and deadly malignancy.    
 
 
 
 
 
 
CHAPTER 2: 
 
INHERITED VARIANTS IN MITOCHONDRIAL BIOGENESIS GENES INFLUENCE 
EPITHELIAL OVARIAN CANCER RISK 
 
ABSTRACT 
Background:  Mitochondria contribute to oxidative stress, a phenomenon implicated in ovarian 
carcinogenesis. We examined whether inherited variants in mitochondrial-related genes influence 
epithelial ovarian cancer (EOC) susceptibility. 
Methods: Through a multi-center study of 1,815 Caucasian EOC cases and 1,900 frequency-
matched controls genotyped with the Illumina 610K Array, we investigated associations between 
EOC risk and 128 single nucleotide polymorphisms (SNPs) from 22 genes/regions within the 
mitochondrial genome (mtDNA) and 2839 nuclear-encoded (nDNA) SNPs localized to 138 genes 
involved in mitochondrial biogenesis (BIO, n=35), steroid hormone metabolism (HOR, n=13), 
and oxidative phosphorylation (OXP, n=90) pathways. Unconditional logistic regression was 
used to estimate odds ratios (OR) and 95% confidence intervals (CI) between genotype and case 
status. Overall significance of each gene and pathway was evaluated using Fisher’s method.  At 
the SNP-level, we investigated whether non-genetic factors (i.e. lifetime ovulation, hormone 
replacement therapy (HRT), cigarette smoking) are confounders or modifiers of observed 
associations.  
Results: Inter-individual variation involving BIO genes was most strongly associated with EOC 
risk (empirical P=0.050), especially for NRF1, MTERF, PPARGC1A, ESSRA, and CAMK2D.  
Several SNP-level associations strengthened after adjustment for non-genetic factors, particularly 
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for MTERF. Statistical interactions with cigarette smoking and HRT use were observed with 
MTERF and CAMK2D SNPs, respectively. Although overall variation within mtDNA, HOR, 
and OXP was not statistically significant (empirical P>0.10), highlighted genes (i.e. MT-CO1, 
ESR2, TUFM) merit follow-up.   
Conclusion: These results suggest that variants in mitochondrial biogenesis genes influence EOC 
susceptibility. Future studies are warranted to replicate these findings and evaluate biologic 
function. 
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INTRODUCTION 
Epithelial ovarian cancer (EOC) is the ninth most commonly diagnosed female cancer 
and the most lethal gynecologic malignancy in the United States 1. Although the etiology remains 
largely unknown, there are two leading hypotheses. The incessant ovulation hypothesis 31 states 
that repeated ovulations over-stimulate the ovarian surface epithelium, causing inflammation and 
increased cellular proliferation during epithelial repair, leading to DNA replication errors and 
malignant transformation. The gonadotropin hypothesis 32 posits that gonadotropins are 
responsible for this process.  Supporting these hypotheses, epidemiologic studies have shown that 
factors which interrupt ovulation and/or lower gonadotropin levels, including pregnancy, oral 
contraceptive use, and lactation, are inversely associated with risk 96.  However, factors unrelated 
to hormones, reproduction, or ovulation may also influence risk, suggesting alternate mechanisms 
may also contribute to the genesis of EOC 96.   
Emerging experimental and epidemiologic evidence suggests EOC development and 
progression may be caused by oxidative stress 69-71,97-101, a phenomenon arising due to 
overproduction of reactive oxygen species (ROS) in the mitochondria 73.  Mitochondria are 
semiautonomous membrane-bound organelles that participate in free radical production, 
apoptosis, and energy metabolism 74. Aside from the nucleus, the mitochondrion is the only 
cellular organelle that contains its own genome (mtDNA) and genetic machinery.  MtDNA is a 
maternally-inherited, 16.6 kilobase double-stranded, closed circular molecule, that encodes 37 
genes (13 polypeptides, 22 transfer RNAs, and 2 ribosomal RNAs) mainly involved in 
oxidative phosphorylation (OXPHOS), a process whereby molecular oxygen is oxidized to 
water, creating adenosine triphosphate (ATP) and the by-product, ROS 74. Approximately 
1500 proteins encoded by nuclear DNA (nDNA) generate new mitochondria (known as 
mitochondrial biogenesis) and maintain mitochondrial structure and function by regulating 
processes such as OXPHOS, apoptosis, and mtDNA replication, transcription, and translation 
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74. Importantly, interplay between the genomes can influence disease processes, and studies 
implicate nDNA-encoded genes involved in mitochondrial biogenesis as regulators of nuclear-
mitochondrial interactions 69,74,102. 
While much attention has been focused on somatic mtDNA mutations 74,103, less research 
has been directed to the influence of germline variants on mitochondrial dysfunction and cancer 
development.  Single nucleotide polymorphisms (SNPs) in mtDNA and/or nDNA may enhance 
cancer risk through subtle changes in encoded proteins, altered OXPHOS activity, and excess 
ROS production over time (Figure 2.1) 73,104. In particular, variation involving mtDNA 104 and the 
following three categories or ‘pathways’ of nDNA may alter cancer risk by promoting oxidative 
stress. Mitochondrial biogenesis (BIO) proteins represent transcription factors and co-activators 
that regulate mtDNA and nDNA involvement in OXPHOS; because defective mitochondrial 
biogenesis may promote slower mitochondrial turnover and altered OXPHOS activity, control of 
this process is integral for maintenance of energy production and prevention of ROS 
accumulation 102,105,106. Similar to their mtDNA-encoded counterparts, nDNA-encoded OXPHOS 
(OXP) proteins, when impaired, may alter OXPHOS activity and contribute to diseases including 
hereditary cancer syndromes 107,108.  Steroid hormone metabolism (HOR) proteins, primarily 
receptors localized to mitochondria, modulate mitochondrial gene expression and OXPHOS 
activity 109,110. SNPs in these pathways may also influence risk by interacting with one another or 
with non-genetic factors known to contribute to ROS accumulation (Figure 2.1).   
Few studies have examined potential associations between inherited mitochondrial SNPs 
and/or haplotypes and cancer risk 111-117. Only one study 117 investigated nDNA in addition to 
mtDNA, and only one small study in China 114 involved ovarian cancer. Thus, there is a need for 
large-scale studies that comprehensively evaluate inherited mitochondrial variation and EOC risk 
and incorporate epidemiologic risk factors into the analysis. 
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METHODS 
Study Design and Population 
The study protocol was approved by the institutional review board at each center, and all 
study participants provided written informed consent. Data derive from four case-control studies 
of EOC: the Mayo Clinic Ovarian Cancer Study (MAY) (Rochester, MN), Duke University’s 
North Carolina Ovarian Cancer Study (NCO) (Durham, NC), the University of Toronto Familial 
Ovarian Tumor Study (TOR) (Ontario, Canada), and H. Lee Moffitt Cancer Center and Research 
Institute’s Tampa Bay Ovarian Cancer Study (TBO) (Tampa, FL).  Study characteristics are 
summarized in Table 2.1. All studies recruited incident, pathologically confirmed primary EOC 
cases, either borderline or invasive, aged 20 and above. Three studies used population-based rapid 
ascertainment for the cases (NCO, TOR, TBO), and one study was clinic-based (MAY). All 
controls had at least one ovary intact at the reference date and were frequency-matched to cases 
on age-group and race/ethnicity.  
Demographic data and information on known and suspected EOC risk factors was 
collected from participants using study-specific questionnaires. Data collected included 
race/ethnicity, age at diagnosis/interview, menstrual and reproductive history, exogenous 
hormone use, medical and surgical history, adult height and weight, smoking history, and family 
history of ovarian and breast cancer in first-degree relatives. To increase etiologic homogeneity, 
we excluded cases with non-epithelial or borderline tumors, non-whites, known BRCA1 and 
BRCA2 mutation carriers, Jewish women (because of the likelihood of carrying a BRCA 
mutation), and women with a prior history of ovarian, breast, endometrial, or early-onset 
colorectal cancer (because of the likelihood of having a mismatch repair defect).  
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Biospecimen Collection and Processing: 
Blood served as the source of genomic DNA and was collected at each study site at the 
conclusion of the interview (NCO, TBO, and TOR) or in the course of medical care (MAY). 
Genomic DNA was isolated from whole blood using PureGene DNA isolation reagents (Gentra 
Systems, Minneapolis, MN), re-suspended in TE buffer, and stored at 4° C.  Samples were bar-
coded with a unique subject identification number to ensure accurate and reliable sample 
processing and storage. 
Genotyping Method and Quality Control:  
All samples were genotyped using the Illumina Infinium 610K Array at the Mayo Clinic 
Genotyping Shared Resource Facility (Rochester, MN) by laboratory personnel blinded to case-
control status.  Each 96-well plate contained 375 ng DNA of random mixtures of case and control 
samples, two blind duplicates, and two replicates of a CEPH family trio (mother, father, child) 
from the Coriell Institute.  A quality assurance (QA) panel of 96 SNPs was run on the Illumina 
Bead Express platform to test sample performance and ensure concordance of replicate samples.  
  Illumina’s Genome Studio™ software was used to perform automated genotype 
clustering and calling of the potential 550,000 beadtypes. SNPs and samples with call rates <95% 
were excluded from further analysis. Among 81 pairs of replicate samples, the overall 
concordance rate was 99.93%.The overall genotype call rate was 99.7%.  
We attempted to genotype unique samples from 4,169 eligible subjects. Of these, 413 
were excluded because genotypes were generated at fewer than 95% of SNPs (i.e. sample call 
rate <95%), and 15 due to sample failure under the QA panel.  Other reasons for exclusion 
included ambiguous gender (n=7), unresolved identical genotypes (n=8), self-report as non-
Caucasian (n=2), and those predicted by STRUCTURE 118 analysis to have less than 80% 
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European ancestry (n=9).  This resulted in a final sample size of 3,715 subjects (1,815 cases and 
1,900 controls).  
Identification of candidate genes and SNPs: 
MtDNA content on the 610K array was determined by comparing an annotation file 
supplied by Illumina with the MitoMap database 119. Of 138 mtDNA SNPs from 22 genes and 8 
regulatory regions included on the 610K array, 128 (92%) had call rates greater than 95%, but 
only 24 SNPs had MAF greater than or equal to 5% (Table 2.2).  Information regarding nDNA 
proteins was derived from published literature and several databases, including MitoProteome 120, 
the Human Mitochondrial Protein Database 121, and the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) Pathway database. A total of 3064 SNPs in 142 nDNA genes of interest (35 
BIO, 14 HOR, and 93 OXP) are on the 610K array and of these, 2839 SNPs (93%) from 138 
genes had call rates greater than 95% (Table 2.2).  
Statistical Methods 
Descriptive statistics were generated using means and standard deviations for continuous 
variables and frequencies and percents for categorical variables.  Distributions of covariates 
among cases and controls were compared within each study site using t-tests and Χ2 tests for 
continuous and categorical variables, respectively. Genotype frequencies of nDNA SNPs among 
controls were tested for HWE using Χ2 goodness-of-fit tests. Statistical analysis was performed 
using SAS Version 9.1 (SAS Inc., Cary, NC) and PLINK software 122. 
Association testing was performed for SNPs, haplotypes, genes, and pathways. To 
examine associations between each SNP and EOC risk, unconditional logistic regression was 
used to estimate odds ratios (OR) and 95% confidence intervals (CI) between carriage of the 
minor versus major allele of maternally-inherited mtDNA SNPs and case status, and between 
genotypes and case status for nDNA SNPs.  Log-additive, dominant, and recessive genetic 
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models were fit for each nDNA SNP; the major allele was considered to be the reference allele 
during modeling.  All models were adjusted for the design variables of age (continuous) and 
study site (indicator variables for NCO, TBO, and TOR).  Due to the potential for population 
stratification, models were also adjusted for a quantitative variable for the first principal 
component representing European ancestry 118. Wald Χ2 tests were used to obtain P values for 
dominant and recessive SNP effects, and the Cochran Armitage trend test was used to estimate P 
for trend for log-additive effects. The best-fitting model was represented by the one with the 
smallest P value. All P values were two-sided, and a nominal P < 0.05 was considered the 
threshold of significance for SNP-level tests.  
We permuted case-control status 100,000 times to generate point-wise empirical p-values 
(EMP1) using PLINK 122. The EMP1 represents the proportion of permutations in which the 
minimum simulated P value was less than the observed P value.  To predict the potential 
functional significance of risk-associated and strongly correlated (r2>0.80) SNPs, we used the 
SNPinfo (http://manticore.niehs.nih.gov/) and FastSNP (http://fastsnp.ibms.sinica.edu.tw/ ) web-
based tools.  
To evaluate whether established or suspected EOC risk factors (lifetime ovulation, 
hormones, cigarette smoking) postulated to contribute to oxidative stress may confound the most 
promising SNP-EOC risk associations, we conducted analyses among subjects with complete data 
for variables of interest (N=2662; 1217 cases, 1445 controls, representing 72% of 3715 total 
subjects). Similar to other studies that estimated lifetime ovulation 123,124, a composite variable for 
lifetime ovulatory cycles (LOC) was estimated by considering self-reported ovulatory and 
anovulatory periods using the following modified formula:  
LOC= [[index age - age at first menstrual period] - [(number of months pregnant + 
number of months of oral contraceptive use)/12 months]] * 13 cycles/year,  
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where 13 cycles/year is assumed based on an average cycle length of 28 days.  For post-
menopausal women, index age was defined as age at menopause. For pre- or peri-menopausal 
women, age at interview/ diagnosis served as the index age. The LOC composite variable was 
subsequently categorized based on tertiles of the distribution among controls. Other factors that 
may influence LOC, such as breastfeeding, missed or irregular periods, or spontaneous or elective 
abortions, were not considered because pertinent data were not ascertained by or available from 
all participating sites. For each SNP investigated, the model included age (continuous), study site 
(indicator variable), LOC category (low, medium, high), duration of unopposed estrogen or 
combined estrogen-progestin hormone replacement therapy (HRT) use (continuous), and pack-
years of cigarettes smoked (continuous).  
To explore SNP-environment interactions, modifying effects of the following non-genetic 
variables were considered: LOC category (high and medium tertile vs. lowest tertile), HRT use 
(ever versus never), smoking history (ever versus never), and menopausal status (peri/pre versus 
post).  Multiplicative interactions were evaluated by fitting logistic regression models with the 
corresponding SNP under a dominant effect, non-genetic variable, and interaction term. P values 
for testing the interaction effects were obtained using Wald Χ2 tests. For interactions with P < 
0.05, stratified analyses were conducted.  
For each gene having multiple SNPs associated with risk, we estimated pair-wise linkage 
disequilibrium (LD) using Haploview v4.1. 125 For regions with high LD (r2 > 0.80), we tested 
for associations between haplotypes and case-control status using the Haplo.stats program and R 
software v2.10.0 according to methods proposed by Schaid et al. 126   Estimates of ORs, 95% CIs, 
and P-values were obtained, with adjustment for age and study site under the specified genetic 
model. Rarer haplotypes (frequencies <10%) were combined into a single category to minimize 
sparse cell counts.  LD plots displaying the SNP correlation structure in selected regions are 
displayed in Figure 2.2. 
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To complement single SNP analysis, we used Fisher’s method (FM) 127,128 to combine 
association evidence from a group of SNPs within a gene for gene-level analysis. This method 
has been shown to have high statistical power in detecting associations 129.  Briefly, the test 
statistic combines multiple results in the following form, F =  , where pi is the SNP-
level p-value (adjusted for age and study site) for the ith SNP within each gene. To enhance power 
to detect associations, only common SNPs (MAF 
∑
=
−
m
i
ip
1
ln2
> 5%) were included in this analysis.   Due to 
the correlation structure of SNP data, the statistical significance for each gene was assessed using 
10,000 permutations with case/control labels permuted. The same statistical test was performed 
for the pathway-level analysis; association tests for each of the 4 pathways (mtDNA, BIO, OXP, 
HOR) were conducted. In a similar fashion, the statistical significance for each pathway was 
assessed using 10,000 permutations. Similar to methods employed by Goode et al. 130, the results 
were interpreted hierarchically at the pathway, gene and SNP levels.  Pathway- and gene-level 
results were not corrected for multiple testing due to the exploratory nature of this analysis. 
RESULTS 
Subject characteristics 
The distributions of selected characteristics of the 1815 EOC cases and 1900 controls are 
summarized by study site and case-control status in Table 2.3. Despite frequency-matching on 
age-group, cases were older (60.0 + 11.6 years) than controls (56.8 + 12.0 years) (P<0.0001). As 
compared to controls, cases tended to have lower education levels (P<0.0001), a higher number 
of LOC (P<0.0001), were less likely to have used oral contraceptives (OC) (P=0.002), had longer 
duration of HRT use (P<0.0001), and a higher number of pack-years of cigarettes smoked 
(P<0.0001).  
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Association Testing Results: 
 Results from association testing for mtDNA and the 3 nDNA pathways are presented in a 
tiered approach, beginning with evaluation at the pathway-level, followed by gene- and SNP-
level results. At the pathway and gene levels, we focused on results significant at empirical 
P<0.10. At the SNP level, we focused on results significant at P<0.05 and EMP1<0.05. 
Adjustment for the first principal component representing European ancestry did not change 
parameter estimates and CIs appreciably, so results from simple models are presented. We 
comment on in silico findings where appropriate, and report on haplotype effects with global 
P<0.05.   
Mitochondrial DNA (mtDNA). Pathway analysis revealed that inherited variation in 
mtDNA (17 genes/regulatory regions, 24 SNPs analyzed) was not significantly associated with 
EOC risk (empirical P=0.510), therefore, gene- and SNP- level results are interpreted with 
caution.  At the gene-level, only MT-CO1 (cytochrome c oxidase 1) was associated with risk 
(empirical P=0.006) (Table 2.4). At the SNP-level, a synonymous SNP in MT-CO1, T6777C 
(OR: 0.68, 95%CI: 0.51-0.92, P=0.006) appeared to decrease risk (Table 2.5), consistent with 
haplotype analysis (data not shown).   
Mitochondrial biogenesis (BIO). Of the three nDNA pathways studied, only the 25 
genes (1051 SNPs) involved in mitochondrial biogenesis had a pathway-wide association with 
EOC risk (empirical P= 0.050). At the gene-level, NRF1 (nuclear respiratory factor 1) had the 
strongest result (empirical P=0.041). Four other genes also demonstrated gene-wide associations, 
including MTERF (mitochondrial transcription termination factor), PPARGC1A (peroxisome 
proliferator-activated receptor gamma, coactivator 1 alpha), ESRRA (estrogen-related receptor 
alpha), and CAMKD (calcium/calmodulin-dependent protein kinase D), with empirical P-values 
of 0.044, 0.060, 0.066, and 0.067, respectively (Table 2.4).   
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Association results for BIO SNPs significantly associated with EOC risk are displayed in 
Table 2.5.  For NRF1, the strongest association with EOC risk was observed under a recessive 
model with rs10245560 (OR (95% CI) =0.80 (0.68-0.95), P=0.010) (Figure 2.2.A). MTERF 
includes several sets of correlated risk-associated SNPs (Figure 2.2.B), with ORs ranging from 
0.89-2.90. PPARGC1A contains 20 statistically significant risk-associated SNPs, the majority of 
which flank the 5’ or 3’ UTR, including several correlated SNP-pairs (Figure 2.2.C). ESRRA 
contains rs11600990, a SNP associated with decreased risk under a dominant model (OR (95% 
CI) =0.83 (0.72-0.97), P=0.016)) that was predicted by SNPinfo to reside in a putative 
transcription factor binding site (TFBS). Finally, we identified several intronic SNPs in 
CAMK2D, including rs2040742, a predicted intronic enhancer by FastSNP associated with 
decreased risk (Figure 2.2.D).  After adjustment for lifetime ovulation, HRT use, and pack-years 
smoked, similar magnitudes of association were observed for the majority of BIO SNPs depicted 
in Table 2.5, although associations seemed to strengthen for several SNPs in MTERF, 
PPARGC1A, and CAMK2D.  
 Steroid hormone metabolism (HOR).  Inter-individual variation within steroid hormone 
metabolism pathway (9 genes, 532 SNPs analyzed) was not significantly associated with EOC 
risk (empirical P=0.35), so gene- and SNP-level results are interpreted cautiously. ESR2 (estrogen 
receptor 2) is the only HOR gene that was associated with EOC risk (empirical P=0.026) (Table 
2.4). Four intronic ESR2 SNPs were individually associated with EOC risk (Table 2.5), and a 
haplotype block including rs1256062, rs1256061, and rs12435857 was associated with a slightly 
increased risk under an additive model (OR=1.22, 95% CI: 1.01-1.49, global P=0.029) (Figure 
2.2.E).   
Oxidative phosphorylation (OXP).  Overall, the OXP pathway (73 genes, 1043 SNPs) 
was not statistically significantly associated with EOC risk (empirical P=0.68) (Table 2.4).  
Individually, seven OXP genes demonstrated statistically significant gene-level empirical P-
 17
values, and TUFM (Tu translation elongation factor) had the strongest gene-level result 
(empirical P=0.014, Table 2.4).  At the SNP level, TUFM rs9972768 resides in a putative TFBS 
and is associated with an 11% increased risk with each copy of the minor allele (Table 2.5).  
SNP-environment interaction analysis: 
 Due to the global significance of the BIO pathway, exploratory models were fitted to test 
interactions between the 51 risk-associated BIO SNPs (Table 2.5) and a set of a priori determined 
non-genetic variables linked to oxidative stress: lifetime ovulation, HRT use, cigarette smoking, 
and menopausal status.  This analysis was limited to a dominant genetic effect, for a total of 204 
tests (51 SNPs x 4 non-genetic factors).  There were 8 interactions significant at P<0.05, close to 
the expected value of 10 based on chance alone, and they involved SNPs from MTERF, 
PPARGC1A, and CAMK2D. Most noteworthy, stratified analyses showed MTERF SNPs 
rs10488506 and rs12667992 were risk factors among ever smokers (OR (95% CI) =1.44 (1.09-
1.91), P=0.011) but not never smokers (OR (95% CI) =0.98 (0.77-1.24), P=0.87). PPARGC1A 
rs1509241 was a risk factor among pre/peri-menopausal women (OR (95% CI) =0.71 (0.56-0.90), 
P=0.004) but not post-menopausal women (OR (95% CI) =0.99 (0.83-1.19), P=0.95). HRT use 
appeared to modify the association between CAMK2D rs13107662 and EOC risk, with an inverse 
association observed among ever users (OR (95% CI) =0.72 (0.58-0.89), P=0.003) but no 
association among never users (OR (95% CI) =0.98 (0.82-1.16), P=0.80).  
DISCUSSION 
Multiple lines of evidence, including animal, in vivo, and epidemiologic studies, point to 
a role for oxidative stress in the etiology and/or progression of EOC 69-71,97-101. This report 
explored the hypothesis that inherited variation in mitochondrial-related genes may influence 
EOC risk by contributing to oxidative stress using a large, homogeneous study population of 
1,815 incident pathologically-confirmed Caucasian EOC cases and 1,900 controls. The analysis 
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focused on 128 mtDNA-encoded SNPs from 22 genes and 8 regulatory regions and 2839 nDNA-
encoded SNPs from 138 genes having functions related to mitochondrial biogenesis, steroid 
hormone metabolism, and oxidative phosphorylation.  We considered various genetic models, 
haplotypes, gene and pathway-level analyses, in silico findings, and evaluation of potential 
confounders and effect modifiers. Findings suggest that inter-individual variation in key genes 
involved in mitochondrial biogenesis represent important contributors to EOC susceptibility that 
merit further investigation.  
Mitochondrial biogenesis, the continuous recycling and regeneration of mitochondria, is 
important due to the DNA damage endured by these organelles over a lifetime. Consequences of 
defective mitochondrial biogenesis include aging, neuromuscular diseases, ovarian insufficiency, 
and cancer 131-134. This process is influenced by environmental stimuli (i.e. temperature, 
nutrients, hormones, exercise) that change the energetic and physiological conditions of the 
cell and in turn increase intracellular calcium concentrations which stimulate kinases to 
activate mitochondrial gene transcription 105. Based on evidence that mitochondrial biogenesis is 
repressed in cancer cells due to the acquisition of a glycolytic phenotype for ATP production 
rather than depending on OXPHOS 132 and the fact that re-activation of mitochondrial biogenesis 
can induce apoptosis in cancer cells 131, knowledge gained regarding molecular factors that 
influence mitochondrial biogenesis in EOC may have implications for biomarker development 
and therapeutics.  
At the transcriptional level, mitochondrial biogenesis is complex because it involves 
coordinated expression of more than 1000 genes and cooperation of two genomes. Two classes 
of nDNA-encoded regulatory proteins direct nuclear-mitochondrial interactions and promote 
mitochondrial biogenesis 105. The first class comprises transcription factors (TF) that enable 
bidirectional mtDNA transcription, including factors necessary for promoter recognition, 
activation, and termination. MTERF, identified in our study as an EOC risk factor, regulates 
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OXPHOS by acting as an mtDNA transcript terminator, initiator, and controller of mtDNA 
replication 135.  We observed what appeared to be independent association signals deriving 
from different MTERF gene regions, many of which strengthened after accounting for 
confounding by and/or interaction with HRT use and smoking history. To our knowledge, this 
is the first report that has implicated MTERF in cancer development.  The second class of TF 
includes nuclear respiratory factors, coactivators, and ubiquitous factors 106,133,136, and our 
study highlighted genes from these respective groups, including NRF1, PPARGC1A, and 
ESRRA and CAMK2D.  
In response to oxidative stress, NRF1 activates transcription of antioxidant and 
detoxification genes 137. Our findings of significant NRF1 gene- and SNP-level associations 
(and identification of a high proportion of associated NRF2 SNPs) appear promising in light of 
a growing body of evidence regarding the role for nuclear respiratory factors, especially 
NRF2, in chemoprevention and therapeutics 138.  PPARGC1A modulates the regulatory 
function of most mitochondrial proteins 139 and serves as a coactivator for ESRRA, an inducer 
of mitochondrial biogenesis and regulator of OXPHOS and oxidative stress defenses 139,140.  In 
ovarian tumors, a PPARGC1A-ESRRA pathway has been shown to regulate expression of 
VEGF (vascular endothelial growth factor), a positive regulator of angiogenesis 141.  
Furthermore, over-expression of PPARGC1A and ESRRA has been associated with poor EOC 
prognosis, suggesting these genes may be useful therapeutic targets 142,143. CAMK2D is part of 
the serine/threonine kinases involved in calcium signaling necessary for initiating 
mitochondrial biogenesis 106; these kinases have been dysregulated in various malignancies 
and participate in cell growth, apoptosis, and angiogenesis 144.  
Taken together, these data underscore the role of mitochondrial biogenesis genes in 
oxidative stress and cancer.  It therefore seems biologically plausible that functional SNPs in 
these candidate genes may promote altered mitochondrial function and ovarian carcinogenesis.  
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Furthermore, exploratory interaction analyses suggest that BIO SNPs may exert their effects 
on cancer risk in combination with certain non-genetic factors, including HRT and cigarette 
smoking, both of which are suspected EOC risk factors 96.   
Given that the HOR, OXP, and mtDNA pathways were not associated with EOC risk 
in our study, caution should be taken when interpreting gene- and SNP-level results.  
Consistent with our finding of gene- and SNP-level associations between ESR2 and EOC risk, 
studies support a role for ESR2 in mitochondrial dysfunction, oxidative stress, and ovarian 
carcinogenesis 110,145,146. Based on data suggesting cross-talk between ESR2 and BIO gene, 
ESRRA 147, the possibility remains that stimulation of mitochondrial proteins by steroid 
hormones may cause altered mitochondrial biogenesis and function, leading to hormone-
related cancers. All nDNA-encoded subunits of the OXP pathway were encompassed on the 
610K array; collectively this pathway may not have been associated with EOC risk because 
expression of these enzymes is most critical in tissues or organs with high energy demands 
(i.e. muscle, brain, heart). However, given the role for OXP enzymes in ovaries and female 
reproductive function, additional research may be warranted in this area 148.  Most mtDNA 
variants are rare (MAF< 1%), possibly due to negative selection of germline changes during 
evolution 149 limiting power to detect SNP-level and higher associations.  Although our 
coverage of mtDNA genes and SNPs is greater than other studies 111,115,117, the array did not 
encompass one polypeptide (ATPase 8) and 14 of 22 tRNAs. Further research is necessary to 
clarify the role of these mtDNA-encoded genes in ovarian carcinogenesis.   
The current study did not evaluate other types of nDNA-encoded SNPs that may 
impact oxidative stress, such as those that influence antioxidant defenses (i.e. MPO, GSTM1), 
DNA repair (i.e. MGMT, XRCC1), carcinogen metabolism (i.e., CYP1A1, GST), and 
inflammation (i.e. TNF-α, IL-6), because they have been previously examined 68,150. 
Mitochondrial variants in genes influencing intrinsic apoptosis (i.e. caspases, APAF1) may alter 
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EOC risk and should be explored. Another limitation pertains to our sub-analysis in which we 
evaluated whether lifetime ovulation, HRT, and cigarette smoking may confound or modify 
observed SNP-EOC risk associations.  Because we generated crude estimates of lifetime 
ovulation that did not consider anovulatory periods due to breastfeeding, menstrual irregularities, 
or incomplete pregnancies, 151 this measurement lacks precision, and observed associations may 
be attenuated.  Furthermore, we lacked data on HRT formulation and could not consider effects 
of unopposed estrogen therapy separately from combined estrogen-progestin HRT. Although sub-
analyses were based on only 72% of our study sample, their profile did not appear to 
systematically differ from the entire study population (data not shown), and comparison of 
parameter estimates for individual SNPs using simple and full models generally showed 
magnitudes of association similar in direction and strength (Table 2.5).  
In summary, this study reports the largest number of inherited mitochondrial 
polymorphisms, genes, and pathways to date for associations with EOC risk, and is the first to 
suggest that SNPs in mitochondrial biogenesis genes represent novel EOC susceptibility loci.  
Major strengths include the large, homogenous study population, the high quality genotype data, 
well-annotated clinical and epidemiologic data, and tiered analytic approach that allowed us to 
minimize the impact of multiple comparisons and better control the type I error rate. Based on 
internal consistency and biologic plausibility, functional validation of the most promising SNPs 
identified and characterized as part of this research is warranted.  Furthermore, due to the 
heterogeneous nature of EOC 96, examination of histology-specific effects in larger sample sizes 
is needed. A deeper understanding of the complex mechanisms implicated in mitochondrial 
biogenesis and oxidative stress may aid in the development of novel strategies to reduce 
morbidity and mortality from this disease.  
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Figure 2.1. Schema illustrating how mitochondrial SNPs and other factors may contribute 
to oxidative stress and ovarian carcinogenesis. Polymorphisms in mtDNA and/or several 
categories of nDNA may interact with one another or with other non-genetic endogenous  
and exogenous exposures to contribute to slight changes in encoded proteins over time, 
leading to altered OXPHOS activity and oxidative stress.  An accumulation of ROS may   
promote DNA damage and genetic instability, increased concentrations of calcium, and altered  
expression of genes involved in cellular proliferation and apoptosis, including oncogenes  
and tumor suppressor genes. This process may ultimately promote ovarian cancer 
development. 
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          Table 2.1. Characteristics of participating epithelial ovarian cancer case-control studies  
Study 
 
Study 
Period 
(month/
year) 
Age range at 
diagnosis/ 
Interview 
(years) 
 
Case 
ascertainment 
 
Control ascertainment 
% White, 
Non-
Hispanic 
Participation 
Ratesa 
(Cases vs. 
Controls) 
MAY 
 
1/00-
11/07 20+ 
Mayo Clinic’s gynecologic 
surgery & oncology 
departments; residents of 
six-state surrounding 
region (MN, IA, WI, IL, 
ND, SD). 
Women from the same 
geographic region 
seeking general medical 
examination through 
Mayo’s departments of 
primary care and internal 
medicine. 
95 84% vs 65% 
NCO 
 
1/99-
11/07 20-74 
Rapid case ascertainment 
(i.e. frequent contact with 
local hospitals and 
physicians); residents of 
contiguous 48-county 
region. 
 
Random digit dialing 
targeted towards women 
residing in the same 
region 
83 70% vs 63% 
TBO 
 
12/00-
9/03 and 
12/05-
2/10 
18-80 
Rapid ascertainment (i.e. 
frequent contact with 7 
regional gynecologic 
oncologists); residents of a 
2-county, heavily 
populated region. 
Women attending a local 
screening clinic for 
routine mammography 
91 87% vs. NA 
TOR 
 
1/95-
12/99 
and 
1/03-
12/04 
20-79 Ontario Cancer Registry. 
Women receiving routine 
screening  (i.e. blood 
pressure checks, 
mammograms, 
cholesterol screening) at 
the Women’s College 
Hospital 
93 64% vs. 95% 
   Abbreviations: MAY=Mayo Clinic Ovarian Cancer Study (Rochester, MN); NCO=North Carolina Ovarian Cancer Study (Durham, NC);  
   TOR=Familial Ovarian Tumor Study (Ontario, Canada); TBO= Tampa Bay Ovarian Cancer Study (Tampa, FL); NA=Not available 
                           a Indicates % of those invited to participate (after excluding those who had died, were too sick, unable to provide informed consent, etc
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 Table 2.2. List of investigated mtDNA and nDNA genes and number of SNPs analyzed by pathway  
Pathway Gene abbreviations 
# SNPs 
on 610K 
array 
# SNPs 
passing  
QC 
# SNPs 
with 
MAF > 0.05 
a 
mtDNA (N=22 genes + 8 regions)     
    Polypeptides (n=12) MT-ATP6,  MT-COI, MT-COII, MT-COIII, MT-CYTB, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6 91 85 10 
    tRNAs (n=8) MT-TR, MT-TN, MT-TD, MT-TC, MT-TQ, MT-TG, MT-TL2, MT-TT 10 10 2 
    rRNAs (n=2) MT-RNR1, MT-RNR2 14 13 5 
    Displacement (D)-Loop region MT-DLOOP, MT-CSB-1, MT-HV2, MT-HV3, MT-TFX 19 16 5 
    Miscellaneous MT-ATT, MT-NCL, MT-NC7  4 4 2 
                                          Subtotal  138 128 b 24 
nDNA (N=142 genes)     
    Mitochondrial Biogenesis   
    (BIO) (n=35)          
ATF2, C10ORF2, CAMK2A, CAMK2B, CAMK2D, CAMK2G, CAMK4, CREB1, 
ESRRA, HCFC1,  MAPK1, MTERF, MT01, MYEF2, NFE2L2,  NR1H3, NRF1, 
PPARA, PPARG, PPARGC1A, PPARGC1B, PPRC1, PRKAA1, PRKAA2, PRKAB1, 
PRKCA, SP1, SSBP1, TFAM, TFB1M, TFB2M, THRA, THRB, TRNT1,  YY1 
1194 1135 1051 
    Steroid Hormone Metabolism   
    (HOR) (n=14) 
AR, ESR1, ESR2, HSD17B1, HSD17B3, HSD17B4, HSD17B8, NR3C1 , PGR, POMC, 
RARA, RARB, RARG, SRD5A2 635 584 532 
     Oxidative Phosphorylation 
     (OXP) (n=93) 
ATP5A1, ATP5C1, ATP5D, ATP5F1, ATP5G1, ATP5G2, ATP5G3, ATP5H, ATP5J, 
ATP5L, ATP5O, ATPAF1, COX10, COX11, COX15, COX17, COX4I1, COX4I2, 
COX5A, COX5B, COX6A1, COX6B1, COX6B2, COX6C, COX7A1, COX7A2, 
COX7A2L, COX7B, COX7B2, COX7C, COX8A, COX8C, GAPDH, GFM1, LRPPRC, 
NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA12L, NDUFA3, NDUFA4, 
NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFAB1, NDUFAF1, 
NDUFB1, NDUFB10, NDUFB11, NDUFB2, NDUFB3, NDUFB4, NDUFB5, 
NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS2, 
NDUFS3, NDUFS4, NDUFS5, NDUFS6, NDUFS8, NDUFV1, NDUFV2, NDUFV3, 
NOX1, POLG, PPA2, SCO1, SDHA, SDHB, SDHC, SDHD, SLC25A14, SLC25A4, 
TSFM, TUFM, UCP1, UCP3, UCRC, UQCRB, UQCRC1, UQCRC2, UQCRFS1, 
UQCRH 
1235 1120 1043 
                                       Subtotal  3064 2839 c 2626 
TOTAL  3202 2967 2650 
  Abbreviations: QC=quality control; MAF=minor allele frequency among controls   
   a  Number of successfully genotyped SNPs having MAF > 0.05; data from these common SNPs were utilized in gene-level and pathway- level  analyses.  
   b 128 mtDNA SNPs from all evaluated polypeptides, tRNAs, and rRNAs passed QC (only MT-TFX SNPs in the D-Loop region did not pass QC)     
c 2839 nDNA SNPs from a total of 138 nDNA genes 35 BIO, 90 OXP, 13 HOR) passed QC; of these 2839 SNPs, 133 (4.7%) deviated from Hardy Weinberg 
Equilibrium (HWE) among controls (PHWE <0.05); 142 were expected by chance.
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Table 2.3. Selected characteristics of study participants, stratified by study site and case-control status 
 MAY (N=879) NCO (N=1149) TBO (N=396) TOR (N=1291) 
Variable Cases 
 (n=359) 
Controls 
(n=520) 
Cases 
(n=494) 
Controls 
(n=655) 
Cases 
 (n=227) 
Controls 
(n=169) 
Cases 
(n=735) 
Controls 
(n=556) 
Age (y), b,d, e   mean (SD)  61.2 (12.4) 60.5 (13.3) 57.0 (10.6) 55.1 (11.9) 61.4 (11.5) 59.6 (10.7) 61.0 (11.5) 54.4 (9.9) 
Education achieved a,c,d,e, N (%) 
     No diploma  
     High school diploma  
     Post high school  
     Missing 
 
19 (5) 
123 (34) 
196 (55)  
21 (6) 
 
18 (3) 
125 (24) 
343 (66)  
34 (7) 
 
42 (9) 
160 (32) 
292 (59) 
0 (0) 
 
59 (9) 
177 (27) 
419 (64) 
0 (0) 
 
12 (5) 
85 (37) 
104 (46) 
26 (11) 
 
3 (2) 
13 (8) 
84 (50) 
69 (41) 
 
217 (30) 
189 (26) 
271 (37) 
58 (8) 
 
74 (13) 
134 (24) 
345 (62) 
3 (1) 
Lifetime ovulatory cycles 2, a,b,d,e , N (%) 
       < 332 
       333-460 
       461+  
       Missing  
 
55 (15) 
114 (32) 
88 (25) 
102 (28) 
 
130 (25) 
164 (32) 
87  (17) 
139 (27) 
 
104 (21) 
207 (42) 
157 (32) 
26 (5) 
 
217 (33) 
281 (43) 
141 (22) 
16 (2) 
 
18 (8) 
17 (7) 
18 (8) 
174 (77) 
 
26 (15) 
24  (14) 
11 (7) 
108 (64) 
 
73 (10) 
121 (16) 
365 (5) 
176 (24) 
 
165 (30) 
236 (42) 
139 (25) 
16 (3) 
Parity 1, b,c,d,e   , N (%) 
      Nulliparous 
      1-2 pregnancies 
      3+ pregnancies 
      Missing 
 
60 (17) 
121 (34) 
169 (47) 
9 (3) 
 
74 (14) 
171 (33) 
239 (46) 
36 (7) 
 
99 (20) 
240 (49) 
151(31) 
4(1) 
 
88 (14) 
369 (56) 
198 (30) 
0 (0) 
 
33 (14) 
94 (41) 
100 (44) 
0 (0) 
 
21 (12) 
45 (27) 
43 (25) 
60 (36) 
 
21 (3) 
324 (44) 
217 (30) 
173 (24) 
 
94 (17) 
283 (51) 
179 (32) 
0 (0) 
OC use a,b,c,e , N (%) 
      Never 
      Ever 
      Missing 
 
159 (44) 
190 (53) 
10 (3) 
 
186 (36) 
295 (57) 
39 (8) 
 
170 (34) 
324 (66) 
0 (0) 
 
181 (28) 
474 (72) 
0 (0) 
 
95 (42) 
110 (48) 
23 (10) 
 
29 (17) 
75 (44) 
65 (38) 
 
302 (41) 
376 (51) 
57 (8) 
 
267 (48) 
286 (51) 
3 (1) 
History of Breastfeeding b,c, e , N (%) 
      Never 
      Ever 
      Missing 
 
44 (12) 
NA 
315 (88) 
 
54 (10) 
NA 
466 (90) 
 
356 (72) 
136 (28) 
2 (0.4) 
 
426 (65) 
229 (35) 
0 (0) 
 
111(49) 
60 (26) 
56 (25) 
 
33 (20) 
50 (30) 
86 (51) 
 
227 (31) 
310 (42) 
198 (27) 
 
210 (38) 
346 (62) 
0 (0) 
Menopausal status at diagnosis/ interview 
b,c,d,e , N (%) 
      Pre/peri 
      Post 
      Missing 
 
 
88 (25) 
256 (71) 
15 (4) 
 
 
117 (23) 
367 (71) 
36 (7) 
 
 
135 (27) 
355 (72) 
4 (1) 
 
 
241 (37) 
412 (63) 
2 (0.3) 
 
 
15 (7) 
186 (82) 
26 (11) 
 
 
35 (21) 
114 (67) 
20 (12) 
 
 
486 (66) 
191 (26) 
58 (8) 
 
 
201 (36) 
350 (63) 
5 (1) 
Body Mass Index 3, a        
      (kg/m2),  mean (SD)      27.8 (6.1) 26.8 (5.5) 27.3 (6.4) 27.2 (6.5) 26.5 (6.5) 26.4 (5.3) 26.6 (5.2) 26.5 (4.5) 
Duration HRT use (mo)b,d,e , N (%) 
         60+ 
         1-59 
         Never 
         Missing 
 
50 (14) 
32 (9) 
133 (37) 
144 (40) 
 
106 (20) 
59 (11) 
241 (46) 
114 (22) 
 
140 (28) 
126 (26) 
204 (41) 
24 (5) 
 
133 (20) 
109 (17) 
388 (59) 
25 (4) 
 
65 (29) 
23 (10) 
101 (44) 
38 (17) 
 
32 (19) 
23 (14) 
28 (17) 
86 (51) 
 
104 (14) 
146 (20) 
484 (66) 
1 (0.1) 
 
12 (2) 
166 (30) 
378 (68) 
0 (0) 
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Family history of ovarian or breast cancer in 
>1 FDR   , N (%) 
     No  
     Yes  
     Missing 
 
 
302 (84) 
57 (16) 
0 (0) 
 
 
431 (83) 
89 (17) 
0 (0) 
 
 
439 (89) 
 51 (10) 
4 (0.8) 
 
 
607 (93) 
48 (7) 
0 (0) 
 
 
217 (96) 
10 (4) 
0 (0) 
 
 
165 (98) 
4 (2) 
0 (0) 
 
NA 
 
NA 
Pack-years smoked,a,d,e , N (%) 
        > 20 
        <20 
        None 
        Missing 
 
60 (17) 
63 (18) 
216 (60) 
20 (6) 
 
49 (9) 
96 (18) 
310 (60) 
65 (13) 
 
97 (20) 
110 (22) 
265 (54) 
22 (5) 
 
128 (20) 
166 (25) 
338 (52) 
23 (4) 
 
26 (11) 
20 (9) 
56 (25) 
125 (55) 
NA 
 
195 (27) 
168 (23) 
315 (43) 
57 (8) 
 
36 (6) 
165 (30) 
322 (58) 
33 (6) 
Histology , N (%) 
     Serous 
     Mucinous 
     Endometrioid 
     Clear Cell 
     Mixed Cell 
     Other 
 
228 (63.5) 
11 (3.1) 
71 (19.8) 
24 (6.7) 
21 (5.9) 
4 (1.1) 
- 
 
294 (59.5) 
 20 (4.1) 
 81 (16.4)  
58 (11.7) 
  0 (0) 
 11 (2.2) 
- 
 
146 (65.8) 
13 (5.9) 
28 (12.6) 
12 (5.4) 
23 (10.4) 
0 (0) 
- 
 
402 (54.7) 
57 (7.8) 
154 (21.0) 
47 (6.4) 
9 (1.2) 
66 (9.0) 
- 
Stage, N (%) 
      I 
      II 
      III 
      IV 
      Unknown 
 
67 (18.8) 
26 (7.3) 
203 (57.2) 
59 (16.6) 
0 (0) 
- 
 
77 (15.6) 
84 (17.1) 
328 (66.7) 
0 (0.0) 
3(0.3) 
- 
 
38 (16.7) 
25 (11.0) 
154 (67.8) 
10 (4.4) 
0 (0) 
- NA - 
Grade, N (%) 
      I 
      II 
      III 
      IV    
      Unknown    
13 (3.6) 
45 (12.5) 
174 (48.5) 
121 (33.7) 
6 (1.7) 
- 
65 (13.5) 
138 (28.7) 
277 (57.6) 
1 (0.21) 
0 (0) 
- 
11 (5.5) 
32 (3.1) 
157 (77.7) 
2 (1.0) 
0 (0) 
- NA - 
Percentages were rounded and may not add up to 100. Abbreviations: NA= Data not available; OC=Oral Contraceptive; HRT=Hormone Replacement 
Therapy; FDR=First degree relative. Case-control differences with p<0.05 at MAY, NCO, TBO, TOR, or overall are denoted by superscripts a, b, c, d, 
and e, respectively. 
1 Parity for MAY, NCO, and TOR was based on the number of full-term births resulting from pregnancies lasting at least 6 months. For TBO, parity was 
based on the number of pregnancies, regardless of length or outcome.  2 Distribution is based on tertiles among controls. 3Body mass index was 
calculated using usual adult or current weight for subjects from TOR and TBO, and was calculated using weight 1 year prior to the age at 
diagnosis/interview for MAY and NCO subjects.
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   Table 2.4. Covariate-adjusted pathway-level and gene-level results, sorted by pathway and then alphabetized by gene 
Pathway 
 Chr 
Gene 
(Alias) 
N common SNPs 
analyzed a 
(Total N 
successfully 
genotyped SNPs) 
Empirical  
P Value b 
N common 
SNPs 
associated 
with EOC risk 
(P<0.05) 
Proportion 
common SNPs 
associated with 
EOC risk c 
MtDNA       
 MT MT-ATT 2 (2) 0.7449 0 0 
 MT MT-CO1 1 (12) 0.0055 1 1 
 MT MT-CO3 1 (7) 0.6113 0 0 
 MT MT-CSB1 1 (1) 0.8465 0 0 
 MT MT-DLOOP 2 (10) 0.5713 0 0 
 MT MT-HV3 2 (4) 0.4220 0 0 
 MT MT-ND1 1 (11) 0.5286 0 0 
 MT MT-ND2 1 (14) 0.6088 0 0 
 MT MT-ND3 1 (4) 0.5934 0 0 
 MT MT-ND4 1 (6) 0.5957 0 0 
 MT MT-ND4L 1 (4) 0.4712 0 0 
 MT MT-ND5 2 (10) 0.3678 0 0 
 MT MT-ND6 1 (3) 0.4400 0 0 
 MT MT-RNR1 1 (4) 0.3752 0 0 
 MT MT-RNR2 4 (9) 0.5108 0 0 
 MT MT-TL2 1 (2) 0.3194 0 0 
 MT MT-TR 1 (1) 0.5443 0 0 
MtDNA  
Overall 
- - 24 (128) 0.5149 1 0.04 
       
BIO       
 2 ATF2 8 (8) 0.7768 0 0 
 10 C10orf2 (TWINL) 2 (2) 0.9198 1 0.50 
 5 CAMK2A 27 (28) 0.5046 0 0 
 7 CAMK2B 19 (19) 0.7368 0 0 
 4 CAMK2D 83 (88) 0.0674 15 0.18 
 10 CAMK2G 4 (5) 0.9007 0 0 
 5 CAMK4 65 (67) 0.7474 3 0.05 
 2 CREB1 24 (28) 0.9999 0 0 
 11 ESRRA 1 (2) 0.0656 1 1 
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 X HCFC1 1 (1) 0.4666 0 0 
 22 MAPK1 11 (12) 0.465 0 0 
 7 MTERF 41 (41) 0.0435 16 0.39 
 6 MTO1 5 (6) 0.5263 0 0 
 2 NFE2L2 (NRF2) 13 (14) 0.3872 2 0.15 
 11 NR1H3 (LXR) 3 (3) 0.983 0 0 
 7 NRF1 46 (46) 0.0414 9 0.20 
 22 PPARA 27 (32) 0.5795 0 0 
 3 PPARG 34 (39) 0.8773 0 0 
 4 PPARGC1A 211 (234) 0.0596 35 0.17 
 5 PPARGC1B 62 (64) 0.2058 3 0.05 
 10 PPRC1 4 (4) 0.1001 0 0 
 5 PRKAA1 12 (12) 0.2598 2 0.17 
 1 PRKAA2 10 (11) 0.2903 0 0 
 12 PRKAB1 4 (4) 0.3842 0 0 
 17 PRKCA 134 (145) 0.1746 20 0.15 
BIO Overall - - 1051 (1135) 0.0504 107 0.10 
       
HOR       
 X AR 98 (119) 0.5442 0 0 
 6 ESR1 88 (96) 0.3169 10 0.11 
 14 ESR2 20 (23) 0.0264 5 0.25 
 9 HSD17B3 50 (53) 0.1654 5 0.10 
 5 HSD17B4 28 (32) 0.2264 8 0.29 
 6 HSD17B8 2 (2) 0.2757 0 0 
 5 NR3C1 (GR) 53 (57) 0.4967 5 0.09 
 11 PGR 63 (68) 0.4097 7 0.11 
 2 POMC(ACTH) 1 (1) 0.4347 0 0 
HOR Overall - - 532 (584) 0.3539 40 0.08 
       
OXP       
 18 ATP5A1 5 (5) 0.9026 0 0 
 10 ATP5C1 3 (3) 0.5549 0 0 
 19 ATP5D 1 (1) 0.2318 0 0 
 1 ATP5F1 3 (3) 0.8744 0 0 
 17 ATP5G1 2 (2) 0.9537 0 0 
 12 ATP5G2 7 (7) 0.6896 0 0 
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 2 ATP5G3 28 (33) 0.6739 2 0.07 
 17 ATP5H 4 (5) 0.5653 0 0 
 21 ATP5J 1 (1) 0.9386 0 0 
 11 ATP5L 1 (1) 0.4143 0 0 
 21 ATP5O 11 (11) 0.3064 1 0.09 
 1 ATPAF1 (ATP11) 3 (4) 0.5626 0 0 
 17 COX10 116 (121) 0.6315 8 0.07 
 17 COX11 1 (1) 0.2033 1 1 
 10 COX15 3 (3) 0.5177 0 0 
 3 COX17 3 (3) 0.9804 0 0 
 16 COX4I1 1 (1) 0.0468 0 0 
 20 COX4I2 4 (4) 0.2714 1 0.25 
 15 COX5A 2 (2) 0.5470 0 0 
 2 COX5B 2 (2) 0.5902 0 0 
 12 COX6A1 4 (4) 0.2634 0 0 
 19 COX6B1 2 (3) 0.7059 0 0 
 19 COX6B2 1 (1) 0.1366 1 1 
 8 COX6C 6 (6) 0.8737 0 0 
 19 COX7A1 2 (2) 0.0288 1 1 
 6 COX7A2 4 (4) 0.1742 0 0 
 2 COX7A2L 6 (6) 0.3588 0 0 
 4 COX7B2 23 (24) 0.4200 2 0.09 
 5 COX7C 25 (31) 0.4903 1 0.04 
 11 COX8A 1 (2) 0.8504 0 0 
 14 COX8C 6 (6) 0.0296 2 0.33 
 12 GAPDH 1 (1) 0.3862 0 0 
 3 GFM1 (EFG1) 5 (5) 0.2248 0 0 
 2 LRPPRC 47 (48) 0.4775 8 0.17 
 X NDUFA1 2 (2) 0.5892 0 0 
 2 NDUFA10 47 (49) 0.745 3 0.06 
 19 NDUFA11 5 (5) 0.0409 3 0.60 
 12 NDUFA12 53 (54) 0.0923 11 0.21 
 5 NDUFA12L (NDUFAF2) 17 (19) 0.4994 0 0 
 19 NDUFA3 1 (2) 0.6372 0 0 
 7 NDUFA4 86 (91) 0.2132 10 0.12 
 7 NDUFA5 12 (12) 0.9202 0 0 
 22 NDUFA6 5 (5) 0.1636 0 0 
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 19 NDUFA7 2 (3) 0.9917 0 0 
 9 NDUFA8 22 (23) 0.2203 4 0.18 
 12 NDUFA9 37 (39) 0.2199 7 0.19 
 16 NDUFAB1 7 (8) 0.4654 0 0 
 15 NDUFAF1 1 (1) 0.5799 0 0 
 14 NDUFB1 4 (4) 0.8480 0 0 
 16 NDUFB10 2 (2) 0.0299 1 0.5 
 X NDUFB11 1 (1) 0.8251 0 0 
 2 NDUFB3 1 (1) 0.4356 0 0 
 3 NDUFB4 5 (7) 0.2902 0 0 
 3 NDUFB5 3 (5) 0.2495 0 0 
 9 NDUFB6 11 (11) 0.9713 0 0 
 19 NDUFB7 1 (2) 0.6512 0 0 
 10 NDUFB8 1 (1) 0.7967 0 0 
 8 NDUFB9 2 (2) 0.9792 0 0 
 4 NDUFC1 1 (1) 0.8204 0 0 
 11 NDUFC2 3 (3) 0.8342 0 0 
 2 NDUFS1 12 (14) 0.6102 0 0 
 1 NDUFS2 4 (4) 0.5051 0 0 
 11 NDUFS3 1 (2) 0.8426 0 0 
 5 NDUFS4 54 (57) 0.3664 4 0.07 
 1 NDUFS5 4 (4) 0.9407 0 0 
 5 NDUFS6 19 (20) 0.5845 2 0.11 
 19 NDUFS7 3 (3) 0.3850 0 0 
 11 NDUFS8 3 (3) 0.4710 0 0 
 18 NDUFV2 16 (16) 0.8391 0 0 
 21 NDUFV3 15 (15) 0.8261 0 0 
 X NOX1 5 (6) 0.8986 0 0 
 15 POLG 17 (18) 0.6747 3 0.18 
 4 PPA2 25 (29) 0.4685 2 0.08 
OXP Overall - - 1043 (1120) 0.6777 78 0.07 
  Abbreviations: Chr=chromosome; EOC=epithelial ovarian cancer; BIO=Mitochondrial biogenesis; mtDNA=mitochondrial DNA;  
HOR=steroid hormone metabolism; OXP=oxidative phosphorylation 
Note: Gene-level results are adjusted for age and study site, and were only estimated for genes containing at least one common SNP.  
Pathway-and Gene-level tests with empirical P-values  <0.10 are in bold type. 
a Common SNPs are those having a minor allele frequency of at least 5% among controls; only data for common SNPs was used in  
pathway and gene-level analyses.  
 32
 33
b Empirical P values generated using Fisher’s method and 10,000 permutations of case-control status. 
c Equivalent to the number of common SNPs significantly associated with EOC risk divided by the number of common SNPs analyzed.  
 
              Table 2.5. Top ranked SNP-epithelial ovarian cancer risk associations 
All subtypes 
(1815 cases, 1900 controls) Gene  
(locus) 
SNP 
(Major/Minor Allele) 
 
Location a MAF  
 
P 
HWE 
Model 
b 
 ORsimple (95% CI)c Psimpled 
EMP1 
simple 
e ORfull (95% CI) 
f Pfull g 
EMP1 
full 
h 
MT-CO1 
(MT) MitoT6777C (A/G) - 0.06 - AL 0.68 (0.51-0.92) 0.013 0.006 0.57 (0.38-0.83) 0.003 0.007 
NRF1 
(7q32) rs10245560 (G/A) 
 flanking 5’UTR 0.45 0.18 R 0.80 (0.68 -0.95) 0.010 0.016 0.77 (0.62 -0.94) 0.010 0.012 
 rs2402976 (A/G) intron 0.46 0.46 A 1.12 (1.02 -1.23) 0.016 0.009 1.19 (1.06 -1.33) 0.003 0.004 
 rs1882095 (G/A) flanking 3’UTR 0.34 0.61 A 1.11 (1.00 -1.21) 0.045 0.029 1.13 (1.00 -1.27) 0.044 0.043 
MTERF 
(7q21-q22) rs2540571 (G/A) flanking 3’UTR 0.50 0.46 A 0.89 (0.81 -0.97) 0.012 0.015 0.91 (0.81 -1.02) 0.107 0.069 
 rs2540592 (G/A) k flanking 3’UTR 0.38 0.03 D 1.19 (1.03 -1.36) 0.015 0.012 1.13 (0.96 -1.34) 0.139 0.055 
 rs2540552 (G/A) k flanking 3’UTR 0.38 0.03 D 1.19 (1.03 -1.36) 0.016 0.013 1.13 (0.96 -1.34) 0.141 0.058 
 rs12673563 (G/A) flanking 3’UTR 0.10 0.02 R 2.20 (1.03 -4.79) 0.043 0.038 2.30 (0.97 -5.42) 0.059 0.031 
 
 rs12668203 (A/G) 
i flanking 3’UTR 0.08 1.00 A 1.27 (1.08 -1.49) 0.005 0.019 3.03 (1.35 -6.80) 0.007 0.004 
 rs10488506 (G/A) i flanking 3’UTR 0.07 0.60 A 1.26 (1.06 -1.50) 0.008 0.021 3.12 (1.33 -7.40) 0.009 0.009 
 rs12667992 (G/A) i flanking 3’UTR 0.09 0.31 A 1.22 (1.04 -1.42) 0.016 0.031 2.07 (1.02 -4.20) 0.043 0.068 
 rs6950538 (A/G ) l flanking 3’UTR 0.39 0.73 A 0.90 (0.81 -0.99) 0.031 0.036 0.86 (0.77 -0.97) 0.015 0.041 
 rs6949881 (G/A) l flanking 3’UTR 0.39 0.63 A 0.90 (0.81 -0.99) 0.033 0.036 0.87 (0.77 -0.97) 0.016 0.045 
 rs13229505 (C/A) l flanking 3’UTR 0.39 0.63 A 0.89 (0.81 -0.99) 0.026 0.028 0.87 (0.77 -0.97) 0.016 0.040 
 rs2049314 (G/A) l flanking 3’UTR 0.39 0.74 A 0.89 (0.81 -0.98) 0.019 0.020 0.86 (0.77 -0.97) 0.012 0.033 
 rs9656002 (G/A) l flanking 3’UTR 0.39 0.77 A 0.89 (0.81 -0.98) 0.023 0.023 0.87 (0.77 -0.97) 0.016 0.038 
 rs974508 (G/A) flanking 3’UTR 0.09 0.16 R 2.90 (1.32 -6.36) 0.008 0.014 3.84 (1.58 -9.36) 0.003 0.001 
 rs2269811 (A/G) j intron 0.10 0.02 R 2.89 (1.31 -6.34) 0.008 0.015 3.30 (1.39 -7.82) 0.007 0.014 
 rs7781767 (G/A) j flanking 5’UTR 0.10 0.02 R 2.82 (1.29 -6.19) 0.010 0.011 3.26 (1.40 -7.66) 0.007 0.010 
PPARGC1A 
(4p15.1) rs13151220 (C/A) 
m flanking 3’UTR 0.08 1.00 A 1.21 (1.02 -1.42) 0.028 0.025 1.11 (0.91 -1.35) 0.317 0.073 
 rs13143346 (G/A) m flanking 3’UTR 0.08 1.00 A 1.19 (1.01 -1.41) 0.039 0.038 1.09 (0.90 -1.33) 0.390 0.101 
 rs1509241 (A/G) flanking 3’UTR 0.45 0.71 R 0.84 (0.71 -1.00) 0.048 0.010 0.92 (0.75 -1.13) 0.427 0.110 
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 rs12498626 (G/A) flanking 3’UTR 0.12 0.75 D 1.17 (1.01 -1.37) 0.042 0.042 1.26 (1.05 -1.52) 0.014 0.014 
 rs6857002 (A/C) flanking 3’UTR 0.24 0.35 D 1.18 (1.03-1.35) 0.015 0.020 1.26 (1.07 -1.48) 0.005 0.012 
 rs4697041 (G/A) flanking 3’UTR 0.37 0.46 A 1.12 (1.02 -1.24) 0.021 0.026 1.11 (0.98 -1.25) 0.092 0.023 
 rs2970882 (A/G) flanking 3’UTR 0.35 0.76 A 0.90 (0.82 -0.99) 0.044 0.030 0.87 (0.77 -0.98) 0.023 0.026 
 rs7682765 (A/G) intron 0.06 0.34 R 3.84 (1.37 -10.8) 0.011 0.005 5.14 (1.62 -16.3) 0.005 0.009 
 rs4550905 (A/G)  intron 0.32 0.96 A 0.87 (0.78 -0.96) 0.005 0.009 0.87 (0.77 -0.98) 0.025 0.017 
 rs4361373 (A/G) intron 0.18 0.47 A 0.84 (0.74 -0.95) 0.006 0.013 0.85 (0.73 -0.98) 0.029 0.024 
 rs10030083 (C/A) flanking 5’UTR 0.10 1.00 D 1.19 (1.01 -1.41) 0.038 0.034 1.30 (1.06 -1.60) 0.011 0.105 
 rs13108219 (C/A) flanking 5’UTR 0.11 0.49 A 1.22 (1.06 -1.40) 0.007 0.004 1.21 (1.02 -1.44) 0.028 0.038 
 rs4697429 (A/G) flanking 5’UTR 0.20 0.15 A 1.13 (1.01 -1.27) 0.031 0.008 1.17 (0.99 -1.38) 0.066 0.070 
 rs9291455 (G/A) n flanking 5’UTR 0.15 0.59 A 1.15 (1.01 -1.30) 0.039 0.039 1.16 (0.99 -1.36) 0.061 0.073 
 rs16874486 (A/G) n flanking 5’UTR 0.15 0.47 A 1.15 (1.01 -1.31) 0.034 0.027 1.20 (1.00 -1.43) 0.044 0.092 
 rs16874509 (G/A) n flanking 5’UTR 0.17 0.10 A 1.13 (1.00 -1.28) 0.044 0.045 1.22 (1.03 -1.45) 0.025 0.064 
 rs16874778 (C/A) flanking 5’UTR 0.29 0.06 D 1.17 (1.03 -1.34) 0.018 0.019 1.28 (1.09 -1.51) 0.003 0.015 
 rs640050 (G/A) flanking 5’UTR 0.38 0.36 A 1.11 (1.01 -1.22) 0.031 0.020 1.25 (1.06 -1.48) 0.009 0.048 
 rs614457 (C/A) flanking 5’UTR 0.34 0.09 D 1.17 (1.02 -1.33) 0.026 0.010 1.22 (1.03 -1.43) 0.018 0.021 
 rs7680610 (G/A) flanking 5’UTR 0.35 3E-3 R 0.78 (0.63 -0.95) 0.015 0.025 0.79 (0.61 -1.01) 0.059 0.005 
ESRRA 
(11q13) rs11600990 (G/A) intron 0.16 0.40 D 0.83 (0.72 -0.97) 0.016 0.042 0.91 (0.76 -1.09) 0.299 0.418 
CAMK2D 
(4q26) rs3733619 (A/G) flanking 3’UTR 0.10 0.90 A 1.22 (1.05 -1.42) 0.009 0.014 1.18 (0.98 -1.41) 0.079 0.044 
 rs7684418 (G/A) flanking 3’UTR 0.09 0.05 R 2.57 (1.02 -6.46) 0.045 0.034 5.11 (1.34 -19.5) 0.017 1.000 
 rs1525000 (A/G) intron 0.40 0.08 R 0.80 (0.66 -0.96) 0.017 0.008 0.76 (0.61 -0.96) 0.019 0.124 
 rs7697831 (G/A) intron 0.20 0.14 D 1.17 (1.02 -1.34) 0.028 0.009 1.14 (0.99 -1.31) 0.057 0.023 
 rs17630328 (A/C) intron 0.07 0.39 A 1.24 (1.04 -1.47) 0.016 0.020 1.30 (1.06 -1.60) 0.014 0.021 
 rs10033037 (A/G) intron 0.15 0.24 A 1.17 (1.03 -1.32) 0.018 0.020 1.13 (0.97 -1.32) 0.114 0.086 
 rs13107662 (A/G) intron 0.35 0.45 A 0.88(0.80 -0.98) 0.018 0.014 0.90 (0.77 -1.06) 0.204 0.036 
 rs1029471 (A/G) intron 0.18 0.88 A 1.13 (1.01-1.28) 0.039 0.039 1.14 (0.97 -1.35) 0.123 0.223 
 rs764830 (A/G) intron 0.37 0.07 R 1.23 (1.02 -1.49) 0.034 0.040 1.19 (0.95 -1.50) 0.133 0.025 
 rs6533711 (A/G) intron 0.38 1.00 R 1.22 (1.02 -1.46) 0.032 0.028 1.21 (0.97 -1.50) 0.093 0.011 
 rs6842343 (A/G) o intron 0.08 1.00 A 0.82 (0.69 -0.98) 0.033 0.049 0.78 (0.63 -0.96) 0.020 0.016 
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 rs2040742 (A/G) o intron 0.08 1.00 A 0.82 (0.69 -0.98) 0.030 0.045 0.77 (0.62 -0.96) 0.019 0.017 
ESR2 
(14q23.2) rs1256062 (A/G) intron 0.10 0.21 A 1.19 (1.03 -1.38) 0.021 0.025 1.16 (0.97 -1.39) 0.106 0.319 
 rs1256061 (C/A) p intron 0.49 0.71 R 0.82 (0.69 -0.95) 0.010 0.012 0.81 (0.67 -0.98) 0.033 0.017 
 rs12435857 (G/A) p intron 0.47 0.64 R 0.79 (0.67 -0.93) 0.006 0.006 0.88 (0.79 -0.99) 0.032 0.026 
 rs6573553 (A/C) intron 0.48 0.68 A 1.11 (1.01 -1.22) 0.032 0.021 1.12 (1.00 -1.26) 0.053 0.019 
TUFM 
(16p11.2) rs9972768 (A/C) flanking 5’UTR 0.38 0.63 A 1.11 (1.00 -1.22) 0.043 0.031 1.14 (1.01 -1.28) 0.029 0.055 
COX7A1 
(19q13.1) 
rs753420 (A/C) 5’UTR 0.26 0.63 R 1.37 (1.07 -1.75) 0.013 0.007 1.48 (1.10 -1.99) 0.010 0.001 
COX8C 
(14q32.12) rs6575325 (G/A) 
q flanking 3’UTR 0.29 0.41 A 1.16 (1.04 -1.28) 0.005 0.011 1.14 (1.01 -1.29) 0.038 0.022 
 rs1503959 (A/C) q flanking 3’UTR 0.29 0.54 A 1.16 (1.04 -1.28) 0.006 0.012 1.13 (1.00 -1.28) 0.049 0.023 
NDUFB10 
(16p13.3) 
rs758335 (G/A) intron 0.19 0.05 D 0.80 (0.69 -0.92) 0.002 0.004 0.82 (0.70 -0.98) 0.027 0.021 
NDUFA11 
(19p13.3) rs1674159 (G/A) flanking 3’UTR 0.13 0.10 D 1.21 (1.04 -1.41) 0.017 0.044 1.22 (1.01 -1.46) 0.036 0.062 
 rs10421538 (G/A) intron 0.21 0.83 A 1.17 (1.05 -1.32) 0.006 0.019 1.23 (1.08 -1.41) 0.003 0.010 
NDUFA12 
(12q22) rs10777629 (A/G) flanking 3’UTR 0.22 0.23 D 0.83 (0.73 -0.96) 0.009 0.023 0.85 (0.72 -1.00) 0.050 0.050 
 rs10777647 (A/G) flanking 3’UTR 0.40 0.47 A 1.12 (1.02 -1.24) 0.020 0.021 1.15 (1.03 -1.30) 0.018 0.045 
 rs6538566 (C/A) flanking 3’UTR 0.23 0.56 A 0.87 (0.77 -0.97) 0.015 0.018 0.63 (0.43 -0.92) 0.016 0.034 
 rs7965624 (G/A) r flanking 3’UTR 0.38 0.01 R 0.75 (0.62 -0.90) 0.003 0.005 0.72 (0.57 -0.91) 0.005 0.003 
 rs2052741 (A/G) flanking 3’UTR 0.48 1E-3 R 0.74 (0.63 -0.87) 2E-4 0.001 0.68 (0.56 -0.83) 1E-4 2E-4 
 rs7306940 (G/A) r flanking 3’UTR 0.37 0.02 A 0.88 (0.79 -0.96) 0.007 0.020 0.74 (0.58 -0.93) 0.012 0.006 
 rs2081595 (C/A) flanking 3’UTR 0.49 0.18 A 1.13 (1.03 -1.24) 0.010 0.017 1.13 (1.01 -1.27) 0.029 0.011 
 rs2033092 (G/A) flanking 3’UTR 0.39 0.25 D 0.83 (0.72 -0.95) 0.008 0.011 0.82 (0.73 -0.92) 0.001 0.001 
 rs7133343 (C/A) flanking 3’UTR 0.33 0.88 A 0.91 (0.81 -1.00) 0.042 0.024 0.86 (0.76 -0.97) 0.014 0.010 
 rs11107851 (A/G) intron 0.21 0.45 R 1.44 (1.06 -1.96) 0.019 0.045 1.45 (1.01 -2.07) 0.042 0.027 
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Abbreviations: MT=Mitochondrial DNA; MAF=minor allele frequency among controls; PHWE =P-value for deviation from Hardy Weinberg Equilibrium among 
controls (PHWE <0.05); OR (CI) = Odds ratio (confidence interval);  a  SNP location was derived from the Illumina Infinium 610K Array annotation file that obtains 
this information from GenBank, a genetic sequence database, along with dbSNP; b Best-fitting genetic model (A = Log-additive; D = Dominant; R = Recessive; 
AL=Allelic); c OR and 95% CI adjusted for the simple model (age at diagnosis/interview (continuous)and study site (indicator variable for NCO, TOR, and TBO), d  
Asymptotic P-value for testing the genetic effects related to overall ovarian cancer risk before permutation testing using the simple model. P-value under an additive 
model represents P-trend. e Empirical point-wise P-value for testing the genetic effects related to overall ovarian cancer risk using the simple model; f OR and 95% 
CI adjusted for the full model (age at diagnosis/interview (continuous), study site (indicator variable for NCO, TOR, and TBO), LOC category (low, medium, high), 
duration of hormone replacement therapy (HRT) use (continuous), and pack-years of cigarettes smoked (continuous)).  g Asymptotic P-value for testing the genetic 
effects related to ovarian cancer risk before permutation testing using the full model. h Empirical point-wise P-value for testing the genetic effects related to ovarian 
cancer risk using the full model;  All P-values are two-sided.  iSNP pair(s)  in linkage disequilibrium (0.76<r2<0.87); jSNP pair in linkage disequilibrium (r2=0.97); k, 
m, o, q, r, t SNP pair(s) in linkage disequilibrium (r2=1.0); l  SNP pair(s) in linkage disequilibrium (0.97<r2<0.99); n SNP pair(s) in linkage disequilibrium (0.86<r2<1.0); 
p SNP pair(s) in linkage disequilibrium (r2=0.86).  Sorted by level of nDNA pathway-level significance and gene-level significance and then by SNP position (base 
pair).   Only SNPs in genes with gene-level P < 0.05 are listed, and only SNPs with P<0.05 and EMP1<0.05 are listed. 
 
 
 
 
 
 
 
 Figure 2.2. Linkage disequilibrium plots for selected gene regions. Linkage disequilibrium (LD) plots for selected 
gene regions.  A. NRF1 B. MTERF C. PPARGC1A D. CAMK2D  E. ESR2.  These plots are based on the 3,715  
genotyped subjects (1815 cases, 1900 controls), and were generated in Haploview 4.1 (Barrett, 2005) using the solid  
spline LD method.  Numbers represent r2 * 100, and are based on genome build 36.3; r2 = 0 =white=not correlated and 
r2 = 1= black=completely correlated.  The spline LD method suggests that SNPs at the edges of each block are in LD  
with some intermediate SNPs, but that intermediate SNPs are not necessarily in LD with each other.
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CHAPTER 3: 
 
POLYMORPHISMS IN LIN28B INFLUENCE  
EPITHELIAL OVARIAN CANCER SUSCEPTIBILITY 
 
ABSTRACT 
 MicroRNAs (miRNAs) are short non-coding RNA molecules that function as post-
transcriptional regulators of nearly one-third of human protein-coding genes.  Since defective 
miRNA biogenesis has been shown to contribute to the development and progression of epithelial 
ovarian cancer (EOC), we hypothesized that single nucleotide polymorphisms (SNPs) in miRNA 
biogenesis genes may influence EOC risk.  In stage 1 we evaluated 318 SNPs in 18 genes among 
1,815 EOC cases and 1,900 controls.  In a stage 2 replication, we conducted a joint meta-analysis 
utilizing data from an additional 2,172 cases and 3,052 controls.   Of 23 SNPs from 9 genes 
associated with risk (empirical P<0.05) during stage 1, meta-analysis replicated 6 SNPs from 4 
genes (DROSHA, FMR1, LIN28, LIN28B) with combined P<0.05, including rs12194974 (G>A), 
a SNP in a putative transcription factor binding site in the LIN28B promoter (summary OR=0.90, 
95% CI: 0.82-0.98; P=0.015). Consistent with evidence of LIN28B over-expression in EOC, we 
provide data to suggest that the inverse association among rs12194974 A allele carriers may be 
due to reduced LIN28B expression.  Variants in miRNA biogenesis genes, particularly LIN28B, 
appear to influence EOC susceptibility. 
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INTRODUCTION 
Epithelial ovarian cancer (EOC) is an important cause of morbidity and mortality (1). 
Given that most cases present with advanced, incurable disease, high-risk women should be 
targeted for primary prevention and early detection. Identification of genetic susceptibility 
markers may help in this endeavor, and inter-individual differences impacting post-transcriptional 
regulation is largely unexplored.  
MicroRNAs (miRNAs) are a class of evolutionarily conserved 19-25 nucleotide long 
non-protein encoding RNAs that function as post-transcriptional regulators by binding to the 3’ 
untranslated region (UTR) of target messenger RNA (mRNA), causing translational inhibition 
and/or mRNA degradation (2, 3). Ovarian tumors exhibit differential miRNA expression profiles 
compared to normal tissues (4), and defective miRNA biogenesis may influence miRNA 
expression, tumorigenesis, and clinical outcomes (2, 5). In EOC, down-regulation of DICER and 
DROSHA and up-regulation of LIN28 and LIN28B have been associated with altered miRNA 
levels and reduced patient survival (6-9). SNPs in miRNA biogenesis genes may influence cancer 
risk by altering miRNA expression (10), and although associations between such SNPs and 
cancer risk have been reported (11-14), no comprehensive studies of EOC have been published.  
In the current investigation, we used a two-stage approach to identify alleles in miRNA 
biogenesis genes that may be associated with EOC risk.  In stage 1, the Illumina Infinium 610K 
array was used to genotype 1,815 EOC cases (59% with serous carcinomas) and 1,900 controls of 
European ancestry. To enhance power to detect true susceptibility loci, we conducted a joint 
meta-analysis of data from an additional 2,172 invasive EOC cases and 3,052 controls of 
European ancestry from 8 studies that are part of the Ovarian Cancer Association Consortium 
(OCAC).   
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METHODS 
Participants  
Characteristics of participating studies are summarized in Table 3.1.  Stage 1 was 
comprised of four case-control studies (MAY, NCO, TBO, TOR).  Cases had incident, 
pathologically confirmed primary invasive EOC. Controls had at least one ovary intact when 
interviewed, and were frequency-matched to cases on age-group and race/ethnicity. To increase 
etiologic homogeneity, we excluded cases with non-epithelial or borderline tumors, non-whites, 
known BRCA1 and BRCA2 mutation carriers, women of Ashkenazi Jewish background, and 
women with a prior history of ovarian, breast, endometrial, or early-onset colorectal cancer.  The 
stage 2 replication included eight additional studies from the OCAC whose eligibility criteria 
have been previously described (15-17).  All studies had data on disease status, age at 
diagnosis/interview, self-reported ethnic group, and histologic subtype. The study protocol was 
approved by the institutional or ethics review board at each site, and all participants provided 
written informed consent.   
Genotyping 
Genomic DNA was extracted from blood, processed and stored using standard 
procedures. All stage 1 samples were genotyped with the Illumina Infinium 610K Array at the 
Mayo Clinic Genotyping Shared Resource Facility (Rochester, MN) by laboratory personnel 
blinded to case-control status.  Each 96-well plate contained 375 ng DNA of random mixtures of 
case and control samples, two blind duplicates, and two replicates of a CEPH family trio (mother, 
father, child) from the Coriell Institute.  A quality assurance (QA) panel of 96 SNPs was run on 
the Illumina Bead Express platform to test sample performance and ensure concordance of 
replicate samples. Illumina Genome Studio™ software was used to perform automated clustering 
and calling for over 550,000 beadtypes. SNPs and samples with call rates <95% were excluded 
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from further analysis. Among 81 pairs of replicate samples, the concordance rate was 99.93%. 
The overall genotype call rate was 99.7%.  
Of 4,169 eligible unique subjects that we attempted to genotype in stage 1, we applied the 
following exclusions: generation of genotypes at fewer than 95% of loci (n=413), failure on the 
QA panel (n=15), ambiguous gender (n=7), unresolved identical genotypes (n=8), self-reported 
non-European ancestry (n=2), or less than 80% European ancestry (n=9) using STRUCTURE 
(18). This resulted in a final sample size of 3,715 subjects (1,815 cases and 1,900 controls).  
As shown in Table 3.1, the second stage replication included the New England Case-
Control Study (NEC), the Polish Ovarian Cancer Study (POL), four UK-based collections of 
EOC cases, and two collections of controls from UK genome-wide association studies of other 
phenotypes.  Genotyping for NEC was performed at the National Institute of Aging (Bethesda, 
Maryland) with the Illumina 317K and 370K Arrays, and genotyping for POL was performed at 
the Core Genotyping Facility, SAIC-Frederick, Inc (NCI-Frederick, Maryland) with the Illumina 
Human 660w-Quad Array. As described previously (15), genotyping for the UK cases was 
conducted using the Illumina Infinium 610K array at the Illumina Corporation.  UK control data 
comes from the Wellcome Trust Case-Control Consortium 1958 Birth Cohort (19) and a national 
colorectal control study (20) that used the Illumina 550K array for genotyping.  Genotyping 
quality control procedures for these studies have been described in detail (15). 
Identification of candidate miRNA biogenesis genes and SNPs 
Genes involved in miRNA biogenesis were identified through a comprehensive PubMed 
search. A total of 19 genes were selected for evaluation in this investigation: AGO1, AGO2, 
DCP1, DGCR8, DICER, DROSHA, LIN28, LIN28B, FMRP, GEMIN3, GEMIN4, GW182, HIWI, 
PACT, RAN, SMAD4, TRBP, TRIM32, and XPO5. A total of 357 SNPs in all but one gene of 
interest (TRBP) are present on the 610K array and of these 336 (94.1%) had call rates >95%. 
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Three hundred and eighteen of the 336 SNPs had MAF of at least 1% and were included in 
statistical analyses. 
Statistical analyses 
Descriptive statistics were generated using frequencies and percents for categorical 
variables, and means and standard deviations (SD) for continuous variables.  Distributions of 
covariates among cases and controls were compared within each study site using Χ2 tests and t-
tests for categorical and continuous variables, respectively. Genotype frequencies among controls 
were tested for Hardy Weinberg Equilibrium (HWE) using Χ2 goodness-of-fit tests. Statistical 
analysis was performed using SAS Version 9.1 (SAS Inc., Cary, NC) and PLINK software (21).  
To examine associations between each SNP and EOC risk, unconditional logistic 
regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI).  In stage 1, 
log-additive, dominant, and recessive genetic models were fit for each SNP; the major allele was 
considered to be the reference allele during modeling.  All models were adjusted for age, study 
site, and a quantitative variable for the first principal component representing European ancestry. 
Wald Χ2 tests were used to obtain P values for dominant and recessive SNP effects, and the 
Cochran Armitage trend test was used to estimate P for trend for log-additive effects. For each 
SNP, the minimum p-value over genetic models was used to represent the best-fitting model, and 
P< 0.05 was considered the threshold of significance. Due to the heterogeneous nature of EOC, 
exploratory subgroup analysis was conducted to estimate genotype-specific odds ratios for serous 
carcinomas (the most predominant histologic subtype). 
We permuted case-control status 100,000 times to generate point-wise empirical p-values 
(EMP1) using PLINK (35). The EMP1 represents the proportion of permutations in which the 
minimum simulated P value was less than the observed P value.   
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The meta-analysis was performed in PLINK by combining results from log-additive 
models across studies using the Mantel-Haenszel method for combining raw data (22). Combined 
ORs, 95% CIs, and P values were generated using fixed-effect models. The I2 test of 
heterogeneity (23) was estimated to quantify the proportion of total variation due to heterogeneity 
across studies.  The R statistical package ‘r-meta’ was used to generate forest plots reporting 
associations between identified SNPs and EOC risk. Haploview software (v4.1) was used to infer 
the LD structure in regions containing risk-associated loci (24). 
In silico functional assessment of SNPs 
The SNPinfo (25) and FastSNP (26) in silico tools were used to predict the functional 
impact of risk-associated and strongly-correlated SNPs.  
Plasmid construction 
To evaluate the functional significance of LIN28B rs12194974, we generated luciferase 
reporter constructs by amplifying the 5’ flanking region of LIN28B spanning -1,414 bases 
upstream of the transcriptional start site to +1,403 bases downstream using previously described 
methods (27). The amplified fragment was cloned into a pGL3 luciferase reporter vector to 
generate pGL3-Lin-28B-P2-IRES, which contained the wild-type allele (-727-G), and served as 
the template for generating the variant construct (-727-A) using the QuikChange site-directed 
mutagenesis (Agilent Technologies, Inc., Santa Clara, CA). The constructs were verified by DNA 
sequencing using BigDye Terminator V31.1 Cycle Sequencing Kits and the 3130X Genetic 
Analyzer (Applied Biosystems, Foster City, CA). 
Cell lines and cultures 
EOC and human immortalized surface epithelial (HIOSE) cells were obtained from 
ATCC and the University of Pennsylvania, and were cultured at 37°C and 5% CO2. OV8 
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cells were cultured in RPMI1640, A2780S and A2780CP cells were cultured in DMEM/F12, 
SKOV3 cells were cultured in McCoy's 5A, and OVCA420, OVCA432, CAOV3, and T80 
HIOSE cells were cultured in M199/MCDB105. All the culture media were supplemented 
with 10% fetal bovine serum (Invitrogen Co., Grand Island, NY). 
Reporter gene analysis 
Cells were transiently transfected with wild-type and variant LIN28B constructs.  The 
amount of DNA in each transfection was kept constant by the addition of empty vector. After 
36 hours of transfection, relative luciferase activity (RLA) was measured using a luciferase 
assay reagent (Promega, Madison, WI). Transfection efficiency was normalized by co-
transfection with a β-galactosidase expressing vector; β-galactosidase activity was measured 
using Galacto-Light (Tropix, Bedford, MA). RLA was expressed as relative light units or fold 
change. All experiments were repeated in triplicate. Differences between wild-type and 
variant LIN28B reporter activity were tested using Student’s t-tests.  A two-sided P value of 
<0.05 was considered statistically significant. 
Quantitative RT-PCR 
To validate the results from reporter assays, qRT-PCR was used to evaluate mRNA 
expression of LIN28B exons 1-3 in the context of -727-G or -727-A promoters. Total RNA was 
isolated from cell lines using Trizol reagents (Invitrogen, Carlsbad, CA). cDNA was prepared 
from total RNA samples using TaqMan RNA Reverse Transcription kit (Applied Biosystems, 
Foster City, CA). qPCR was perfomed using TaqMan Universal Polymerase Chain Reaction 
(PCR) Master mix (Applied Biosystems, Foster City, CA) according to the manufacturer’s 
protocol. PCR cycling began with template denaturation and hot start Taq polymerase activation 
at 95°C for 1 min, then 40 cycles of 95°C for 5 sec, and 60°C for 30 sec performed on a 7900HT 
Fast Real-Time PCR System with data collected during each cycle at the 60°C extension step 
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with 7900HT SDS v2.3 (Applied Biosystems, Foster City, CA). Threshold and baselines were 
manually determined with thresholds typically set between 0.05 to 0.1 paired with a baseline 
starting at 1–3 cycle thresholds (Cts) and finishing at 15–17 Cts. Relative LIN28B expression was 
determined by the delta-delta comparative threshold (ΔΔCt) method with actin. P-values were 
determined by a two-tailed Student's t test from Ct values for normalization to total RNA.  
RESULTS 
 Despite frequency-matching on age-group, cases were slightly older (60.0 + 11.6 years) 
than controls (56.8 + 12.0 years) (P<0.0001). As compared to controls, cases tended to have 
lower education levels (P<0.0001), were less likely to have used oral contraceptives (OC) 
(P=0.002), and had longer duration of hormone replacement therapy use (P<0.0001) (data not 
shown).  The distributions of selected clinical and pathologic characteristics of stage 1 cases are 
summarized by study site in Table 3.3.  Most EOC were of serous histology, were diagnosed at 
stage III, and were high-grade.  
In stage 1, 32 SNPs from 10 of the 18 genes were associated with EOC overall or with 
serous histology (n=1070). Twenty-three SNPs from 9 genes retained statistical significance 
(point-wise empirical P-value, EMP1< 0.05) after permutation testing (Table 3.2). SNPs within 
DCP1 (rs2240610 and rs6489338) and DROSHA (rs13186629, rs17404622, and rs2161006) are 
in linkage disequilibrium (LD) (r2 > 0.80). Most statistically significant associations were based 
on a recessive or dominant model and/or were inversely associated with risk. The most notable 
association (EMP1=0.004) with EOC overall was observed with AGO2 rs2176397 (AA genotype 
versus the AG/GG genotype, OR (95% CI) =0.72 (0.57-0.92)). Sub-group analysis of cases with 
serous histology revealed trends in association of similar direction and magnitude as the overall 
analysis (Table 3.2).   
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The joint meta-analysis included data from a total of 3,987 EOC cases and 4,952 controls 
(Table 3.1).  Under a fixed-effects model, the association for 6 SNPs demonstrated evidence for 
replication, with the strongest associations observed for DROSHA rs13186629, rs2161006 and 
rs17404622, three SNPs in high LD (0.97<r2<0.99) that flank the 3’UTR of the gene and map to a 
17kb region of LD within 5p13.3 (Figure 3.1.A). rs13186629 showed the strongest evidence of 
association in this region, with a summary OR  of 1.09 (95% CI: 1.02-1.16, P =0.008, I2 =0%). 
The next strongest association was with LIN28B rs12194974 (summary OR=0.90, 95% CI: 0.82-
0.98, P=0.015, I2 =21.8%), a SNP flanking the 5’UTR of LIN28B (Figure 3.1.B). We also 
observed statistically significant associations for rs25704, a SNP in the 3’UTR of the X-linked 
FMR1 gene (summary OR=1.12, 95% CI: 1.02-1.24, P =0.020, I2 =0%) (Figure 3.1.C), and for 
intronic SNP LIN28 rs12728900 (summary OR=0.93, 95% CI: 0.86-0.99, P =0.031, I2 =24.3%) 
(Figure 3.1.D).  Forest plots for these 6 SNPs appear in Figure 3.2.  
To predict the possible functional relevance of risk-associated and strongly correlated 
SNPs (r2>0.80) listed in Table 3.3, we used the SNPInfo (25) and FastSNP (26) in silico tools; 
results suggest that 29 of these 78 SNPs are predicted to influence gene expression. Of the SNPs 
with evidence for statistical significance in the replication stage, the DROSHA tagSNPs have no 
known function, rs12194974 is predicted by SNPinfo to reside in a transcription factor binding 
site (TFBS) in the highly conserved LIN28B promoter, FMR1 rs25704 is located in a putative 
miRNA-binding site according to SNPinfo, and LIN28 rs12728900 is predicted by FastSNP to be 
an intronic enhancer.  Of particular interest is the LIN28B rs12194974 SNP because transcription 
factors (TF) predicted to bind there include PPARG (peroxisome proliferator-activated receptor 
gamma), YY1 (yin yang 1), and PAX2 (paired box gene 2), each of which have been implicated in 
ovarian carcinogenesis (28-30).  Based on evidence that LIN28B/LIN28 over-expression 
negatively regulates biogenesis of let-7, a known tumor suppressor miRNA family frequently 
down-regulated in EOC and other malignancies, (8, 27, 31) it seems plausible that a binding site 
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created or destroyed by rs12194974 may enable such TFs to activate or repress LIN28B activity, 
ultimately affecting the level or timing of LIN28B and let-7 expression.   
Based on statistical analyses, in silico bioinformatics-based predictions, and biologic 
plausibility, we explored the functional significance of the rs12194974 G>A SNP located 727 
bases upstream from the LIN28B transcriptional start site by constructing LIN28B G>A reporters, 
which contain the first 3 exons of LIN28B following IRES and the luciferase gene (Figure 3.3.A). 
Luciferase reporter assay was used to measure promoter activities of wild-type (-727-G) and 
variant (-727-A) constructs in eight cell lines.  EOC cells transfected with -727-A had 30-84% 
lower relative luciferase activity (RLA) than the common -727-G reporter (P<0.05); Figure 
3.3.B). Real time RT-PCR of exons 1-3 of LIN28B confirmed 24-29% reduced relative mRNA 
LIN28B expression of -727-A compared to -727-G (Figure 3.3.C).  These results suggest the A 
allele has lower promoter activity which leads to downregulation of LIN28B, consistent with the 
decreased risk among A allele carriers. 
DISCUSSION  
This study examined whether inherited variants in miRNA biogenesis genes contribute to 
EOC risk by integrating multiple lines of evidence, including statistical, in silico, biological, and 
functional data.  Our findings are noteworthy because several candidate genes highlighted here 
have been implicated in ovarian carcinogenesis (LIN28, LIN28B, DROSHA, DICER, AGO2) (6-9, 
32, 33).  Importantly, associations identified with LIN28/LIN28B have biologic relevance because 
these genes are over-expressed in advanced stage EOC and may contribute to tumorigenesis by 
repressing let-7 and upregulating let-7 target oncogenes KRAS and MYC (8, 27).  Indeed, a study 
of 211 EOC tumors showed high LIN28B expression, low let-7a, and high IGF-II were correlated 
with a poorer prognosis compared to tumors with low LIN28B expression (9), consistent with a 
role for LIN28B in tumor growth (34).  
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Our meta-analytic results, which were largely influenced by stage 1, reinforced evidence 
for a protective role of rs12194974, a G>A SNP shown experimentally to reduce LIN28B activity. 
Due to the low frequency of the rs12194974 A allele, we have not been able to identify human 
cancer cell lines that harbor this variant, limiting functional analyses. As such, future studies 
involving knock-in of the rs12194974 A allele into the LIN28B gene may be warranted to 
evaluate LIN28B expression. Taken together, SNPs in LIN28B may serve as biomarkers of risk, 
and given the role of LIN28B in stem cell renewal, disrupting its function in tumors where it is 
over-expressed may promote let-7 expression and therapeutic benefit (8, 9). Interestingly, 
polymorphisms within LIN28B may also influence the reproductive lifespan and human growth, 
as SNPs residing in the same LD block as rs12194974 (Figure 3.1.B) have been associated with 
age at menarche, timing of puberty, height, and finger-length ratio (35-39).   
Major strengths of our study include the large sample size, the genotyping platform 
which enabled comprehensive coverage of a significant number of miRNA biogenesis genes and 
SNPs for which an association with EOC is biologically plausible, the quality control measures 
put into place to generate high quality genotype data, and the procedures used (i.e. strict 
inclusion/exclusion criteria and assessment of population substructure) to ensure a genetically 
homogeneous study population of women with European ancestry. Furthermore, this represents 
the first report involving miRNA biogenesis SNPs and cancer risk to follow-up on observed 
associations by conducting a joint meta-analysis and incorporating functional data.  Since we did 
not adjust for multiple comparisons in a strict sense, our findings should be considered suggestive 
that inherited variants in miRNA biogenesis genes, particularly LIN28B, affect EOC risk. Efforts 
are underway to replicate the most promising associations reported herein in the Ovarian Cancer 
Association Consortium, and to evaluate variants that may impact miRNA primary transcripts or 
miRNA-target interactions. Knowledge of inherited variation in miRNA-related genes may help 
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to identify high-risk populations and aid in the development of diagnostic, prognostic, and 
therapeutic strategies for EOC and likely other cancers.   
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           Table 3.1. Characteristics of participating studies of epithelial ovarian cancer  
Number of 
subjects1  
 
Study Name 
(Abbreviation) 
(Location) 
 
Study 
Type 
Case ascertainment Control ascertainment 
cases controls 
Stage 1 
Mayo Clinic Ovarian Cancer Study 
(MAY) 
(Upper Midwest, USA)  
 
Clinic 
based 
 
Mayo Clinic’s gynecologic 
surgery & oncology departments; 
residents of six-state surrounding 
region (MN, IA, WI, IL, ND, 
SD). 
Women from the same geographic 
region seeking general medical 
examination through Mayo’s 
departments of primary care and 
internal medicine. 
 
359 
 
520 
North Carolina Ovarian Cancer Study 
(NCO) 
(North Carolina, USA) 
 
Population 
based 
 
Rapid ascertainment (i.e. frequent 
contact with local hospitals and 
physicians); residents of 
contiguous 48-county region  
 
Random digit dialing targeted towards 
women residing in the same region 
494 655 
Tampa Bay Ovarian Cancer Study 
(TBO) 
(Tampa, USA) 
 
Population 
based 
Rapid ascertainment (i.e. frequent 
contact with 7 regional 
gynecologic oncologists); 
residents of a 2-county, heavily 
populated region 
Women attending a local screening 
clinic for routine mammography 227 169 
Familial Ovarian Tumor Study 
(TOR) 
(Ontario, Canada) 
 
Population 
based 
Enrollment of patients aged 20-79 
and identified by the Ontario 
Cancer Registry.  
Women receiving routine screening  
(i.e. blood pressure checks, 
mammograms, cholesterol screening) at 
the Women’s College Hospital 
735 556 
Subtotal    1815 1900 
Stage 2 
New England Case-Control Study of 
Ovarian Cancer 
(NEC) 
(New Hampshire and Eastern  
Massachusetts, USA) 
Population 
based 
Ascertainment through hospital 
tumor boards and statewide 
cancer registries.2 
 
Selected through a combination of 
random digit dialing, townbooks, and 
drivers’ license lists in eastern 
Massachusetts and New Hampshire. 
137 142 
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Polish Ovarian Cancer Study 
(POL) 
(Warsaw and Lodz, Poland) 
Population 
based 
Rapid ascertainment at 
participating hospitals in 
Warsaw and Lodz 
Identified at random through the Polish 
electronic system; stratified by city and 
5-year age categories 
218 557 
SEARCH 
(SEA) 
(Cambridge, UK) 
Population 
based 
Ascertained from East Anglian 
West Midlands & Trent regions 
of England. Prevalent cases 
diagnosed 1991-1998; incident 
cases diagnosed 1998 onwards.  
- 1120 - 
United Kingdom Ovarian Cancer 
Population Study 
(UKO) 
(UK) 
Population 
based 
 
Incident cases from 10 
gynecological oncology 
National Health Service centers 
throughout the UK.  
- 506 - 
Cancer Research UK Familial Ovarian 
Cancer Register 
(FOCR) 
(UK) 
Familial 
Cancer 
Register 
 
Ascertained from a registry of 
women at high-risk for ovarian 
cancer based on having a 
positive family history of the 
disease and/or a BRCA1 or 
BRCA2 mutation. 
- 44 - 
Royal Marsden Hospital Study 
(RMH) 
(UK) 
Hospital 
based 
 
Ascertained from cases treated 
at this internationally recognized 
research hospital.  
- 147 - 
UK 58 Birth Cohort 
(58 BC) 
(UK) 
Cohort - 
Survivors from an original sample of  
17 000+ births in England, Wales, and 
Scotland during 1 week in 1958, and 
followed-up by parental interview and 
examination at ages 7,11,16 years, by 
cohort member interview at 23, 33, and 
42 years, and medical examination at 
44-45. 
  
- 1436 
UK Colorectal control 
(NSCR) 
Population 
based - 
Spouses or partners of familial 
colorectal cancer cases who themselves - 917 
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(UK) do not have a personal or family history 
of colorectal cancer. 
UK Subtotal    1817 2353 
Validation Phase Subtotal    2172 3052 
TOTAL    3987 4952 
 
 1 Totals represent the number of non-Hispanic white Europeans passing genotyping quality control criteria and meeting study site-specific inclusion/exclusion criteria. 
           2  Cases from NEC that were evaluated as part of this investigation represent postmenopausal advanced papillary serous carcinomas.
                     Table 3.2. MiRNA biogenesis SNPs significantly associated with epithelial ovarian cancer risk overall  
                     and/or serous carcinoma after permutation testing among stage 1 participants   
All subtypes 
(1815 cases, 1900 controls) 
Serous Carcinomas 
(1070 cases, 1900 controls) Gene  
(locus) 
SNP 
Major/ Minor Allele* 
MAF 
 
 
Model d 
 
OR (95% CI)e Pf EMP1g OR (95% CI)e Ph EMP1i 
AGO2 
(8q24.3) 
rs11996715a  (A/C) 
 0.48 R 0.85 (0.73-0.99) 0.043 0.027 0.80 (0.66-0.96) 0.018 0.019 
 rs2176397 (G/A) 0.30 R 0.72 (0.57-0.92) 0.008 0.004 0.80 (0.60-1.05) 0.112 0.078 
 rs3864659 (A/C) 0.11 R 2.53 (1.38-4.65) 0.003 0.005 2.10 (1.04-4.21) 0.038 0.037 
DCP1 
(12p13.33) rs10505725 (G/A) 0.28 R 1.24 (0.98-1.58) 0.078 0.095 1.40 (1.07-1.83) 0.015 0.013 
 rs2240610 
b (A/G) 0.49 D 0.83 (0.71-0.96) 0.012 0.019 0.86 (0.72-1.02) 0.090 0.149 
 rs6489338
 b (G/A) 0.46 R 1.20 (1.02-1.40) 0.025 0.022 1.11 (0.92-1.33) 0.284 0.329 
DICER 
(14q32.13) 
rs1110386a  (G/A) 
 0.22 R 1.53 (1.12-2.09) 0.008 0.017 1.31 (0.90-1.90) 0.159 0.220 
 rs11621737  (G/A) 0.24 R 0.71 (0.53-0.95) 0.022 0.017 0.65 (0.45-0.92) 0.016 0.018 
 rs2353726 a (G/A) 0.43 R 0.85 (0.72-1.01) 0.059 0.042 0.80 (0.65-0.98) 0.028 0.037 
DROSHA 
(5p13.3) rs10067066 (A/G) 0.07 R 2.57 (1.04-6.35) 0.040 0.037 3.44 (1.34-8.82) 0.010 0.002 
 rs13186629 c (G/A) 0.40 A 0.90 (0.82-0.99) 0.027 0.029 0.90 (0.80-1.00) 0.058 0.189 
 rs17404622 c (A/G) 0.37 A 0.90 (0.82-0.99) 0.034 0.036 0.90 (0.80-1.01) 0.060 0.155 
 rs2161006 c (G/A) 0.37 A 0.90 (0.81-0.99) 0.028 0.030 0.90 (0.80-1.01) 0.062 0.158
 rs6450839 (G/A) 0.30 D 1.16 (1.01-1.32) 0.032 0.031 1.20 (1.03-1.40) 0.020 0.019 
FMR1 
(Xq27.3) rs25704 (G/A) 0.23 A 1.12 (1.01-1.25) 0.041 0.026 1.05 (0.92-1.20) 0.437 0.259 
LIN28 
(1p36.11) 
rs11247946 (A/G) 
 0.34 R
 1.25 (1.02-1.52) 0.029 0.010 1.28 (1.02-1.60) 0.037 0.005 
 rs11581746 (A/G) 0.19 D 0.87 (0.75-1.00) 0.047 0.036 0.92 (0.78-1.08) 0.294 0.170 
 rs12728900 (G/A) 0.26 A 0.86 (0.77-0.96) 0.008 0.007 0.85 (0.75-0.97) 0.015 0.011 
 rs6598964 (G/A) 0.36 R 1.26 (1.04-1.53) 0.017 0.004 1.17 (0.93-1.46) 0.179 0.026 
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LIN28B 
(6q16.3-q21) 
rs12194974 (G/A) 
 0.15 A
 0.84 (0.74-0.97) 0.015 0.015 0.84 (0.72-0.99) 0.037 0.026 
 rs17065417 (A/C) 0.09 D 1.23 (1.04-1.46) 0.018 0.016 1.24 (1.02-1.51) 0.034 0.035 
PACT 
(2q31.2) 
rs2059691a (G/A) 
 0.30 R 0.77 (0.61-0.97) 0.028 0.044 0.77 (0.59-1.01) 0.062 0.092 
SMAD4 
(18q21.1) 
rs948588 (G/A) 
 0.08 R 2.80 (1.22-6.40) 0.015 0.006 2.27 (0.88-5.91) 0.092 0.055 
Abbreviations: Chr=chromosome; MAF=minor allele frequency in controls; OR (CI) = Odds ratio (confidence interval); * The major 
allele represents the most frequently-occurring allele and serves as the reference allele during modeling. a SNPs deviating from Hardy 
Weinberg  Equilibrium among controls (PHWE <0.05), with PHWE values for AGO2 rs11996715, DICER rs1110386 and rs2353726, and 
PACT rs2059691 of 0.009, 0.007, 0.013, and 0.007, respectively. b SNP pair in linkage disequilibrium (r2=0.93);  c SNP pair in linkage 
disequilibrium (0.97>r2>0.99); d Best-fitting genetic model (A = Log-additive; D = Dominant; R = Recessive); e OR and 95% CI adjusted 
for age, study site, and the first principal component for European ancestry; f  Wald test  P-value for testing genetic effects related to 
overall ovarian cancer risk before permutation testing. g Empirical pointwise P-value for testing genetic effects related to overall ovarian 
cancer risk; h Wald test P-value for testing the genetic effects related to serous carcinoma  risk before permutation testing.  i Empirical 
pointwise P-value for testing the genetic effects related to serous carcinoma risk;  Statistically significant P and EMP1-values (< 0.05) 
are in bold type. All P-values are two-sided.
                   Table 3.3. Clinical and pathologic description of stage 1 epithelial ovarian cancer cases by study site  
 
Variable  MAY (N=359) 
 
NCO (N=494) 
 
TBO (N=227) 
 
TOR (N=735) 
 
TOTAL (N=1815) 
Histology , N (%) 
     Serous 
     Mucinous 
     Endometrioid 
     Clear Cell 
     Mixed Cell 
     Other 
 
228 (63.5) 
11 (3.1) 
71 (19.8) 
24 (6.7) 
21 (5.9) 
4 (1.1) 
 
294 (59.5) 
20 (4.1) 
81 (16.4) 
58 (11.7) 
0 (0) 
11 (2.2) 
 
146 (65.8) 
13 (5.9) 
28 (12.6) 
12 (5.4) 
23 (10.4) 
0 (0) 
 
402 (54.7) 
57 (7.8) 
154 (21.0) 
47 (6.4) 
9 (1.2) 
66 (9.0) 
 
1070 (59.1) 
101 (5.6) 
334 (18.5) 
141 (7.8) 
53 (2.9) 
116 (6.1) 
Stage , N (%) 
      I 
      II 
      III 
      IV 
      Unknown 
 
67 (18.8) 
26 (7.3) 
203 (57.2) 
59 (16.6) 
0 (0) 
 
77 (15.6) 
84 (17.1) 
328 (66.7) 
0 (0.0) 
3(0.3) 
 
38 (16.7) 
25 (11.0) 
154 (67.8) 
10 (4.4) 
0 (0) 
NA 
 
182 (19.0) 
135 (12.6) 
685 (63.8) 
69 (6.4) 
3 (0.3) 
Grade , N (%) 
      I 
      II 
      III 
      IV    
      Unknown    
 
13 (3.6) 
45 (12.5) 
174 (48.5) 
121 (33.7) 
6 (1.7) 
 
65 (13.5) 
138 (28.7) 
277 (57.6) 
1 (0.21) 
0 (0) 
 
11 (5.5) 
32 (3.1) 
157 (77.7) 
2 (1.0) 
0 (0) 
NA 
 
89 (8.5) 
215 (20.6) 
608 (58.4) 
124 (11.9) 
6 (0.6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Percentages were rounded and may not add up to 100.  
                   Abbreviations: MAY=Mayo Clinic Ovarian Cancer Study (Rochester, MN); NCO=North Carolina Ovarian Cancer Study (Durham, NC);  
                   TOR=Familial Ovarian Tumor Study (Ontario, Canada); TBO= Tampa Bay Ovarian Cancer Study (Tampa, FL); 
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        Table 3.4. Findings from in silico analysis of risk-associated and strongly correlated SNPs  
 
Gene 
(locus) 
Genotyped 
SNP 
 
# 
SNPs 
Tagged
* 
Tagged 
SNP(s) 
Nucleotide 
Position 
(build 36)  Location  
 
Possible function 
and/or conservation** 
r2 between 
significant 
genotyped 
SNPs 
 
rs11996715 
 
 
27 
 
- 
rs10088475 
rs10089107 
rs10104479 
rs10107434 
rs10108814 
rs10282830 
rs10283164 
rs10283368 
rs10875457 
rs11166986 
rs11166990 
rs11166991 
rs11166992 
rs11776239 
rs11784281 
rs11995049 
rs11995103 
rs13264524 
rs13268978 
rs13273096 
rs13274713 
rs13275969 
rs4413752 
rs7460 
rs7820179 
rs9324533 
rs9644447 
 
141716473 
141739448 
141767633 
141763253 
141741747 
141787496 
141740716 
141740811 
141748999 
141772777 
141725337 
141733154 
141735595 
141746652 
141787883 
141735192 
141762271 
141762443 
141723840 
141748567 
141745113 
141734379 
141742598 
141758154 
141738042 
141770658 
141761186 
141761976 
 
flanking 5’UTR  
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
3’UTR (PTK2) 
intron (PTK2) 
intron (PTK2) 
intron (PTK2) 
 
TFBS 
intronic enhancer 
intronic enhancer 
intronic enhancer 
intronic enhancer 
no known function 
no known function 
no known function 
no known function 
no known function 
no known function 
no known function 
no known function 
no known function 
intronic enhancer 
no known function 
no known function 
no known function 
no known function 
no known function 
no known function 
no known function 
no known function 
no known function 
MBS (miR-137,-335,-539); Conserved 
no known function 
intronic enhancer 
no known function  
 
r2 =0.30 
between 
rs11996715 
and rs2176397 
 
r2 =0.13 
between 
rs11996715 
and rs3864659 
 
 
rs2176397 
 
 
 
2 
 
- 
rs4961277 
rs6995141 
 
141691719 
141693901 
141701149 
 
intron 
intron 
intron 
 
no known function 
intronic enhancer 
intronic enhancer 
r2 =0.03 
between 
rs2176397 and 
rs3864659 
 
AGO2 
(8q24.3) 
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rs3864659 
 
 
4 - 
rs2944758 
rs2944762 
rs2944767 
rs2977485 
141625044 
141638360 
141637401 
141627062 
141635739 
intron 
intron 
intron 
intron 
intron 
no known function 
intronic enhancer 
intronic enhancer 
intronic enhancer 
intronic enhancer 
 
rs10505725 
 
 
0 
 
- 
 
94623895 
 
 
intron 
 
no known function 
r2 =0.09 
between 
rs10505725 
and rs2240610; 
r2 =0.11 
between 
rs10505725 
and rs6489338; 
r2 =0.20 
between 
rs10505725and 
rs725779  
 
rs2240610 
 
 
 
 
8 
 
- 
rs1860048 
rs2240611 
rs2240612 
rs2470425 
rs2470427 
rs2470448 
rs4765874 
rs7966355 
rs7222 
 
1927853 
1928956 
1927962 
1928506 
1948158 
1946245 
1937696 
1993943 
1945913 
1925527 
 
intron 
intron  
intron 
intron 
intron 
intron 
intron 
intron 
intron 
3’UTR 
 
intronic enhancer 
no known function 
no known function 
splice site 
intronic enhancer 
no known function 
no known function 
intronic enhancer 
no known function 
MBS (miR-32, -1279)  
 
r2 =0.93 
between 
rs2240610 and 
rs6489338 
 
  
DCP1 
(12p13.33) 
 
rs6489338 
 
 
 
 
5 
 
- 
rs2470425 
rs2470427 
rs2470448 
rs4765874 
rs7966355  
 
1930841 
1948158 
1946245 
1937696 
1993943 
1945913   
 
intron 
intron 
intron 
intron 
intron 
intron 
 
intronic enhancer 
intronic enhancer 
no known function 
no known function 
intronic enhancer 
no known function  
 
  
 
rs1057035 
 
 
0 
 
- 
 
94623895 
 
3’UTR 
 
MBS (miR 574-3p); ESE   DICER (14q32.13) 
 
rs1110386 
 
 
0 
 
- 
 
94623895 
 
 
flanking 3’UTR 
 
no known function r2 =0.10 
between  
rs1110386 and 
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 rs11621737 
 
r2 =0.16 
between  
rs1110386 and 
rs2353726 
 
rs11621737 
 
 
1 
 
- 
rs11625422 
 
 
94592587 
94595367 
 
 
flanking 3’UTR 
flanking 3’UTR  
 
no known function 
no known function; conserved  
 
r2 =0.38 
between  
rs11621737 
and rs2353726 
 
rs2353726 
 
 
 
4 
 
- 
rs11622458 
rs11622522 
rs7160684 
rs8022945 
 
94604622 
94605251 
94605456 
94607134 
94606883  
 
flanking 3’UTR 
 
no known function 
no known function 
no known function 
no known function 
no known function 
 
DROSHA 
(5p13.3) 
 
rs10067066 
 
 
0 
 
- 
 
31482473 
 
 
intron 
 
intronic enhancer 
 
r2 =0.006 
between 
rs10067066 
and 
rs13186629, 
rs17404622, 
and rs2161006  
 
r2 =0.002 
between 
rs10067066 
and rs6450839  
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rs13186629 
 
 
2 
 
- 
rs17404622 
rs2161006 
 
31411810 
31417087 
31417271 
 
flanking 3’UTR 
flanking 3’UTR 
flanking 3’UTR 
 
no known function 
no known function 
no known funciton 
r2 =0.93 
between 
rs13186629, 
rs17404622, 
and rs2161006 
 
r2 =0.244 
between 
rs13186629 
and rs6450839  
 
 
rs6450839 
 
0 
 
- 
 
31419659 flanking 3’UTR 
 
no known function  
FMR1 
(Xq27.3) rs25704 0 - 146839230 3’UTR MBS (miR 548b-5p, miR-382)  
 
rs11247946 
 
 
0 
 
- 
 
26591702 
 
 
flanking 5’UTR 
 
no known function 
r2 =0.17 
between 
rs11247946 
and 
rs12728900 
 
r2 =0.12 
between 
rs11247946 
and 
rs11581746 
 
 
r2 =0.61 
between 
rs11247946 
and rs6598964  
LIN28 
(1p36.11) 
 
rs11581746 
 
0 - 26616674 Intron no known function 
r2 =0.60 
between 
rs111581746 
and 
rs12728900 
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rs12728900 
 
 
0 
 
- 
 
26619394 
 
 
intron 
 
intronic enhancer 
r2 =0.28 
between 
rs12728900 
and rs6598964 
 
rs6598964 
 
 
0  
 
- 
 
26618914 
 
intron 
 
no known function  
 
rs12194974 
 
 
 
1 
 
- 
rs12212292 
 
 
105510891 
 105533637 
 
flanking 5’UTR 
intron 
 
TFBS; Conserved 
intronic enhancer 
r2 =0.02 
between 
rs12194974 
and 
rs17065417 
 
  
LIN28B 
(6q16.3-
q21) 
 
rs17065417 
 
 
1 
 
- 
rs1149280 
 
 
105512967 
105561492 
 
intron 
intron 
 
TFBS 
no known function 
r2 =0.07 
between 
rs17065417 
and rs314263 
 
 
PACT 
(2q31.2) 
 
rs2059691 
 
 
 
0 
 
- 
 
179010130 
 
 
intron 
 
no known function - 
SMAD4 
(18q21.1) 
 
rs948588 
 
 
1 
 
- 
rs17663887 
 
 
46840342 
46843716 
 
Intron 
 
no known function - 
 
          Abbreviations: TFBS=transcription factor binding site; UTR=untranslated region; MBS=microRNA binding site; miR= miRNA; EXE=exon splicing enhancer 
Note:  SNPinfo http://snpinfo.niehs.nih.gov/ and FastSNP http://fastsnp.ibms.sinica.edu.tw/pages/input_SNPListAnalysis.jsp/  were used for in silico predictions of risk-
associated SNPs (Table 2) and their tagSNPs. 
               * TagSNPs defined as r2 > 0.80 and within 250kb of genotyped SNP using HapMap2 data (http://hapmap.ncbi.nlm.nih.gov/) . 
               **Based on Vertebrate Multi-Alignment and Conservation Score (17 species) downloaded from the UCSC genome bioinformatics web site (http://genome.ucsc.edu/)  
           and obtained through SNPInfo (http://snpinfo.niehs.nih.gov).  
 
 
Figure 3.1. Linkage disequilibrium (LD) plots for regions of DROSHA, LIN28B, 
FMR1, and LIN28.  A. DROSHA B. LIN28B C. FMR1 D. LIN28. These plots are 
based on 3,715 subjects genotyped in stage 1, and were generated using Haploview 
4.1 (Barrett, 2005) using the solid spline LD method.  Numbers represent r2 * 100, 
and are based on genome build 36.3; r2 = 0 =white=not correlated and r2 = 1= 
black=completely correlated.  The spline LD method suggests that SNPs at the edges 
of each block are in LD with some intermediate SNPs, but that intermediate SNPs 
are not necessarily in LD with each other. 
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Figure 3.2. Forest plots for the six SNPs associated with epithelial ovarian cancer risk in the joint meta-analysis 
A.DROSHA rs13186629 B. DROSHA rs2161006 C. DROSHA rs17404622 D. LIN28B rs12194974 E. FMR1 rs25704 F. LIN28 rs12728900.  
Boxes denote OR point estimates, their areas being proportional to the inverse variance weight of the estimate.  Horizontal lines represent 95% 
CIs.  The diamond represents the summary OR computed under a fixed-effects model. The vertical line is at the null value (OR=1.0). 
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Figure 3.3. Functional analysis of the LIN28B rs12194974 (-727 G/A) polymorphism in vitro  
A. Schematic representation of the LIN28B luciferase Reporter which contains an 1.4-kb promoter and 3 exons of LIN28B following IRES and luciferase gene.  
B. LIN28B SNP Promoter Activity in Ovarian Cancer Cell Lines. The -727-G and -727-A allele constructs were transfected into OV420, OV432, CAOV3, SKOV3, 
OV8, A2780CP, and A2780S ovarian adenonocarcinoma cell lines and T80 human immortalized ovarian surface epithelial cell line (HIOSE).  β-galactosidase was 
used to standardize transfection efficiency.  Relative luciferase activity (RLA) was measured.  RLA units are presented as means, and the T bars represent standard 
deviations (SD).  Mean + SD from triplicates.  Statistical analysis was conducted using Student’s t test. C. LIN28B SNP mRNA Expression in Ovarian Cancer Cell 
Lines and Immortalized Cell Line. The -727-G and -727-A allele constructs were transfected into A2780CP and A2780S and the T80 human cells. LIN28B SNP 
mRNA expression was determined by real-time PCR, and normalized with β-actin. 
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CHAPTER 4: 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
Our findings provide strong support for novel biologically-plausible associations between 
EOC risk and inherited variants in mitochondrial biogenesis and miRNA biogenesis genes. After 
considering various genetic models, influence of potential confounders, and histology, our results 
highlight polymorphisms in several candidate genes as possible contributors to EOC risk, 
including mitochondrial biogenesis genes NRF1, PPARGC1A, MTERF, and ESRRA, and miRNA 
biogenesis genes, LIN28, LIN28B, AGO2, DICER, and DROSHA. Importanty, data supports a 
role for several of these genes in EOC development and/or progression. 142,143,154-157,171,175,176,183,184 
Major strengths of our investigation include the large sample size, the genotyping platform which 
enabled coverage of genes and SNPs of interest that is far greater than any other published 
investigation in these areas, the quality control procedures put into place to make certain that high 
quality genotype data was generated, and the strict inclusion/exclusion criteria used to ensure a 
genetically homogeneous study sample of white individuals.  
Despite these strengths, we recognize the limitations of our research. Given that four 
case-control studies have collectively provided the data and biospecimens used in stage I of this 
study, the internal validity of the component studies should be considered when analyzing and 
interpreting data generated from our investigations.  Because the majority of these studies 
ascertained population-based cases and the participation rates were relatively high, the cases 
enrolled appear to be representative of cases in the respective geographic regions. Although the 
Mayo study is not a true population-based study, ascertainment was limited to counties in which 
greater than 50% of cases are treated at Mayo. Moreover, when compared to the case 
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demographics of the neighboring Iowa SEER registry, Mayo cases are representative of the 
broader case population. However, it is possible that selection bias may have arisen if the controls 
were not representative of the source population they are purported to represent.  For example, in 
the Tampa Bay Ovarian Cancer Study (TBO), controls represent healthy women ascertained at a 
local cancer screening clinic. Such controls may not be representative of women in the 
geographic region because they may be more concerned about health matters and therefore more 
motivated to seek health care and follow medical recommendations than women not attending 
such a clinic. Similar concerns could be raised about the Familial Ovarian Tumor Study (TOR); 
cases were ascertained through the Ontario Cancer Registry and controls were ascertained from 
the Women’s Health Clinic, a clinic in the Toronto area.  Thus, it is unlikely that these controls 
are representative of the women in the entire province of Ontario. However, since the main 
“exposure” under investigation was genotype, it is unlikely that there are systematic differences 
between the frequency of certain genotypes in the control group from the screening clinic vs. the 
source population. Similar concerns were raised for a genome-wide association (GWA) study 
conducted by the Wellcome Trust Case Control Consortium (WTCCC) in which non-population-
based controls were used.  185 Comparison of the genome-wide genotypic distributions from two 
constituents of the control group (i.e. one derived from a population based cohort, the other from 
volunteer blood donors), did not reveal an excess of significant associations, indicating that 
ascertainment and selection biases had little impact on genotype distributions. 185 
Although information bias may have impacted the validity of the component case-control 
studies if subjects were misclassified with respect to EOC status, this possibility seems unlikely 
due to the stringent case definition and restriction to pathologically confirmed cases. However, 
misclassification of histologic subtype of EOC is possible. 186 With respect to possible 
misclassification based on exposure(s), we recognize the potential for recall bias that is inherent 
in case-control studies. While there is the potential for cases to think harder and remember past 
medical history and exposures that healthy controls may have forgotten, the main “exposure” 
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under study is genotype. Thus, for studies that primarily aim to evaluate the impact of genomic 
changes on disease risk, the potential for recall bias is not as likely.   However, since our 
secondary aims do consider self-reported data regarding several covariates (i.e. age at menarche 
and menopause, length of oral contraceptive and hormone replacement therapy use), there is 
potential for recall bias. However, validation studies have generally reported good reproducibility 
and reliability for these factors187-190, and differential exposure recall between cases and controls 
has not been observed. 190,191  
It is also possible that confounding may have impacted our results. Because the primary 
source of confounding in genetic association relates to population stratification, precautions were 
taken (i.e. restriction to non-Jewish, non-Hispanic Caucasians, use of principal components 
analysis and application of ancestry informative markers) to identify and exclude subjects whose 
genotyping data revealed significant differences in ethnic background.  Thus, the influence of 
population stratification on type I error is probably slight to negligible. Additionally, although we 
adjusted for several potential confounders of individual SNP-EOC risk associations, it is possible 
that residual confounding exists due to known or unknown potential confounders.  
Missing data also have the potential to jeopardize the validity of study results.  We 
encountered issues related to missing covariate data when trying to adjust for potential 
confounders of individual mitochondrial SNP-EOC risk associations, including lifetime ovulatory 
cycles (LOC), hormone replacement therapy, and cigarette smoke exposure.  As discussed in 
manuscript 1, a composite LOC variable was generated using values from several component 
variables, including age at menses, age at menopause (or age at interview/diagnosis for pre- or 
peri-menopausal women), months of oral contraceptive use, and months of pregnancy.  Initially it 
was observed that the LOC variable could not be generated for a significant proportion of study 
participants due to missing component values. To minimize the amount of missingness, 
supplemental data from the covariate dataset was used.  For example, if the total months of 
pregnancy (or oral contraceptive use) was missing yet data was available to indicate that the 
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respondent had never been pregnant (or had never used oral contraceptives), the value was 
changed from missing to ‘0.’ Similarly, if the total months of pregnancy was missing, yet it was 
known that the woman had 2 full-births (defined as live births lasting at least 6 months), the value 
was changed from missing to 12 (2 fullbirths x 6 months each).   Additionally, if a woman 
reported being post-menopausal and the age at menopause was missing, yet the woman reported 
having surgery to remove an ovary and/or her uterus, the age at which her surgery was performed 
was used. With regard to missing values for duration of HRT use or smoking, if a woman 
reported that she had never used HRT or had never smoked, the duration for these variables was 
changed from missing to ‘0’. We then attempted to determine the extent (i.e. amount and pattern) 
of missingness as it pertained to each of these variables, and it appeared to be missing at random 
(MAR), as described by Donders et al. 192  Unconditional logistic regression was subsequently 
conducted on the participants having complete data for each of the covariates (N=2662; 1217 
cases, 1445 controls), which represents 72% of the entire sample. We then compared parameter 
estimates for individual SNPs using our simple model (only adjusting for age and study site) and 
our full model (adjusting for age, study site, LOC category, duration of HRT use, and pack-years 
smoked), and generally observed magnitudes of association that were in the same direction and of 
similar strength. 
 Although excluding observations with missing values from analysis is simple, this 
approach loses information and ignores the possibility of systematic differences between the 
subjects with complete and incomplete information. Thus, the resulting inference may not be 
applicable to the entire study population.  As such, we next evaluated profiles of those missing 
and not missing the LOC variable, the main potential confounder of interest.   The LOC variable 
could not be generated for approximately 20% of all participants (n=757; 478 cases, 279 
controls).  We learned that those missing the LOC variable were similar to those having the LOC 
variable with respect to several variables (i.e. age at menarche, number of ovulatory years, 
educational attainment, ever use of hormone replacement therapy). Additionally, the distribution 
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of tumor stage and grade was similar among cases missing and not missing the LOC variable.  On 
the other hand, those missing the LOC variable were slightly older, more likely to be nulliparous, 
and less likely to be users of oral contraceptives than those subjects for whom the LOC variable 
was generated.  However, the mean age, parity status, and history of oral contraceptive use 
among those not having the LOC variable is actually representative of the entire dataset. We then 
decided to impute values for the covariates of interest.  We chose not to use single imputation 
because it does not reflect the uncertainly about the predictions of the unknown missing values.  
Rather, we used Rubin’s multiple imputation procedure 193 using SAS to replace missing values 
with a set of plausible values that represent the uncertainty about the right value to impute. This 
imputation mechanism assumes that the missing data are missing at random.  For an arbitrary 
missing pattern, a Markov chain Monte Carlo (MCMC) method that assumes multivariate 
normality is used as the default to impute missing values.  The multiple imputation process then 
occurs in three phases: 1) creation of 5 multiple imputed datasets, 2) analysis of complete data 
using standard procedures (i.e. unconditional logistic regression), and 3) combining the complete 
data results for inference. After conducting multiple imputation, we compared parameter 
estimates for SNPs from our non-imputed dataset that included 2662 individuals with values from 
the imputed dataset, and observed that estimates were several standard deviations apart, with 
some occurring in the opposite direction.  Considering that we imputed data on these covariates 
for ~30% of the sample, we did not feel comfortable reporting those estimates that were very far 
from those generated from our non-imputed datasets derived from our simple and full models.  
Thus, for manuscript 1, we decided to simply report that we conducted a sub-analysis on those 
individuals having complete data, and commented on the caveats of doing so.   
All in all, despite these shortcomings and the limited generalizability to non-Caucasians, 
it appears that the degree to which our study population will generate results that are accurate for 
our source population of Caucasian women from 4 geographic regions in North America is high.  
To further examine the association between inherited variation in these genes and EOC risk, the 
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most promising SNPs identified in our investigation are being carried forward into the next stage 
of our GWAS in which a larger, more heterogeneous population will be evaluated. This will 
enable extension into multiple ethnicities so that generalizability and consistency of the proposed 
association(s) can be examined.  Furthermore, in the next stage, we plan to evaluate other types of 
miRNA-related SNPs that may impact miRNA primary transcripts or miRNA-target 
interactions.158   Additionally, we are in the process of working with established consortiums such 
as the international Ovarian Cancer Association Consortium (OCAC) to foster further analysis of 
the most promising SNPs identified in our study along with other types of common variants, rarer 
variants, and gene-gene and gene-environment interactions. If association signals are validated, 
re-sequencing and fine mapping may be necessary to identify the causal variant(s) of interest. 
194,195 Functional assays may subsequently be conducted to validate and elaborate upon our most 
promising findings, and to explore the molecular mechanisms by which the associations may 
influence disease risk.  Thus, the findings from our research have the potential to be the first of 
many important steps to evaluate the influence of inherited mitochondrial and miRNA-related 
variation on EOC risk. 
The ultimate goal of this research was to identify variants that underlie EOC 
susceptibility so that promising findings could be translated into clinically beneficial 
improvements that may reduce the public health burden from EOC.  We suggest that this 
undertaking be accomplished via two main routes. First, the insight gained into the importance of 
these genes and pathways in EOC etiology and pathogenesis may provide opportunities for 
advances in therapeutic and preventive approaches. For example, with regard to miRNA-related 
genes, antagonization of the function of the LIN28 homologues in tumors that over-express these 
genes may provide a means to reactivate the expression of let-7 tumor suppressors and confer 
therapeutic benefit. 156,157,174  Similarly, given that mitochondria and their genomes are the 
primary target of toxicities induced by various drugs (i.e. antineoplastic, immunosuppressant, 
anti-inflammatory), mitochondrial-related genes such as those highlighted in our research (i.e. 
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PPARGC1A, ESRRA, NRF1)  may also provide novel targets for pharmaceutical approaches. 
196,197  Additionally, one of the optimal ways to diagnosis cancer early, monitor disease 
progression, and predict therapeutic response is by using biomarkers, measurable biological 
molecules found in the body or its products that may influence or predict the incidence or 
outcome of disease. 198 The most characterized biomarker for EOC is CA-125, and determination 
of its concentration in circulation is essential for monitoring OC treatment response.  However, its 
utility in screening is poor because of its low sensitivity and specificity. For example, its 
expression is increased in fewer than 50% of early-stage ovarian cancers and it is not expressed in 
20% of women diagnosed with advanced disease. Furthermore, CA-125 has high false-positive 
rates because its expression is increased in many benign gynecologic diseases and in non-ovarian 
tumors.199 For these reasons, it is comforting that recent studies have started to identify other 
promising EOC biomarkers. 200-202  
Furthermore, in light of our findings on the possible importance of miRNA-related and 
mitochondrial-related genes in EOC development, it is also promising that noninvasive and 
reliable sampling methods are being developed in the area of miRNA and mitochondrial 
biomarkers. For example, differentially expressed miRNAs have been detected when comparing 
the serum of ovarian cancer patients and controls203, and differential miRNA profiles of 
circulating tumor exosomes have been detected between serum of ovarian cancer patients and 
patients with benign disease. 204  Studies suggest that mitochondrial DNA mutations in bodily 
fluids may also serve as useful diagnostic and prognostic biomarkers,205,206 with evidence that 
elevated levels of circulating cell-free nuclear DNA and mitochondrial DNA in plasma are 
present in OC patients compared with healthy controls or those with benign ovarian disease.207  
Based on the detection of markers of oxidative stress and DNA damage, such as 8-hydroxy-2’-
deoxyguanosine, in ovarian tumors 70,71,97, it also seems plausible that the detection and 
quantitation of such markers in urine and/or serum samples may be of clinical utility. It is also 
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possible that administration of antioxidants such as vitamin E through nutrition and supplements 
may protect against the harmful effects of ROS. Thus, future studies are warranted in these areas. 
Importantly, in addition to gaining insight into the pathogenesis of the disease, the second 
route by which the identification of EOC susceptibility variants may be translated into clinically 
beneficial improvements is through personalized medicine (genetic profiling). Since EOC 
prevention begins with identifying women at increased risk for the disease so that strategies for 
risk reduction can be recommended, the inclusion of genetic susceptibility markers in existing 
EOC risk prediction models may help to enhance risk assessment.  Such risk assessment may aid 
in medical decision making and may help when designing and recruiting for chemoprevention 
trials. 208 Currently, only one risk prediction model for ovarian cancer has been developed. 
Created by the Collaborative Ovarian Cancer Group in 1994,209 this model provides estimates of 
absolute, age-adjusted and lifetime risk of developing ovarian cancer while taking into account a 
family history of ovarian cancer in a first-degree relative, duration of oral contraceptive use, and 
the number of full term pregnancies. Another model from 2003 estimates the probability of 
having preclinical ovarian cancer based on age and the pattern of serial CA-125 levels.210  Given 
that EOC is a multifactorial disease attributed to both genetic and environmental factors, the 
identification of a panel of EOC susceptibility markers  (i.e. BRCA1 and BRCA2 mutations, and 
lower penetrance alleles such as those mentioned in a review by Fasching et al.68) that can be 
utilized in conjunction with known and suspected epidemiological risk factors (i.e. parity, oral 
contraceptive use, family history of ovarian cancer, endometriosis, tubal ligation, history of 
breast-feeding, talc exposure and various lifestyle factors) to better stratify OC risk may help to 
reduce ovarian cancer incidence and mortality by improving implementation of prevention and 
screening strategies. This sentiment is consistent with the long-term goal of the OCAC, and 
although evidence suggests that including SNPs may only add incrementally to the predictive 
ability of models211-213, it is hoped that even modest gains in predictive power may have 
significant implications for medical decision making 211,214.  For exposures and high-risk alleles 
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that are common in the population (i.e. prevalence >30%), the corresponding population 
attributable risk will tend to be large even if the strength of the interaction is relatively small. 
Thus, common genetic variants have the potential to have a far-reaching impact on the 
population.  
Considering the relative rarity of EOC, an approach that focuses on targeting high-risk 
women may be more feasible and cost-effective, and possibly more readily accepted than 
population-based approaches.  If high-risk women can be identified, risk-reducing options such as 
oral contraceptives and bilateral salpingo-oophorectomy (for women who have completed child-
bearing) can be offered along with screening modalities such as an annual or semiannual 
transvaginal ultrasound, pelvic exam, and CA-125 blood test.  A multidisciplinary team of 
professionals, including genetic counselors, can help to discuss the benefits and limitations of 
these options with at-risk women. The overall estimated protection is approximately 30-40% in 
ever users of oral contraceptives, and a steady inverse relation is observed with duration of use 
4,17-21.  Prophylactic bilateral salpingo-oophorectomy reduces EOC risk by more than 96%.215 
Additionally, high-risk populations can participate in research to develop novel biomarkers for 
prevention and early detection such as those alluded to previously. However, as suggested by 
McCarthy et al.,194 for genetic profiling to become widely applied in clinical practice, there is a 
need to: improve the accuracy of risk prediction through identification of additional susceptibility 
variants; utilize prospective studies to show that profiling results in beneficial modifications of 
medical care; and establish a regulatory environment for the use of such tests. 
In conclusion, the findings reported herein provide valuable insight into the importance 
of miRNA-related and mitochondrial-related SNPs, genes, and pathways in the etiology of EOC. 
Furthermore, our data support the consideration of miRNA- and mitochondrial- related genetic 
variants as candidates when building risk prediction models.  Most importantly, this work has 
provided a strong foundation for further lines of research that may help to reduce morbidity and 
mortality from this grim disease. 
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APPENDICES 
 
 
 
 
 
 
APPENDIX A:  
 
LITERATURE REVIEW 
 
A. Magnitude of the Problem 
Ovarian cancer is a leading cause of morbidity and mortality in the United States, causing 
more deaths per year than any other gynecologic malignancy. 1 Annually, approximately 22,000 
new cases of ovarian cancer are diagnosed and 15,000 ovarian cancer-related deaths are expected. 
1 Mortality is high because women typically present with advanced disease when the overall 5-
year survival rate is 30%. 2  
The lifetime risk of developing ovarian cancer for a woman in the United States 
approximates 1 in 71 (less than 1%), and incidence increases with age (median age at diagnosis = 
63 years)  2. The highest age-adjusted incidence rates are observed in developed parts of the 
world, including North America and Western and Northern Europe, with rates in these areas 
exceeding 10 per 100,000. 216  Rates are intermediate in South America (7.7 per 100,000), and 
lowest in Asia and Africa.  Even within the United States racial differences in risk are apparent 
that mimic the observed international variation. Rates are highest among Whites (14.3 per 
100,000), intermediate for Hispanics (11.5 per 100,000) and lowest among Blacks (10.1 per 
100,000), and Asians (9.7 per 100,000) 2.  Despite the high incidence and mortality rates, the 
etiology of this heterogeneous disease is only partially understood.  
B. Epidemiology of Epithelial Ovarian Cancer (EOC) 
Epithelial ovarian cancer (EOC), the predominant and most lethal subtype of ovarian 
cancer, reflects a heterogeneous group of diseases.  Malignant (invasive) EOC are known as 
carcinomas, and can be classified into four main categories of histological subtypes: serous, 
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mucinous, endometrioid, and clear cell tumors.217 Within each of these categories are tumors of 
uncertain malignant behavior (known as borderline tumors or tumors of low malignant potential) 
that contain microscopic features of malignancy without frank invasion into the surrounding 
stroma.  Epidemiologic studies have reported etiologic differences according to histological 
subtype in both invasive and borderline tumors. 40,41,79-84 
Aside from age, reproductive and hormonal factors are the main risk factors for EOC. 
While factors such as early age at menarche and late age at menopause are only slightly positively 
associated with EOC risk 3,4, increasing parity is a well established protective factor. Parous 
women are estimated to have a 30-60% lower cancer risk compared to nulliparous women, 5-10 
with each additional full-term pregnancy estimated to lower risk by approximately 15% 4,8,11 . 
Breastfeeding may also confer a slight decrease in EOC risk, with odds ratios approximating 0.6-
0.7 4,7,10,12-17.  The most consistent exogenous protective factor against EOC is oral contraceptive 
(OC) use; the overall estimated risk reduction is approximately 30-40% amongst ever users, with 
greater protection observed with longer duration of use 4,17-21. Prolonged use of post-menopausal 
HRT, especially unopposed estrogen therapy, may increase the risk for certain subtypes of EOC. 
22-24 Obesity, a condition that influences circulating levels of hormones, has also been found to 
impact EOC risk. 25-30  It is hypothesized that pregnancy, breastfeeding, and OC use may be 
protective by reducing the number of lifetime ovulatory cycles (LOC), which may in turn reduce 
levels of gonadotropins, oxidative stress, DNA replication errors, and formation of inclusion cysts 
in the ovarian surface epithelium, thereby decreasing EOC risk. 5,31,32 Alternatively, pregnancy 
and OC use are characterized by surges of progesterone which may subsequently exert protection 
by inducing apoptosis of genetically damaged ovarian epithelial cells. 33  
Risk factors that do not affect hormonal or ovulatory events have also been identified. A 
reduced risk of EOC has also been associated with either a hysterectomy or tubal ligation, with 
the protective effect for each of these procedures ranging from 30-40% 6,17,34-38, possibly by 
preventing potential carcinogens such as talc from ascending the genital tract 39.  EOC risk may 
 94
also be increased by lifestyle factors such as cigarette smoking 40-43, alcohol consumption, 44-46 
and certain aspects of diet 47. Thus, it is most probable that a combination of mechanisms underlie 
ovarian carcinogenesis, with emerging evidence suggesting that EOC development and 
progression may be caused by oxidative stress. 69-73,97,100,101,218-220 
C. Inherited Susceptibility to EOC 
A family history of EOC also represents a significant risk factor for the disease. First-
degree relatives of EOC probands have an approximately 2-3 fold increased risk, with higher 
risks associated with multiple affected relatives and earlier ages at onset 48-52.  Although familial 
aggregation may be due to a combination of genetic and shared environmental factors, twin 
studies suggest that the majority of familial EOC risk is attributed to genetic factors.53  A subset 
of EOC occur as part of a hereditary cancer syndrome that is inherited in an autosomal dominant 
pattern. The majority of hereditary EOC can be attributed to highly penetrant mutations in the 
BRCA1 and BRCA2 genes 54,55, with risks by age 70 years approaching up to 44% in BRCA1 
families 56 and up to 27% in BRCA2 families  57.  EOC also occurs in families with Hereditary 
Non-Polyposis Colorectal Cancer Syndrome (HNPCC), also known as Lynch Syndrome II 58. The 
genetic defects underlying HNPCC (the mismatch repair genes hMLH1, hMSH2, hPMS1, hPMS2, 
and hMSH6), 58,59 may account for roughly 2% of EOC, 60 and confer up to a 12% lifetime EOC 
risk 61-63.  Overall, mutations in highly penetrant genes are believed to account for 10-15% of 
EOC 64,65. Studies to identify other major EOC susceptibility genes provide little evidence for 
their existence 66,67. Thus, it is generally held that most of the inherited component of ovarian 
cancer may be attributed to common, low penetrant variants that have yet to be identified. 68 The 
most common type of variant, a single nucleotide polymorphism (SNP), involves a single base 
pair substitution at a particular site in the DNA sequence. More than 14 million SNPs have been 
identified in the human genome, and estimates suggest that on average there is one SNP every 
300 base pairs across the genome. 221 Although most SNPs would increase risk to a lesser degree 
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than highly penetrant alleles, they may contribute to the development of a higher proportion of 
EOC by virtue of their higher population frequencies. 
Our global hypothesis is that inter-individual variation in two understudied yet 
biologically important types of genes, mitochondrial-related genes and miRNA-related 
genes, may contribute to EOC susceptibility.  In the remainder of this section, we summarize 
our rationale for evaluating the association between individual SNPs and haplotypes (block of 
SNPs in physical close proximity that are often inherited together) in these genes and EOC risk. 
D. Rationale for Studying Inherited Mitochondrial Variation 
D.1. Introduction to mitochondrial-encoded (mtDNA) and nuclear-encoded (nDNA) 
mitochondrial genomes   
  Mitochondria are semiautonomous membrane-bound organelles that play a central role in 
free radical production, cellular energy metabolism, programmed cell death (apoptosis), and 
maintaining stability of the nuclear genome 222-227. Aside from the nucleus, the mitochondrion is 
the only cellular organelle that contains its own genome and genetic machinery. The 
mitochondrial genome (mtDNA) is a maternally-inherited 16.6 kilobase, double-stranded, 
closed circular molecule, whose complete nucleotide sequence has been characterized 228,229 . A 
unique set of polymorphisms accumulated in the maternal lineage of mtDNA are represented in 
classes known as haplogroups; the European population is almost exclusively distributed among 
nine haplogroups designated H, I, J, K, T, U, V, W, and X, whereas haplogroups A, B, C, D, and 
E are specific to the Asian population, and haplogroups L1, L2, and L3 correspond to the African 
population 230.  
MtDNA encodes 37 genes: 13 polypeptides, 22 transfer RNAs (tRNA), and 2 
ribosomal RNAs (rRNA) 74,223. Each of the 13 polypeptides encoded by mtDNA provide 
instructions for making enzymes involved in the respiratory chain/ oxidative phosphorylation  
(OXPHOS) system, a process that oxidizes molecular oxygen to water, creating adenosine 
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triphosphate (ATP), the cells’ primary energy source. The rRNAs and tRNAs are required to 
synthesize the 13 polypeptides. 226 
Mammalian cells usually contain more than 1000 mitochondria and up to 10,000 copies 
of mtDNA 74. Typically, all mitochondria within a given cell are homoplasmic, meaning they 
share identical DNA sequences.  Heteroplasmy, or differences in mtDNA sequences within the 
same cell, can arise due to somatic or “de novo” mutations. Disease manifests only when the 
levels of mutated DNA reach a certain threshold. This threshold varies by tissue type and is 
dependent on a particular cell’s energy status and requirement for oxidative metabolism 74. 
In addition to the 13 mitochondrial proteins encoded by mtDNA, approximately 1500 
mitochondrial proteins are encoded by nuclear DNA (nDNA) as a consequence of proto-
mitochondrial genes integrating into the nuclear genome throughout evolution 75,231. The 
nuclear-encoded mitochondrial proteins are ultimately imported from the cytoplasm into 
mitochondria. Although the mitochondrial and nuclear genomes are physically distinct, they 
appear to have a high degree of functional interdependence, with recent studies suggesting that 
cross-talk between the two genomes influences disease processes 69,74,223,224,232.  
D.2. The importance of mitochondrial biogenesis 
Evidence suggests that the coordinated expression of mtDNA and nDNA is critical to 
the complex process of generating new mitochondria, known as mitochondrial biogenesis. 
Mitochondrial biogenesis is influenced by external stimuli that change the energetic and 
physiological conditions of the cell, including temperature, the availability of nutrients, the 
presence or absence of hormones, and exercise. 133These external stimuli can increase 
intracellular concentrations of calcium which in turn stimulate different kinases to activate 
transcription. At the molecular level, certain transcription factors and transcriptional 
coactivators are then responsible for regulating mitochondrial genes involved in key processes 
such as OXPHOS, heme biosynthesis, mitochondrial import, and mtDNA transcription and 
replication 106,133, ultimately leading to mitochondrial biogenesis. These transcription factors 
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can be categorized into three main groups: ubiquitous transcription factors (i.e. SP1, YY1, 
CREB), nuclear respiratory factors (i.e. NRF-1, NRF-2), and coactivators (i.e. PPARGC1A, 
PRC). 136 Defective mitochondrial biogenesis can lead to slower mitochondrial turnover, 
altered OXPHOS activity, and increased accumulation of damaged DNA, lipids, and proteins. 
102,106,233,234 Thus, a disturbance in the genes regulating any of these processes may promote 
altered mitochondrial function and disease state, with evidence to support a role for defective 
mitochondrial biogenesis in cancer cells.132 
D.3. Biologic Plausibility for a Mitochondrial Dysfunction-Cancer Link 
 Mitochondrial dysfunction has been implicated in a broad range of conditions, including 
neurodegenerative diseases, deafness, diabetes mellitus, aging and longevity, and cancer 108,205,230. 
Defects in mitochondria were first suggested to contribute to the development and progression of 
carcinogenesis in 1973 when quantitative and qualitative electron microscopy showed structural 
differences in this organelle between cancer patients and controls 235.  Currently, one of the most 
common and consistent features of cancer cells is their defective mitochondria, with differences 
reported between normal and cancerous mitochondrial cells in terms of their molecular 
composition, production level of certain metabolites, and copy numbers per cell. 74,231   
Studies have specifically suggested that a by-product of the mitochondrial OXPHOS 
process, reactive oxygen species (ROS), plays a role in promoting oxidative stress and cancer 
development. Oxidative stress is a phenomenon arising due to an imbalance between the 
production of antioxidant species and ROS.  Although low levels of ROS regulate cellular 
signaling and are essential in normal cell proliferation, increased ROS production may cause 
oxidative stress and subsequent mtDNA and nDNA damage, leading to genetic instability and 
ultimately cancer. 77,236  Importantly, experimental and epidemiologic evidence suggests EOC 
development and progression may be caused by oxidative stress. 69-73,97,100,101,218-220 Because ROS 
is generated in the mitochondria, mtDNA is more susceptible to damage and mutagenesis than 
nDNA, especially when considering that mtDNA contains no protective histones, is devoid of 
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introns, and has inefficient DNA repair capacity 226,231.   During carcinogenesis, the higher 
levels of ROS accelerate the somatic mutation rate in mtDNA at an approximately ten-fold 
greater rate than in nuclear DNA 237  Thus, it is not surprising that somatic mtDNA mutations 
have been identified in a wide range of tumor cells (Figure D1), including ovarian cancer cells, as 
reviewed by Verma et al. 238  Studies of somatic mutations in ovarian cancers 239,240 have 
identified mtDNA mutations in CYTB, 241 COI, 103 COII, 242 ATP6, 242 the 16S and 12S rRNA 
subunits, 240,242 and the displacement loop (D-Loop) 239,240,242, the main mtDNA regulatory 
region and most common site of mtDNA mutations in different tumors. 238 Certain somatic 
mtDNA mutations may also reliably distinguish between histologic subtypes of EOC. 103,242 
While much attention has been focused on somatic mtDNA mutations in tumor tissue, 
little attention has been directed to the possible role of germline mitochondrial polymorphisms 
in causing impaired mitochondrial function and subsequent cancer development.  It has been 
hypothesized that SNPs in mtDNA and/or nDNA may contribute to subtle changes in encoded 
proteins, altered OXPHOS activity, and excess ROS production over time, potentially leading to 
DNA damage and cancer. 73,76,111,236,243  Inter-individual variation involving mtDNA 104 and the 
following categories or ‘pathways’ of nDNA may alter cancer risk by promoting oxidative stress: 
mitochondrial biogenesis (BIO) proteins represent transcription factors and co-activators that 
regulate mtDNA and nDNA involvement in OXPHOS and mtDNA transcription and 
replication 102,105,106; OXPHOS (OXP) proteins, when impaired, alter OXPHOS activity and have 
been implicated in various conditions 244, including hereditary cancer syndromes 107,245; and 
steroid hormone metabolism (HOR) proteins, primarily receptors that have been localized to 
mitochondria, can directly influence OXPHOS, mitochondrial biogenesis, transcription, and 
apoptosis. 110,246-248  These SNPs may also influence cancer risk by interacting with one another or 
with non-genetic exogenous or endogenous factors known to contribute to ROS accumulation.  
Such factors, some of which are known or putative EOC risk factors, include hormones, aging, 
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inflammation (possibly ovulatory trauma-induced), high dietary fat, radiation, alcohol use, and 
cigarette smoke. 76-78 
D.4. Epidemiologic Studies Evaluating Inherited Mitochondrial Variation-Cancer Associations 
 
The association between inherited mitochondrial polymorphisms or haplogroups and 
cancer risk has been evaluated in several case-control studies involving various cancer types 
(Table D.4.), with several studies reporting significant positive or inverse associations. 111-116 
Although Caucasians represent the study population for the majority of the studies in Table D.4., 
African American 113 and Chinese 114,116 individuals are represented in others. The majority of 
studies evaluated SNPs occurring in mtDNA only; only one study 117 also investigated variation 
in nuclear-encoded mitochondrial genes (nDNA). While most studies 111,112,115,117,249 focused on 
SNPs based on their distribution across the mitochondrial genome and/or because they defined 
common haplotypes in Europeans, several studies 113,114,116 evaluated a few SNPs that were 
selected based on research findings in non-cancerous diseases. Selected studies in Table D4 have 
also primarily focused on evaluating the independent effects of certain mtDNA SNPs or 
haplotypes and cancer risk, and most did not consider the impact of non-genetic factors or 
heterogeneity defined by histopathological characteristics.  To date, only the Chinese study by 
Liu et al. 114 has investigated the association between inherited mtSNPs and ovarian cancer risk, 
with no significant associations detected.  However, only a few mtSNPs were genotyped and the 
sample size was small. 
Table D.4. Characteristics of selected case-control studies that have evaluated the association between inherited 
mitochondrial polymorphisms and cancer risk.  
Study 
(Country) 
Cancer 
Type(s) 
# 
Cases 
# 
Controls 
# SNPs/haplotypes 
evaluated 
Statistically Significant Findings (p <0.05) 
Reported 1    
Bai et al, 
2007 111 
(USA) 
Breast 156 260 69 mtDNA SNPs 
G9055A (OR=3.03, 95% CI: 1.61-5.63); A10398G 
(OR=1.79, 95% CI: 1.14-2.81); T16519C (OR=1.98, 
95% CI:1.25-3.12); T3197C (OR=0.31, 95% CI: 
0.13-0.75); and G13708A (OR=0.47, 95% CI: 0.24-
0.92)  
Booker et 
al, 2006 112 
(USA) 
Prostate 
Renal 
121  
221  
246 9 mtDNA haplotypes 
Haplotype U (OR=1.95 for prostate cancer and 
OR=2.52 for renal cancer)  
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Canter et al, 
2005 113 
(USA) 
Breast 654 605 1 mtDNA SNP 
G10398A (OR=1.60, 95% CI:1.10-2.31) in African 
Americans 
Liu et al, 
2003 114 
(China) 
Endometria
l 
Cervical 
Ovarian 
51 
67 
53 
107 3 mtDNA SNPs 
T16189C (OR=2.77, 95% CI: 1.35-5.70 for 
endometrial cancer), p=0.009 2 
Xu et al, 
2006 116 
(China) 
Endometria
l 
49 31 3 mtDNA SNPs Haplotype D, p=0.017 2 
Wang et al, 
2007 115 
(USA) 
Pancreatic 955 1102 24 mtDNA SNPs None 
Wang et al., 
2008 117 
(USA)  
Prostate 1000 495 
24 mtDNA SNPs & 
376 SNPs localized 
to 78 nDNA genes 
None 
Webb et al., 
2008 249 
Colorectal 2854 2822 132 mtDNA SNPs None 
Abbreviations: mtDNA=mitochondrial DNA; SNPs=single nucleotide polymorphisms; OR=odds ratio; CI= 
confidence interval  
1 Results are as reported in the original publication; absence of p-values or CI indicates none were provided  
2  Unclear if adjustments were made for multiple comparisons. 
 
Taken together, experimental and epidemiologic research suggests that mitochondrial 
genetic background can play a role in modifying an individual’s cancer risk. To date, only one 
small study based on 53 cases 114  has explored the role of germline mitochondrial sequence 
variation in the occurrence of ovarian cancer. Much larger epidemiologic studies are needed to 
further test this hypothesis. 
Thus, in our first manuscript, we evaluate the hypothesis that SNPs and haplotypes in 
mitochondrial-related genes (i.e. mitochondrial genes encoded by mtDNA or nDNA involved in 
BIO, OXP, or HOR) may play an important role in the etiology of EOC. We further hypothesize 
that the germline mitochondrial variation-EOC link may be influenced by hormones, ovulation, 
and smoking, and that observed associations may differ by histologic subtype. We also sought out 
to assess the overall significance between each pathway and gene and EOC risk.  
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E. Rationale for Studying Inherited Variation in MicroRNA (miRNA)-related Genes 
E.1. MiRNAs: function, biogenesis, and role in carcinogenesis 
Since gene deregulation is one of the main mechanisms by which carcinogenesis can 
occur 85, the evaluation of inherited variants in post-transcriptional regulators of gene 
expression also represents an understudied area of high importance in EOC epidemiologic 
research. MicroRNAs (miRNAs) are a class of evolutionarily conserved 19-25 nucleotide long 
non-protein encoding RNAs that function as gene regulators by binding to the 3’ untranslated 
region (UTR) of target gene messenger RNA (mRNA), causing inhibition of translation and/or 
mRNA degradation 250,251.  MiRNAs have been implicated in a broad range of biological and 
pathological processes, many of which are routinely altered in cancer, including cell growth, 
differentiation, apoptosis, and metastasis. 86  
Almost 700 human miRNAs have been identified thus far 252,253, and computational 
analyses predict that that up to 1,000 human miRNAs exist. 254 MiRNAs are distributed 
throughout the genome as single genes or gene clusters, with the latter generating large 
polycistronic transcripts from which the individual miRNAs are processed 251,255.  While some 
miRNA genes are found in intergenic regions, the majority are located in defined transcription 
units (i.e. introns or exons of both protein coding and long non-protein coding transcripts), and 
are co-transcribed with the gene in which they reside 251. Furthermore, the majority of miRNAs 
deregulated in human cancer have been aligned to genomic fragile sites or regions associated with 
cancers. 256 While miRNA genes only represent a small component of the human genome, they 
are predicted to regulate up to 30% of all human protein-coding genes, with a single miRNA 
family regulating hundreds to thousands of different genes. 257  
MiRNA biogenesis, the synthesis and maturation of miRNAs, includes several key steps. 
MicroRNAs are transcribed by RNA polymerase II into several kilobase long primary RNAs (pri-
miRNAs) that contain a 5’ Cap structure and a 3’ polyadenylated tail. In the nucleus, the pri-
miRNAs are then processed by DROSHA, a member of the RNAase III enzyme family, and its 
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double stranded binding protein DGCR8, into miRNA precursor(s) (pre-miRNAs) of 65-85 
nucleotides in length which are folded in stem-loop structures.  The pre-miRNAs are then 
exported from the nucleus to the cytoplasm by exportin-5 and its cofactor RAN-GTP, where they 
are processed by another RNase III enzyme, DICER, and its binding partners, TRBP and PACT. 
This creates a ~22 nucleotide double stranded RNA duplex that recruits the Argonaute proteins, 
forming a RNA-induced silencing complex (RISC). In this complex, one strand is retained as the 
mature miRNA, whereas the other strand is usually degraded.  The RISC complex subsequently 
binds to the 3’UTR of the target mRNA by imperfect Watson-Crick complementarity in that the 
5’ end of the miRNA tends to have more bases complementary to the target mRNA than the 3’ 
end. 258 Such binding causes repression of translation and possible mRNA degradation. 255,259  
Ground-breaking studies on chronic lymphocytic leukemia (CLL) provided the first 
evidence that miRNAs play a direct role in cancer, with frequent deletion of the 13q14 region in 
the majority of B-cell CLL cases suggesting the presence of a tumor suppressor gene in that 
locus. 260 Ultimately, a non-protein coding gene called leukemia associated gene 2 (LEU2) was 
identified as the common region lost in CLL patients, and mir-15a and mir-161 were detected in 
the first intron of the LEU2 gene.261   Since miRNAs are a critical component of several cellular 
regulatory networks and serve as global regulators of gene expression, it is postulated that 
defective miRNA function and/or altered miRNA expression may cause an imbalance in cellular 
homeostasis and subsequent development of complex diseases such as cancer 251,262. While many 
disrupted miRNAs have not been implicated in cancer causation because they are indirectly 
altered by genomic, epigenomic, or physiological changes that take place during carcinogenesis, 
251,255 other miRNAs and components of miRNA biogenesis machinery are believed to directly 
participate in cancer development and are known as oncomirs. 255,263 Oncomirs are classified as 
tumor suppressor genes (TSG) when they impair tumor progression or as oncogenes (OG) when 
they promote it. For example, expression levels of let-7 and the mir-15a/mir 16-1 cluster are 
reduced (down-regulated) in some tumors, suggesting their potential function as TSG. 264 On the 
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other hand, some miRNAs (i.e. mir-155 and mir-21) are up-regulated in certain tumors when 
compared to normal tissue, illustrating oncogenic properties 265  Furthermore, the genes that are 
targeted by miRNAs are usually TSG or OG. 258,266 
E.2. Differential miRNA expression profiles in ovarian tumors 
Differential miRNA expression profiles have been demonstrated when comparing human 
tumors and their normal counterparts, with correlations reported between certain miRNA profiles 
and the etiology, classification, progression, and prognosis of numerous tumor types. 258,264,267  Of 
studies that have investigated miRNA expression patterns in malignant versus normal ovarian 
tissue, most have detected altered expression profiles in tumors 268-273. For example, Iorio et al 269 
conducted genome-wide miRNA expression profiling on 69 malignant epithelial ovarian tissues 
and 15 normal ovarian tissue sections, and found that the overall miRNA expression could clearly 
distinguish tumor versus normal tissue. MiRNAs significantly overexpressed in ovarian tumors 
included mir-200a, mir141, mir-200c, and mir200b, while mir199a, mir-140, mir145, and 
mir125b1 were significantly down-regulated. Additionally, Iorio et al. 269 identified miRNAs 
whose expression profile was correlated with characteristics such as histological subtype and 
level of tumor invasion.   Nam et al. 270 used a customized miRNA microarray to evaluate 
miRNA signatures in 20 serous ovarian cancers compared with corresponding normal tissue, and 
found that 23 miRNAs were differentially expressed in at least 12 of the 20 cancers.  The most 
frequently up-regulated miRNA was mir-21, while the most frequently down-regulated miRNA 
was mir-125b. 270 Using a mirCURY™ LNA miRNA assay,  Dahiya et al.268 also detected 
numerous miRNAs with altered expression in ovarian tumors and cell lines, including significant 
up-regulation of mir-221 and down-regulation of mir-21 and members of the let-7 family.  
Similarly, in a study by Yang et al.273 that used a miRNA microarray containing 515 human and 
mouse miRNAs, several miRNAs were deregulated in ovarian cancer; whereas mir-199a, mir-
200a, and mir-214 were up-regulated. To validate microarray results, each of these studies 268-
270,273 performed Northern Blots on some of the differentially expressed miRNAs, and found 
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agreement between the methods.  However, overall there are few deregulated miRNAs in 
common between these studies of ovarian tumors, possibly due to the different array platforms 
used or the choice of normal control (immortalized ovarian surface epithelial cells 268 versus 
whole ovaries 269,270), with surface epithelial cells postulated to be more representative of the 
origin of the cancer. Furthermore, it is possible that technical variables (i.e. time between sample 
removal and RNA isolation, amplification yield, hybridization efficiency) may influence results 
from miRNA expression studies. 274 
E.3. SNPs in miRNA-related genes as contributors to altered miRNA expression and cancer risk  
MiRNA expression profiles in ovarian tumors have been associated with copy number 
alterations, epigenetic alterations, and alterations in miRNA biogenetic machinery,269,271,272 yet 
causal support for such associations is lacking. One mechanism that may lead to deregulated 
miRNA expression involves germline sequence variations, such as SNPs, in miRNA-related 
genes, with functionally relevant SNPs potentially impacting transcription of miRNA primary 
transcripts, processing of miRNA precursors to mature miRNAs, or miRNA-target interactions.158  
As such, case-control studies have been conducted to identify SNPs in miRNA-related genes (i.e. 
primary, precursor, and mature miRNAs, miRNA biogenesis genes, and miRNA binding regions 
of target TSG and OG) that are associated with cancer risk, with some reports of positive or 
inverse associations (Table E.3.) 93-95,266,275,276.   However, we are unaware of published studies on 
the topic in EOC. 
Table E.3.  Characteristics of selected case-control studies evaluating the association between 
inherited SNPs in miRNA- related genes and cancer risk. 
Study Cancer 
type 
#  
Cases 
#  
Controls 
# SNPs 
investi
gated 
# miRNA-related 
genes  
investigated  
(type of genes) 
Statistically Significant  
(p <0.05) Findings 1, 2 
Yang et al. 
94  
Bladder 746 746 41 26 (11 biogenesis 
genes, 7 pre-, & 8 
pri-miRNAs) 
-rs197414 in GEMIN3: 
(OR=2.50, 95% CI: 1.08-5.78, 
p=0.03 (R)) 2 
-Common haplotype in 
GEMIN4:(OR=1.25, 95% CI: 
1.01-1.54, p=0.04) 2 
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Ye et al. 95 Esophageal 346 346 41 26 (11 biogenesis 
genes, 7 pre-, & 8 
pri-miRNAs) 
-Seven SNPs (residing in pre-, 
pri-, and miRNA biogenesis 
genes), with rs6505162 in pre-
mir423 representing the most 
significant association 
(OR=0.64, 95% CI: 0.51-0.80), 
p for trend <0.0001 (A)) 
-Common haplotype in 
GEMIN4: (OR=0.65, 95% CI: 
0.42-0.99, p=0.044) 
Horikawa  
et al. 93 
Renal Cell 279 279 40 26 (11 biogenesis 
genes, 7 pre-, & 8 
pri-miRNAs) 
-rs2740348 in GEMIN4: 
(OR=0.67, 95% CI: 0.47-0.96, 
p for trend=0.014 (A)) 
-rs7813 in GEMIN4: 
(OR=0.68, 95% CI: 0.47-0.98, 
p=0.039 (D)) 
-Common haplotype in 
GEMIN4: (OR=0.66, 95% CI: 
0.45-0.97, p=0.035)  
Jazdewski 
et al. 276 
Thyroid 
(papillary) 
608 901 1 1 (pre-miRNA) -rs2910164 in pre-mir-146a: 
(GC vs GG (reference): 
OR=1.62, 95% CI: 1.3-2.0, 
p=0.000007); (CC vs GG+GC: 
OR=0.42, 95% CI: 0.24-0.73, 
p=0.0027); (GG vs CC+GC: 
OR=0.69, 95% CI: 0.57-0.85, 
p=0.0006); (CC vs GG: 
OR=0.5, 95% CI: 0.28-0.89, 
p=0.024) 3 
Hu et 
al.275 
Breast 
 
1009 1093 4 4 (pre-miRNAs) -rs11614193 in pre-mir-196a2: 
(OR=1.23, 95% CI: 1.02-1.48, 
p=0.032 (D)) and rs3746444 in 
pre-mir-499: (OR=1.25, 95% 
CI: 1.02-1.51, p=0.028 (D)) 3 
Landi et 
al. 266 
Colorectal 697 624 8 8 (miRNA binding 
sites) 
-rs17281995 in CD86: 
(OR=2.74, 95% CI: 1.24-6.04 
(R)) -rs1051690 in INSR: 
(OR=1.94, 95% CI: 1.03-3.66 
(R))  
Abbreviations: SNPs=Single nucleotide polymorphisms; OR=odds ratio; CI=confidence interval 
1 Most significant genetic model (A= Additive, D=Dominant, R=Recessive); 2 Results did not hold after adjustment for 
multiple comparisons; 3 Adjustment for multiple comparisons not reported  
 
Data suggests that defective miRNA biogenesis may influence miRNA expression, 
tumorigenesis, and clinical outcomes. 89,90 In EOC, down-regulation of key miRNA biogenesis 
proteins DICER and DROSHA have been associated with global miRNA changes and reduced 
survival. 154,155 An unfavorable EOC prognosis has also been correlated with over-expression of 
the pluripotent RNA binding protein homologues, LIN28 and LIN28B. 156,157  By directly blocking 
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DROSHA and DICER-mediated processing, these homologues negatively regulate biogenesis of 
let-7 miRNAs, TS down-regulated in EOC and other tumors. 174   Since SNPs in miRNA 
biogenesis genes may alter miRNA expression 91, and a few published studies of diverse tumor 
types have found an association between such SNPs and cancer risk (Table E.3.), 92-95 for our 
second manuscript we evaluate the hypothesis that SNPs and haplotypes in miRNA biogenesis 
genes may influence EOC risk overall and/or the risk of serous carcinomas, the predominant 
subtype of EOC. 
F. Overview of Resources Used to Conduct this Research 
To evaluate our hypotheses and corresponding aims, we utilized genotype and 
epidemiologic data obtained through stage 1 of an ongoing, multi-center, case-control study that 
uses a genome-wide association (GWA) study approach to investigate the influence of >550,000 
SNPs in the human genome and EOC risk. Stage 1 of the parent study and the investigations 
reported herein include data from 4 participating study sites, for a combined study population of 
3,715 subjects (1,815 primary invasive EOC cases and 1,900 controls frequency-matched to cases 
on age-group, race, and geographic region). A description of the parent study and component 
case-control studies, study eligibility criteria, the genotyping platform, quality assurance and 
quality control procedures, integration of covariate data used, definitions of outcome and 
independent variables, and sample size calculations appear in Appendices B-H, respectively.    
G. Significance of this Research 
This research is significant because it is the first to comprehensively investigate 
associations between SNPs in mitochondrial-related and miRNA-related genes and EOC risk. 
Furthermore, this research is innovative because it evaluates underexplored yet biologically 
relevant paradigms for EOC susceptibility. The knowledge gained in this endeavor will not only 
allow for identification of women at high-risk for EOC, but will advance our understanding of the 
pathogenesis and progression of this incompletely understood and deadly malignancy.  
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APPENDIX B: 
 
BRIEF OVERVIEW OF THE PARENT STUDY AND  
COMPONENT CASE-CONTROL STUDIES 
 
 The research reported herein utilizes resources and expertise from a large, ongoing multi-
center case-control study of epithelial ovarian cancer (EOC), the “Haplotype-Based Genome 
Screen for Novel Ovarian Cancer Loci,” initiated in March of 2007 (Principal Investigator, 
Thomas A. Sellers, Ph.D. (R01 CA114343)).   Also informally referred to as a United States 
Ovarian Cancer Genome-Wide Association Study (US OC GWAS), the goal of the 
aforementioned study is to use a genome-wide association (GWA) approach to identify common 
genetic variants, or SNPs, in the human genome that are associated with EOC risk.  Unlike a 
candidate gene approach, a GWA approach is not predicated upon knowledge of the function, 
location, sequence, or regulatory structure of relevant genes.  Instead, the strategy entails using a 
dense array of genetic markers to capture a substantial proportion of the estimated 10 million 
common SNPs in the human genome, with the goal of identifying where the frequency of SNPs 
systematically differs between cases and controls. 194   
Given that the majority of the human genome is contained in blocks (haplotypes) within 
which little variation exists 277, the subset of SNPs that reside in a particular haplotype are 
typically inherited together and may serve as proxies or “tags” for other SNPs in that region.  The 
power to detect an association depends on the linkage disequilibrium (r2) between such a 
haplotype-tagging SNP (htSNP or tagSNP) and an adjacent causative SNP, with a high r2 (>0.80) 
indicating that two SNPs are good proxies for one another. 277,278 The use of tagSNPs enables 
researchers to capture genome-wide variation with great efficiency by dramatically reducing the 
total number of SNPs required to assess disease associations while maintaining similar 
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information and power as if one had genotyped a larger number of randomly-selected SNPs. 278,279 
Furthermore, testing fewer redundant SNPs also minimizes data handling and computation time 
and reduces false positive errors from multiple hypothesis testing. 278 
To increase study efficiency, two main strategies incorporated into the US OC GWAS 
include use of tagSNPs and a two-stage design. Whereas the first stage of the study entails 
identifying SNPs that may be significantly associated with EOC risk in a relatively homogeneous 
population, the second stage involves carrying forward the most promising SNPs from stage I 
into a larger, more heterogeneous study population with the intent of replication and validation.  
Since successful conduct of a GWA study also requires a large, well-characterized and 
representative study population, 4 large case-control studies of EOC collaborated to form the first 
stage of our US OC GWAS.  Informed consent was obtained from study participants from the 
contributing case-control studies so that their de-identified biospecimens (DNA samples) and data 
could be used for the US OC GWAS and the research reported herein. The four contributing 
studies to stage I (and the current research) include the Mayo Clinic Ovarian Cancer Study 
(MAY), the North Carolina Ovarian Cancer Study (NCO), the University of Toronto Familial 
Ovarian Tumor Study (TOR), and the Tampa Bay Ovarian Cancer Study (TBO).  All studies 
recruited incident cases of pathologically confirmed primary epithelial ovarian cancer (EOC), 
either borderline or invasive. Controls recruited from each of these studies represent healthy 
women with at least one ovary intact at the time of the interview date. All studies frequency-
matched controls to cases on age-group, race/ethnicity, and geographic region. Three studies used 
population-based ascertainment for the cases (NCO, TOR, TBO), and one study was clinic-based 
(Mayo).  Although the Mayo study is not a true population-based study, ascertainment has been 
limited to counties in which greater than 50% of cases are treated at Mayo. When compared to the 
case demographics of the neighboring Iowa SEER registry, Mayo cases are in fact representative 
of the broader case population.  
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APPENDIX C:  
 
STAGE I INCLUSION/EXCLUSION CRITERIA 
 
Case definition:      Women aged 20+ with incident, pathologically confirmed primary EOC.  
Control definition:  Healthy women aged 20+ with at least one ovary intact at date of interview 
(frequency-matched to cases on age-group, race, and study site). 
 
Exclusion criteria, in order of priority*  Cases Controls N ineligiblea 
Inadequate DNA X X unknown 
Primary peritoneal and fallopian tube cancers X NA 124 
Personal history BRCA1/2 mutation  X X 155 
Personal history ovarian, breast, uterine, or early-onset colorectal 
cancer 
X X 
296 
Non-epithelial ovarian tumors (sarcomas, germ-cell, sex-cord 
stromal) 
X NA 
98 
Race as Non-White (African Americans, Asians, Others) X X 502 
Ethnicity as Hispanic or Jewish X X 89 
Borderline (low malignant potential) ovarian tumors X NA 355 
NA=Not applicable  
* Starting N=~5747 (3117 Cases, 2630 controls); After applying exclusion criteria, N=~4128 (1941 cases, 
2187 controls) available for genotyping. 
a N equals subjects from component studies deemed ineligible to participate in stage I after applying 
exclusion criteria (based on data from April 2009). 
 
 
 
 
 
 
APPENDIX D: 
 
ILLUMINA INFINIUM 610K ARRAY  
WHOLE-GENOTYPING PLATFORM DESCRIPTION 
 
The Illumina Infinium 610K Array (also known as the Illumina Human 610-quad 
Beadchip) Whole-Genome Genotyping Platform (WGG), the platform for stage I of the US OC 
GWAS, assays more than 610,000 tagSNPs and markers per sample, capturing the majority of 
variation in regions of the human genome. Compared to other WGG platforms, Illumina’s 
platform has been identified as superior due to the marker selection strategy. 280  The >550,000 
tagSNPs residing on the Beadchip were selected from over 2 million common SNPs discovered in 
Phase I and II of the International Hap Map Project using an algorithm for the linkage 
disequilibrium (LD) statistic, r2, to select SNPs in each of the four HapMap populations: the US 
Utah population with Northern and Western European ancestry (CEU), the Yoruban population 
from Ibadan, Nigeria (YRI), the Japanese in Tokyo, Japan (JHT), and the Han Chinese in Beijing, 
China (CHB).221,279,281 Additional SNPs are utilized on the 610K array to supplement tagSNP 
content to ensure even spacing across the genome. In addition to mitochondrial SNPs, other 
categories of included markers are non-synonymous SNPs, tagSNPs in the major 
histocompatibility complex, and sex-chromosome SNPs.   An estimated 60,000 additional 
markers on the 610K Array include established and postulated copy number variants (CNV).  The 
610K array also offers comprehensive coverage across the HapMap study populations, with 
approximately 93%, 91%, and 75% genomic coverage of CEU (European), CHB/JHT (Asian) 
and the YRI (African) populations, respectively (r2>0.8). All SNPs represented on the array have 
been subjected to functional testing to ensure strong performance.  
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Highlights of the 610K Array also include the ability to process 4 samples simultaneously 
using low sample input (200 ng DNA per sample).  Furthermore, perhaps one of the most 
remarkable features of the platform is the assay that is used. Illumina’s Infinium ™ HD assay 
features single-tube sample preparation and whole-genome amplification without polymerase 
chain reaction (PCR) or ligation steps, dramatically minimizing labor and sample handling errors. 
The Infinium ™ assay also incorporates Beadchips, which are micro-electrical-mechanical 
systems in which DNA immobilized beads are randomly dispersed and assembled into wells on 
silicon wafers through a combination of photo lithography and plasma etching. A decoding 
process ultimately maps the location and identity of each bead on the array, creating an adaptable 
system that is capable of targeting almost any SNP of interest.  
As reviewed by Steemers and Gunderson, 279,282 the Infinium assay ™ protocol consists 
of four main steps, including: 1) whole genome amplification (WGA), 2) hybridization to a 
‘gene-expression-like’ (i.e. Beadchip) capture array, 3) array- based enzymatic scoring, 4) and 
signal amplification. The WGA step amplifies the input genomic DNA by over 1000 times, 
leading to hundreds of micrograms of WGA product. The unlabeled WGA DNA is then 
hybridized to the bead array of oligonucleotide capture probes (50-mers), enabling individual 
targets to bind to their cognate bead. Each SNP locus is then scored (genotyped) by an enzymatic-
based extension assay using labeled nucleotides. Specifically, a single-color allele-specific primer 
extension (ASPE) format is employed.  In the ASPE format, two probe pairs (designated bead 
types A and B corresponding to alleles A and B) are used per locus.  The two probes are identical 
except for their terminal 3’ base, which is designed to perfectly match one allele or the other.  
Perfect 3’ complementarity between the probe and the hybridized target allows efficient primer 
extension (allele A), whereas a single base mismatch at this site (allele B) greatly reduces 
extension efficiency.  
After extension, these labels are visualized via a signal amplification step by staining 
with an immunohistochemistry-based assay (i.e. the XStain HD reagent) that increases overall 
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sensitivity because it is optimized to provide a higher signal to noise ratio.  The image is then 
scanned using Illumina’s iScan Reader system, a cutting-edge high-resolution scanner that 
supports rapid, sensitive, and accurate imaging. It uses high-performance lasers, optics, and 
detection systems, resulting in significantly reduced scanning times without sacrificing data 
quality and reproducibility. Automated genotype clustering and calling can then be performed 
using Illumina’s GenomeStudio software, which is described in greater detail in appendix D.    
Overall, all of the features referred to above enable Infinium Beadchips to offer benefits 
in terms of several critical parameters that contribute to the statistical power in GWA studies: 
genomic coverage, array efficiency, call rate, and call accuracy.  
  
 
APPENDIX E: 
STAGE I GENOTYPING PLATFORM QUALITY ASSURANCE AND  
QUALITY CONTROL PROCEDURES 
 
All genomic DNA samples for stage I of the US OC GWAS were sent to the Mayo Clinic 
Genotyping Shared Resource (GSR) Facility (Rochester, Minnesota) for genotyping. Stage I 
sample requirements included 2.7 μg of DNA (35 μL at 75 ng/μL). Each study site was asked to 
quantify DNA concentration of each sample via the PicoGreen assay (Molecular Probes, Inc., 
Eugene, OR) before aliquoting samples into a 0.8 mL 96-deepwell MIDI storage plate (96-well 
plate). Contents of each plate included 92 samples from unique study participants (cases and 
controls), with alternating case and control samples interspersed throughout each plate.  All 
laboratory personnel were blinded as to the case-control status of the samples. To ensure 
successful quality of genotyping, two duplicate study participant samples were also included on 
each plate. The remaining two wells were uniquely positioned and were left blank so that the 
GSR facility could insert samples from two members of a family trio (mother, father, child) 
collected by the Centre d’Etude du Polymorphisme Humain (CEPH). 283 The CEPH samples, 
obtained from the non-profit Coriell Institute of Medical Research (Camden, NJ), supply 
inheritance data that is used to review and refine clustering, and serve as duplicate samples used 
to compare concordance between plates.  
After preparation by individual sites, all well-plates were heat-sealed, placed on dry ice, 
and shipped overnight to the GSR. Upon receipt at the GSR, DNA concentrations of all samples 
were verified using the PicoGreen dsDNA quantitation kit (Molecular Probes, Inc., Eugene, OR) 
and the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
Another procedure that was put into place to ensure high quality genotyping data included use of 
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a quality assurance (QA) panel.  The QA panel, designed to test sample performance, involved 
genotyping samples for 96 of the SNPs that are encompassed on the 610K array. Samples from 
each well of the mother 96-well plate were aliquoted into the corresponding well on a daughter 
96-well plate using automated procedures, and genotyping was performed for the 96 SNPs using 
Illumina’s Bead Express technology. This step allowed the identity of samples to be verified (i.e. 
to ensure replicate samples are concordant, no samples were switched, etc.). Samples identified as 
problematic were not plated onto the 610-quad Beadchip for genotyping. 
Illumina’s GenomeStudio software was used to perform automated genotype clustering 
and calling and to implement numerous quality control filters to minimize the number of 
problematic samples and SNPs in subsequent analyses. Intensity data was loaded into the 
GenomeStudio program using a sample sheet that contains the unique identifier for the sample, 
the position for the genotypes of the specific sample, and the location of the intensity file. The 
data points were clustered using the automatic clustering function in GenomeStudio. Because one 
sample from the HapMap CEPH trios were plated for the quality control purposes, all pairs of the 
replicate and parent-child inheritance using the plated CEPH controls were generated and 
manually reviewed to check for replicate or Mendelian inheritance errors. SNPs with unresolved 
replicate errors, poor performance, and call rate below 95% were excluded from subsequent 
analysis. Samples with call rates less than 95%, overall low intensity, or wrongly predicted 
gender were also excluded. After genotyping, blinded replicate pairs were used to evaluate the 
reproducibility and overall quality of the genotypes.  
Checking for gross departure to Hardy Weinberg equilibrium (HWE) has been shown to 
help in identifying SNPs with possible genotyping errors. 284 As such, SNPs with significant 
departures from Hardy-Weinberg Equilibrium (p< 10-4) among controls were flagged. 
Additionally, as most clustering based calling algorithms tend to perform poorly for SNPs with 
rare alleles, SNPs with minor allele frequencies (MAF) less than 5% were flagged since they are 
generally less informative and GWAS are not powered to study such variants.  
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Population stratification, or confounding by ethnicity, can lead to spurious associations 
between SNPs and disease risk. Although it is not anticipated that population stratification played 
a large role in stage I of the parent study due to the relatively homogeneous nature of the study 
population (i.e. restriction to Caucasian, non-Jewish, non-Hispanic subjects without a prior 
history of cancer or BRCA mutation), principal components analyses (PCA) were conducted.  
PCA is a multivariate data analysis procedure that involves a transformation of numerous 
possibly correlated variables into a smaller number of uncorrelated variables known as principal 
components. 285 Eigenstrat/Eigensoft software uses data from the HapMap populations to evaluate 
and address principal components related to population substructure. 286,287 Ancestry informative 
markers (AIMs) were also used to evaluate population substructure286,288.   
  
 
APPENDIX F: 
INTEGRATING COVARIATE DATA FROM 
 PARTICIPATING CASE-CONTROL STUDIES 
 
 
 Demographic data and information on known and suspected EOC risk factors were 
collected from study participants at each site using study-specific questionnaires. A data 
dictionary comprising 87 common data elements was created for stage I of the parent study, and 
all stage I partners (MAY, NCO, TBO, TOR) were asked to contribute coded data corresponding 
to the list of 87 common variables for purposes of subsequent analyses. A similar data dictionary 
that includes 67 common data elements was compiled by the international Ovarian Cancer 
Association Consortium (OCAC).  Although the majority of data elements overlap, the OCAC 
ascertains a) more detailed information about the type of hormone replacement therapy (HRT) 
used (i.e. combination HRT vs. estrogen-only HRT) and b) pathology-related information such as 
tumor stage and grade. As such, subject data for these variables was requested from the stage I 
partners. 
For purposes of this dissertation research, risk factor questionnaires were compared 
across study sites to ensure that data were collected on key variables we planned to investigate.  
Furthermore, the actual questions used to ascertain data on the variables of interest were 
compared to determine if they used the same operational definition(s).  Table F.1. lists the main 
covariates that were evaluated during this dissertation. The majority of variables were collected 
via the questionnaire at all 4 study sites in a comparable manner and had compatible response 
types/categories. However, as noted in the ‘comments’ column, several discrepancies were 
uncovered. Some general themes observed and our solutions for dealing with these discrepancies 
were as follows: 
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1) Some sites did not use the same operational definition when collecting information on a 
particular variable.   
• To calculate body mass index (BMI), values for height and weight were needed. 
However, data was collected for ‘current weight’ for subjects from TOR and TBO, and 
for ‘weight 1 year prior to the reference age’ for MAY and NCO subjects.  Due to the 
potential for reverse causality (i.e. current weight could occur as a consequence rather 
than a cause of disease), the definition used by MAY and NCO is more appropriate. 
However, since we did not have data available on weight 1 year prior to the reference age 
for TBO and TOR subjects, we did include the values for ‘current weight’ when 
calculating BMI for those subjects.   Footnotes are utilized to make this distinction when 
commenting on BMI throughout the manuscript.  
• Among hormone replacement therapy users, some sites (NCO, MAY) specifically asked 
about the type of hormone replacement therapy used (i.e. estrogen-only versus combined 
therapy), while others (TBO, TOR) did not ask for or include this information in the 
datasets we were given.  Since the majority of participants did not have data on the type 
of hormone replacement therapy used (among ever users), we collapsed type-specific 
data into the more general category of HRT status (ever/never use, regardless of type) 
and HRT duration (months, regardless of type). 
2) Some sites had a high percentage of missing data for a particular variable, so a less precise 
variable  was used for subjects from that particular site.   
• To evaluate the role of parity in our study population, we decided to utilize the variable 
‘fullbirths’, which is based on the number of full-term births lasting at least 6 months.  
For the TBO site, values for the ‘fullbirths’ variable were missing for 9% of participants, 
yet values for the variable related to the number of pregnancies, regardless of outcome, 
were present for all TBO participants. As such, the number of pregnancies, regardless of 
outcome, was used to represent parity for TBO subjects.  
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Table F.1. Comparison of key study variable content and format available from the four contributing parent studies. 
Variable (type) MAY NCO TOR TBO Comment 
Age at diagnosis/interview (numeric) X X X X  
Age at menarche  (numeric) X X X X  
Age at menopause (numeric) X X X   
Parity (numeric) X X X X 
Parity for MAY, NCO, and TOR was based 
on the number of full-term births resulting 
from pregnancies lasting at least 6 months. 
For TBO, parity was based on the number of 
pregnancies, regardless of length or outcome.
Breastfeeding status (dichotomous) 
     Never 
     Ever 
 X X X  
Duration of breastfeeding (numeric)  X X X  
Menopausal status at reference age (dichotomous) 
    Peri/Pre 
    Post 
X X X X  
Duration of oral contraceptive use (numeric) X X X X  
Oral contraceptive (OC) use (dichotomous) 
    Never 
    Ever 
X X X X  
Hormone replacement therapy (HRT) use 
    Never 
    Ever 
X X X X 
Although data was available on use of 
unopposed estrogen HRT vs. combination 
estrogen-progestin HRT at NCO and MAY, 
this data was not available from other sites. 
Duration of hormone replacement therapy use 
(numeric) 
X X X X  
Body mass index (kg/m2), mean (SD) X X X X 
Calculated using usual adult or current weight 
for subjects from TOR and TBO, and using 
weight 1 year prior to the reference age for 
MAY and NCO 
Smoking status 
   Never 
   Former 
   Current 
X X X X  
Duration of Cigarette Smoking (pack-years smoked) 
 
X X X X 
Number of pack-years= ((# of cigarettes 
smoked per day) X (# of years smoked))/20 
(1 pack=20 cigarettes) 
Family history ovarian or breast cancer in  >1  1° 
relative 
   No 
   Yes 
X X  X  
Histology 
  Serous 
  Endometrioid 
  Mucinous 
  Clear Cell 
  Other known epithelial cancer 
X X X X  
Stage 
  I 
  II 
  III 
  IV 
X X  X  
Grade 
  I 
  II 
  III 
  IV 
X X  X  
Note: ‘X’ denotes that a particular variable was available in the covariate dataset from a particular study site. 
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Table G.1. Variables Evaluated in Mitochondrial Manuscript  
Variable Name 
       
Description Classification and Coding 
Outcome Variables 
Casecon (sub-aim a.) Case-control status Binary 
    1=Ovarian cancer case 
    2=Control 
Histology (sub-aim 
b.) 
Histologic subtype of ovarian 
cancer 
Categorical (nominal) 
    1= Serous 
    2= Mucinous 
    3= Endometrioid 
    4= Clear cell        
    5= Control (Ref) 
Primary Independent Variables 
SNP_n  Genotype of individual nuclear-
encoded SNPs 
Categorical 
       2=2 normal (wild-type) alleles (Ref*) 
     1= 1 normal allele, 1 abnormal (variant) allele 
     0= 0 normal alleles  
Haplotype_n Haplotype in nuclear-encoded 
gene region 
Categorical 
        2=2 copies most common haplotype (Ref*) 
      1=1 copy common haplotype, 1 other haplotype 
      0= 0 copies common haplotype 
SNP_m  Carrier status of individual 
mtDNA-encoded SNPs 
Categorical 
      1= 1 normal allele (Ref) 
      0= 0 normal alleles 
Haplotype_m Haplotype in mtDNA-encoded 
gene region 
Categorical 
      1= 1 copy most common haplotype (Ref) 
      0= 0 copies common haplotype 
Secondary Independent Variables 
Age Reference age at diagnosis/ 
interview 
Continuous 
         
 
Site Unique ID to identify study site Categorical 
        1=MAY 
        2=NCO 
        3=TBO 
        4=TOR 
Aim for Mitochondrial Manuscript: To comprehensively examine associations between  
SNPs and haplotypes in mitochondrial DNA (mtDNA) and nuclear-encoded mitochondrial  
DNA (nDNA) and epithelial ovarian cancer risk.  
Sub-aim a.: To evaluate whether lifetime ovulation, hormone replacement therapy use,  
                     and/or smoking confound or modify the most promising observed associations. 
Sub-aim b.: To determine whether observed associations differ by histologic subtype. 
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LOC_cat  Total # of Lifetime Ovulatory 
Cycles (LOC) 
[(months between index age and  
age at menarche) – (months of 
pregnancy + months of oral 
contraceptive use)] X 13 cycles/yr 
Index age= age at menopause (for 
post-menopausal women) and age 
at diagnosis/interview for pre-
/peri-menopausal women  
Categorical (based on tertiles in controls) 
       1= High  
       2= Medium 
       3= Low (Reference)  
HRT  Duration (months) of hormone 
replacement therapy (HRT) use 
Continuous 
Smoke Duration (pack-years) of cigarette 
smoking, where  
Number of pack-years= [(number 
of cigarettes smoked per day) X 
(number of years smoked)]/ 20  
(1 pack=20 cigarettes)) 
Continuous 
Abbreviation: REF=Reference Group 
*Recessive Model: 0 vs 1 and 2;   Dominant Model: 0 and 1 vs 2; Log-Additive Model: 2 vs 1 vs 0 
 
Analytic Plan for Sub-aim 1a: 
To examine the association between each individual SNP and EOC risk, unconditional 
logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) 
between carriage of the minor versus major allele of mtDNA SNPs and case status, and between 
genotypes and case status for nDNA SNPs.  Three different genetic models were fit for each 
nDNA SNP, including a dominant model (comparing variant allele-carrying genotypes to the 
referent homozygous wild-type genotype), a recessive model (comparing the homozygous variant 
genotype to the referent genotype), and a log-additive model (assumes heterozygote risk is 
intermediate between the two homozygotes). All models were adjusted for the design variables of 
age (continuous) and study site (indicator variables for NCO, TBO, and TOR), and are referred to 
as ‘simple’ models.  Wald Χ2 tests were used to obtain P values for dominant and recessive SNP 
effects, and the Cochran Armitage trend test was used to estimate P for trend for log-additive 
models. The best-fitting model was represented by the genetic model with the smallest P value. 
All P values were two-sided, and a nominal P < 0.05 was considered the threshold of 
significance. 
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To evaluate whether established or suspected EOC risk factors (lifetime ovulation, 
hormones, cigarette smoking) postulated to contribute to oxidative stress 23,43,124,151,289-292 may 
confound the most promising SNP-EOC risk associations, we conducted a sub-analysis among 
subjects having complete data for the secondary independent variables highlighted in Table G.1. 
(N=2662; 1217 cases, 1445 controls). Due to the significant number of independent SNPs 
assessed (i.e. 2839 nDNA SNPs and 128 mtDNA SNPs) and various genetic models evaluated, it 
was impractical and computationally demanding to add potential confounders to each model one 
at a time (or to provide backward stepwise elimination for each potential confounder in each 
model) and to check the fit of each model using diagnostic tools. Thus, for each SNP 
investigated, the final ‘full’ model included 5 covariates: age at diagnosis/interview (continuous), 
study site (indicator variable for NCO, TOR, and TBO that is treated as a fixed effect), LOC 
category (low, medium, high), duration of unopposed estrogen or combined estrogen-progestin 
hormone replacement therapy (HRT) use (continuous), and pack-years of cigarettes smoked 
(continuous). If the parameter estimate changed by more than 10% when comparing the 
magnitudes of the measures of association from the ‘simple’ versus the ‘full’ model, we 
determined that confounding was present, all other factors being equal.   
Additionally, since a confounder should not represent an intermediate step in the causal 
sequence between the primary exposure (SNP/haplotype) and disease (EOC), we pondered 
whether any of the potential confounding factors evaluated (i.e. age, lifetime ovulation, HRT use, 
cigarette smoking), represent mediators/ intervening variables that may explain why there’s an 
exposure-disease relationship (i.e. that the SNP causes the potential confounder which in turn 
causes EOC). Although it does seem plausible that SNPs involved in steroid hormone metabolism 
(HOR) may influence ovulation and endogenous hormone levels, ultimately impacting EOC risk, 
adjustment for lifetime ovulation category and exogenous HRT use seems justified because we 
deliberately set out to explore whether each SNP contributed to EOC risk by mechanisms other 
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than ovulation and exogenous HRT use. In any case, if overadjustment occurred, the results 
would likely have been biased towards the null. 
To explore SNP-environment interactions, the modifying (moderating) effects of the 
following non-genetic variables were considered: LOC category (LOC_cat2) (high and medium 
tertile vs. lowest tertile), HRT use (HRT_cat) (ever versus never), smoking history (smoke_cat) 
(ever versus never), and menopausal status (menstat) (peri/pre versus post).  We primarily 
focused on dominant genetic effects for the most promising SNP-EOC risk associations (SNP_d). 
Multiplicative interactions were evaluated by fitting logistic regression models with the 
corresponding SNP, non-genetic variable, and the interaction term. P values for testing the 
interaction effects were obtained using Wald Χ2 tests. For interactions with P < 0.05, stratified 
analysis were conducted to obtain OR and 95% CI estimates.  
We also conducted haplotype analysis for each mtDNA- or nDNA-encoded gene having 
multiple SNPs associated with risk using Haploview v4.1. 125 For regions with high LD (r2 > 
0.80), we tested for associations between haplotypes and case-control status by calculating a 
global score statistic using the Haplo.stats program and R software v2.10.0 according to methods 
proposed by Schaid et al. 126   We then obtained estimates of ORs, 95% CIs, and P-values using 
the Haplo.glm function, and all models were adjusted for age and study site using pre-specified 
genetic models. Rarer haplotypes (frequencies <10%) were combined into a single category to 
minimize sparse cell counts. 
 
Example of nDNA SNP Logistic Regression Models for Sub-aim 1a: 
 
Since there are 3 categories for SNP_n, 2 indicator variables were created. For SNP_n, I chose to 
have the lowest risk group, homozygous wild-type, as the reference group for which no indicator 
variable was created. 
 
Snp_ndum1=  1, if 1 copy variant allele 
                        0, if otherwise 
 
Snp_ndum2= 1, if 2 copies variant allele 
                       0, if otherwise  
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Since there are 4 categories for study site, 3 indicator variables were created. For site, I chose to 
have MAY as the reference group for which no indicator variable was created. 
 
Site_dum1=  1, if site is NCO 
                      0, if otherwise 
 
Site_dum2=  1, if site is TBO 
                       0, if otherwise  
 
Site_dum3=  1, if site is TOR 
                      0, if otherwise  
 
Since there are 3 categories for LOC_category, 2 indicator variables were created. I chose to have 
the lowest risk group as the reference group for which no indicator variable was created. 
 
LOC_cat_dum1= 1, if category is high                      
                             0, if otherwise 
 
LOC_cat_dum2=1, if category is medium                  
                           0, if otherwise 
 
Simple model:       
Logit {Pr (ovarian cancer=1|X)}= β0 + β1 (SNP_ndum1) + β2 (SNP_ndum2) + β3 (Age) + β4 
(Site_dum1) + β5 (Site_dum2) + β6 (Site_dum3)  
 
 
Full Model:             
Logit {Pr (ovarian cancer=1|X)}= β0 + β1 (SNP_ndum1) + β2 (SNP_ndum2) + β3 (Age) + β4 
(Site_dum1) + β5 (Site_dum2) + β6(Site_dum3) + β7 (LOC_cat_dum1) + β8 (LOC_cat_dum2) +Β9 
(HRT) + β10 (Smoke) 
                                                                               
Interaction Model(s):  
Logit {Pr (ovarian cancer=1|X)}= β0 + β1 (SNP_d) + β2 (LOC_cat2) + β3 (SNP_d*LOC_cat2)+ β4 
(Age) +  β5(Site_dum1) + β6 (Site_dum2) + β7 (Site_dum3) 
 
Logit {Pr (ovarian cancer=1|X)}= β0 + β1 (SNP_d) + β2 (HRT_cat) + β3 (SNP_d*HRT_cat)+  β4 
(Age) +  β5(Site_dum1) + β6 (Site_dum2) + β7 (Site_dum3) 
                                                                        
Logit {Pr (ovarian cancer=1|X)}= β0 + β1 (SNP_d) + β2 (smoke_cat) + β3 (SNP_d*smoke_cat)+ β4 
(Age)  + β5(Site_dum1) + β6 (Site_dum2) + β7 (Site_dum3) 
                                                                             
Logit {Pr (ovarian cancer=1|X)}= β0 + β1 (SNP_d) + β2 (menstat) + β3 (SNP_d*menstat)+  β4 
(Age) +β5(Site_dum1) + β6 (Site_dum2) + β7 (Site_dum3) 
    
Analytic Plan for Sub-aim 1b: 
 
To evaluate SNP-EOC risk associations by the four main histologic subtypes (serous, 
endometrioid, clear cell, mucinous), we used a polytomous logistic model 293, comparing cases 
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having a specific histology with all controls. Pre-specified genetic models were fitted for each 
individual SNP, and adjustment for age and study site was performed.   
Polytomous Logistic Regression Model for Sub-aim 1b: 
         
 Logit {Pr (histology =k | X)}    =    β0 + β1 (SNP_ndum1) + β2 (SNP_ndum2) + β3 (Age) + β4 
(Site_dum1) + β5 (Site_dum2) + β6 (Site_dum3)  
 
Where k=1=serous; k=2=mucinous; k=3=endometrioid; k=4=clear cell; k=5=control 
 
  
 
 
Table G.2. Variables Evaluated in MiRNA Manuscript 
Aim(s) for MiRNA Manuscript :  To comprehensively evaluate associations between SNPs  
and haplotypes in miRNA biogenesis genes and a) EOC risk overall and b) serous carcinomas.  
Variable Name 
       
Description Classification and Coding 
Outcome Variables 
Casecon (sub-aim 2a) Case-control status Binary 
      1=Ovarian cancer case 
      2=Control       
 
Serous (sub-aim 2b) Serous case-control status Binary 
      1=Serous carcinoma 
      2=Control 
Primary Independent Variable 
SNP_n  Genotype of individual SNP Categorical 
      2= 2 normal (wild-type) alleles  (Ref*) 
      1= 1 normal allele, 1 abnormal (variant) allele 
      0= 0 normal alleles 
Haplotype Haplotype in gene region Categorical 
       2=2 copies most common haplotype 
     1=1 copy common haplotype, 1 other haplotype 
     0= 0 copies common haplotype 
Secondary Independent Variables 
Age Reference age at diagnosis/interview Continuous 
         
 
Site Unique ID to identify study site Categorical 
      1=MAY 
      2=NCO 
      3=TBO 
      4=TOR 
PC1 Principal component 1 (the first 
principal component representing 
European ancestry derived from 
principal components analysis that is 
used to correct for possible genetic 
admixture) 
Continuous 
Abbreviation: REF=Reference Group 
*Recessive Model: 0 vs 1 and 2;   Dominant Model: 0 and 1 vs 2; Additive Model: 2 vs 1 vs 0 
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Analytic Plan for Aim 2: 
To examine the association between each individual SNP and EOC risk, unconditional 
logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI).   
Three genetic models were fit for each SNP, including a dominant model, a recessive model, and 
a log-additive model. All models were adjusted for the design variables of age and study site. 
Additionally, to correct for possible genetic admixture, we included as a quantitative variable the 
first principal component representing European ancestry derived from principal components 
analysis using STRUCTURE162 and use of European AIMS. 163 None of the potential confounders 
in this analysis appear to represent intervening (mediating) variables. Wald Χ2 tests were used to 
obtain two-sided P values for SNP effects. The best-fitting model was represented by the genetic 
model with the smallest P value, and P < 0.05 was considered the threshold of significance. Due 
to the heterogeneous nature of EOC, subgroup analysis was conducted to estimate genotype-
specific odds ratios for serous disease (the most predominant histologic subtype). We also 
conducted haplotype analysis for gene regions of interest according to methods specified for the 
nDNA-encoded mitochondrial genes. 
Example of SNP Logistic Regression Models for Aim 2: 
 
Simple model (overall):       
Logit {Pr (ovarian cancer=1|X)}= β0 + β1 (SNP_ndum1) + β2 (SNP_ndum2) + β3 (Age) + β4 
(Site_dum1)+ β5 (Site_dum2) + β6 (Site_dum3)  
                                                                               
Simple model (serous):       
Logit {Pr (serous carcinoma=1|X)}= β0 + β1 (SNP_ndum1) + β2 (SNP_ndum2) + β3 (Age) + β4 
(Site_dum1) + β5 (Site_dum2) + β6 (Site_dum3)  
                                                                                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX H:   
 
SAMPLE SIZE AND POWER CALCULATIONS 
  
To address our hypotheses that inherited variation in the genes of interest influence EOC 
risk,  sample size and power estimates were calculated using Quanto version 1.2, a computer 
program designed to calculate power or the required sample size for association studies of genes, 
environmental factors, gene-environment interactions, or gene-gene interactions. 294-296  Quanto is 
flexible in that it can calculate these parameters in the context of various study designs and under 
various assumptions regarding the nature of the alleles and environmental factors of interest.  
Our primary interest was to detect significant main effects of independent SNPs. 
Assuming an unmatched case-control study (with a 1:1 ratio of cases and controls) with a binary 
outcome (where D=1=diseased and D=0=non-diseased), and an overall disease risk in the general 
population, kp, of 1 in 71 (1.41%),297  we estimated the sample size needed to detect the main 
effect of a particular gene (SNP) on disease risk using log-additive and dominant genetic models.  
All calculations assumed a frequency of the risk allele (minor allele) to be between 0.05 and 0.35. 
Since the odds ratios (OR) for specific alleles influencing a complex disease such as ovarian 
cancer are expected to be small to modest, 298  ORs ranging from 1.2 to 3.0 were used to generate 
calculations related to the main effect of a particular gene on disease risk.   
Table H.1. represents the sample sizes needed to reflect the assumptions outlined above 
while achieving 80% power on a two-tailed test of significance with a type I error rate of 
alpha=0.05 and a more stringent alpha=0.05/M, with M equaling the number of SNPs tested 
simultaneously. The maximum number of SNPs tested simultaneously in the proposed research 
will approximate 2839, which is the number of nuclear-encoded mitochondrial SNPs to be tested. 
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Thus, the more stringent alpha value is 1.76 X 10-5. However, correction for multiple testing in 
association studies using a simple Bonferroni correction such as this is likely too conservative due 
to the assumption of independence between tests. 299 
Table H.1. Total sample size (N) requirements to detect gene-only effects across a range of minor allele frequencies, 
effect sizes, and p-values in an unmatched case-control study.  
 
MAF ORg Total N 
p=0.05  
Log-Additive (Dominant) 
Total N 
p=1.76 X 10-5 
Log-Additive (Dominant) 
0.05 1.2 9192 (10008) 30870 (33618) 
 1.5 1692 (1864) 5686 (6262) 
 1.8 748  (832) 2516 (2796) 
 2.1 442 (496) 1488 (1666) 
 2.4 302 (342) 1016 (1148) 
 2.7 226 (256) 758 (860) 
 3.0 178  (202) 598 (682) 
0.15 1.2 3490 (4540) 11722 (15252) 
 1.5 660 (884) 2218 (2968) 
 1.8 300 (410) 1006 (1378) 
 2.1 182 (254) 610 (850) 
 2.4 126 (180) 426 (604) 
 2.7 96  (138) 324 (466) 
 3.0 78 (112) 262 (378) 
0.25 1.2 2418 (3806) 8120 (12790) 
 1.5 470 (768) 1576 (2582) 
 1.8 218 (368) 732 (1234) 
 2.1 134 (232) 452 (782) 
 2.4 96 (170) 322 (568) 
 2.7 74 (132) 250 (446) 
 3.0 60 (110) 204 (370) 
0.35 1.2 2030 (3936) 6816 (13222) 
 1.5 404  (818) 1356 (2750) 
 1.8 192  (400) 642 (1348) 
 2.1 120 (258) 404 (870) 
 2.4 86  (192) 292 (642) 
 2.7 68  (152) 228 (512) 
 3.0 56 (128) 190 (430) 
                                     Abbreviations: MAF=Minor Allele Frequency; ORg=Odds ratio for the gene-only test 
 
Data from approximately 3715 total subjects was available for analysis.   Thus, even with 
the more stringent p-values, we will have adequate power to detect ORs of 1.5 and greater for 
SNPs with a MAF >0.15, especially if a log-additive model is assumed.  Under recessive models, 
we will be underpowered to detect such associations (data not shown). 
Our secondary interest lies in exploring important interactions between a SNP and an 
environmental factor (GxE).  We also assessed the interaction between two SNPs (GxG). When 
estimating sample sizes needed to detect GxE interactions, the prevalence of a binary exposure 
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was estimated to be 0.20, which is the prevalence of a high number of lifetime ovulatory cycles 
amongst controls. When calculating GxG interactions, the frequency of the risk allele was 
estimated to be 0.27, which is the mean and median minor allele frequency amongst controls in 
our largest dataset. To assess GxE and GxG interactions in Quanto, we needed to estimate main 
effects of the second factor (i.e. genetic and/or environmental factor) on disease risk.  The main 
effect of an environmental factor refers to the effect in genetically normal (G=0) subjects, and 
was estimated to approximate 1.5.  Similarly, the main effect of a genetic factor refers to the 
effect in unexposed (E=0) subjects, and was estimated to be 1.3. We assumed 2.0 as the 
magnitude of interaction effect. With these assumptions, the total sample size needed to detect 
gene-gene and gene-environment interactions while achieving 80% power on a two-tailed test of 
significance with a type I error rate of alpha=0.05 under dominant models is shown in Table H.2. 
Table H.2. Total sample size requirements to detect gene-gene and gene-environment interactions using estimates of 
allele frequencies, main effects, and exposure prevalence. 
MAF Total N 
p=0.05  
SNP-Environment Interactions  
0.05 7416  
0.10 4440 
0.15 3556 
0.20 3220 
0.25 3128 
0.30 3186 
0.35 3364 
0.40 3666 
SNP-SNP Interactions  
0.05 2494 
0.10 1516  
0.15 1234  
0.20 1120 
0.25 1134 
0.30 1158 
0.35 1240 
0.40 1368 
         Abbreviations: MAF=Minor Allele Frequency 
 
Calculations reveal that we should be able to detect GxG and GxE interactions in our 
study population of 3715 subjects if we assume a p-value of 0.05.  However, if we assume a more 
stringent p-value, we will be underpowered to detect some of these associations, especially those 
that consider SNPs with low minor allele frequencies (data not shown).  Furthermore, the 
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estimated sample sizes may reflect over-or under-estimates depending on the SNP(s) and 
environmental exposure of interest.  
Although we will be underpowered to detect small effects (odds ratios <1.5) such as 
those generated by GWA studies, our investigation will still provide valuable exploratory 
information about the possible contribution of genetic and environmental factors in the etiology 
of EOC. 
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